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Summary
Human tuberculosis (TB), caused by the bacterium M. tuberculosis, is the leading cause of
death due to an infectious agent. In 2017, there were an estimate of 10 million new cases
and 1.6 million deaths caused by TB. The evolution of drug resistant M. tuberculosis vari-
ants is threatening disease control efforts. Whereas the treatment of drug-susceptible TB
isolates involves a treatment regimen of 4 drugs which have to be taken on a daily basis for
6 months, treating drug resistant TB involves the administration of more toxic and expen-
sive drugs for up to two years. Generating timely and accurate drug susceptibility testing
results is essential for the administration of effective treatment. Effective treatment will
result in fewer secondary cases generated per patient, as well as lower the probability of
treatment failure and amplification of resistance. Drug resistance is primarily conferred
by well-defined chromosomally encoded mutations, which offers the possibility of deduc-
ing antibiograms by sequencing the drug-resistance related target genes and detecting
mutations therein. In Chapter 4, we assessed the utility of whole genome sequencing in
predicting accurate drug susceptibility profiles, as well as predicting quantitative levels of
drug resistance. For this, we compared whole genome sequences with results of two differ-
ent methods suitable in determining quantitative levels of drug resistance. We concluded
that whole genome sequencing is highly effective in predicting drug resistance profiles and
is in part able to predict quantitative levels of drug resistance.
It has generally been assumed that drug resistant M. tuberculosis variants do not trans-
mit efficiently, as drug resistance comes at a cost. Drug resistance-conferring mutations
often target essential, highly conserved genes, causing a physiological cost, resulting in a
reduced number of secondary cases generated. However, these costs may be mitigated by
secondary, so-called compensatory mutations. Examples of compensatory evolution in M.
tuberculosis are limited to a few examples. In chapter 6 we attempted to identify biolog-
ical pathways mutated more frequently than expected by chance in multidrug-resistant
(MDR: resistance against rifampicin (RIF) and isoniazid (INH)) M. tuberculosis strains
which generated secondary cases, compared to strains which did not transmit frequently.
We identified nucleotide biosynthesis pathways as more frequently mutated than expected
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by chance in strains that transmit frequently, potentially hinting at a connection to RIF-
resistance and altered nucleotide requirements of RIF-resistant strains. Although only
560000 cases of rifampicin resistant M. tuberculosis infections were reported in 2017, the
incidence is not equally distributed globally. For instance, countries of the former Soviet
Union are heavily affected by drug resistant variants for reasons not well understood.
In Chapter 5, we analysed a population-based, nation-wide collection of clinical MDR
M. tuberculosis strains, isolated between 2011 and 2013 in Georgia. We identified Geor-
gian prisons as a hotspot for transmission of MDR TB. Furthermore, we were able to
demonstrate that MDR strains belonging to lineage 2 transmit more frequently com-
pared to lineage 4 strains. Strains harbouring compensatory mutations transmitted more
frequently than non-compensated strains. Furthermore, strains connected directly or in-
directly to prisons were more likely to harbour compensatory mutations, indicating that
prisons act as incubator for highly transmissible M. tuberculosis strains. In total, 41 %
of all transmission events of MDR-TB isolates were directly or indirectly associated with
incarceration.
Since the discovery that single drug regimens for the treatment of M. tuberculosis
quickly lead to resistance, TB is treated with combination therapies. The current WHO-
endorsed regimen for drug susceptible TB contains four drugs, including RIF and INH.
Patient non-adherence and pharmakogenomic variation among patients have been demon-
strated to generate sub inhibitory drug concentrations, which in turn are implicated in the
evolution of drug resistance. In chapter 7 we investigate the influence of sub inhibitory
concentrations of RIF and INH alone and in combination. Out data hints at the possibility
that katG mutations, conferring INH resistance, are also involved in conferring low-level
RIF resistance. This observation might explain the observation why, compared to INH
mono-resistance, RIF mono-resistance is rare in clinico and can be used as a surrogate
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1. Introduction
Human tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is by far
the deadliest infectious disease in the history of the human species, having claimed more
lives than any other pathogen, bacterial or viral. In the past 200 years, TB has claimed
the lives of at least 1 billion people (Paulson, 2013). In 2017, there were an estimated 10
million new cases of TB and an estimated 1.6 million deaths caused by TB (World Health
Organization 2018a). A number of factors have contributed to the success of the pathogen.
First, M. tuberculosis is transmitted aerogenously via bacteria-containing droplet nuclei
and is believed to have a low infectious dose of 1-200 cells (Sakamoto, 2012), greatly fa-
cilitating host-to-host transmission. Furthermore, TB infections lead to chronic disease
which, in absence of effective treatment, can last for years, during which the host may
spread the disease (Behr et al., 2018). Cleared TB infections do not lead to the develop-
ment of long-lasting protective immunity, resulting in possible multiple infections during
the lifetime of a person in high-incidence settings (Shen et al., 2006). However, global
incidence of TB has been dropping continuously since accurate records on incidence have
been collated (Wilson, 1990). The discovery of the tubercle bacillus by Robert Koch in
1882 (Koch, 1882) paved the way for implementing effective public health interventions,
especially isolation of TB patients (Zürcher et al., 2016). In the Western hemisphere, TB
incidence has dramatically declined, to the extent of rendering TB an anecdotal disease;
which is linked to the reduction of transmission possibilities. Improved living conditions
lead to less crowding, which reduces the exposure of, for example, family members living
together with a person infected with TB. The discovery of antimicrobial compounds active
against M. tuberculosis helped to speed up the decline in TB incidence in the Western
world. Early setbacks due to the evolution of drug resistance when using a single drug to
treat TB were soon circumvented by the establishment of combination therapy (Dickinson
et al., 1977). However, the TB epidemic is far from contained. Especially the emergence
and spread of the human immunodeficiency virus (HIV) in population-rich regions causes
frequent and detrimental HIV-TB co-infections (Brites et al., 2012) and poses a sub-
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stantial challenge to reducing TB mortality and morbidity (World Health Organization,
2018a).
1.1. Treatment of TB and the evolution of drug
resistance
While TB is a curable disease, doing so it is not trivial. At least 4 active drugs are required
to treat drug-susceptible TB, and these drugs need to be taken for 6 months on a daily
basis without interruption. The long treatment duration, as well as the high cost of treat-
ing drug-resistant TB (Marks et al. 2014) poses considerable challenges for weak health
systems (Atun et al., 2010). The current treatment standard, directly observed therapy
short course (DOTS), widely implemented in the last decade of the 20th century, aims to
ensure that patients take the prescribed drugs on a regular basis without missing doses
(World Health Organization, 1997). However, patients can fail to adhere to treatments
for a multitude of reasons, including severe side effects of antituberculous drugs, lack of
financial capabilities to access drug treatment, and drug unavailability. Interruption of
treatment is therefore to be expected in a certain proportion of patients (Munro et al.,
2007). Interrupted treatment is a risk factor for developing drug resistance. However,
drug resistant strains have been demonstrated even in patients who take the prescribed
drugs on a regular basis (Calver et al., 2010). There are several factors thought to con-
tribute to the evolution of drug-resistant strains within patients. Individual variation in
drug metabolism can result in fixed-dose regimens not providing sterilizing concentrations
in each patient for the required period of time (Srivastava et al., 2011). Pharmacogenomic
differences, as well as treatment interruption lead to sub-inhibitory drug concentrations,
which are known to facilitate the evolution of drug-resistant variants (Andersson et al.,
2014). In Chapter 7, we investigate how drug environments below the minimal inhibitory
concentration (sub-MIC) may select for MDR phenotypes. There is preliminary evidence
that combinations of sub-MIC RIF and INH concentrations effectively select for MDR
TB strains.
Limiting the evolution of drug resistance requires the acquisition of timely and accu-
rate drug resistance profiles. Undetected resistance may lead to the administration of
less than four effective antituberculous drugs, and in many cases the consequence will be
treatment failure and the amplification of resistance (Zhang et al., 2015a). The current
gold standard for drug susceptibility testing in TB involves the assessment of bacterial
growth at defined concentrations, testing growth of patient isolates at defined drug con-
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centrations to determine if a strain is deemed clinically resistant. The reliance on these
time-consuming tests may have slowed the investigation of distributions of minimal in-
hibitory concentrations of resistant strains. There is considerable variability between the
levels of resistance conferred by drug resistance mutations. Some resistance mutations do
not elevate the MIC far beyond the critical concentration; strains carrying these muta-
tions may still be treated with increased doses of the drug. In light of the limited set of
drugs active against M. tuberculosis, quantifying the distribution of MICs conferred by
different drug resistance mutations warrants more investigation. As reviewed in Chapter
3, drug resistance in M, tuberculosis is thought to be conferred predominantly by chro-
mosomal mutations. This makes detection of resistance mutations using whole genome
sequencing (WGS) a powerful tool in predicting drug susceptibility testing (DST) profiles.
However, the utility of WGS to accurately predict DST profiles relies on being able to
correlate identified mutations with high-quality drug susceptibility testing results, which
are still rare. In Chapter 4, we examined how well WGS is able to predict DST profiles
and quantitative levels of drug resistance after filtering for known phylogenetic markers.
We concluded that WGS has great potential to replace culture-based DST in the future,
and discovered that there is potential room for improvement in treatment regimens, as
not all drug resistance mutations render strains resistant to drug concentrations beyond
the therapeutic window of a drug.
1.2. Control of the TB epidemic and prisons
It is unlikely that the TB epidemic is going to be ended with antibiotics alone. Even
in highly developed health systems, there are still cases among the resident population
(World Health Organization, 2018a). TB is able to enter a latent phase, which generates
a currently undetectable reservoir from which new cases can continuously emerge and
generate secondary cases, which in turn may enter dormancy again, restarting the cycle
of hide and seek (Jassal et al., 2010). Ending the TB epidemic will require a highly
effective vaccine that generates long-lasting protective immunity, which is currently not
in sight (Kaufmann et al., 2014). Until an effective vaccine is developed, public health
interventions, including active case-finding campaigns, will remain important to reduce
TB incidence. Although the benefits of active case-finding campaigns on the population at
large remain unclear (Kranzer et al., 2013), active screening is able to reduce the burden
of TB in “stationary” high risk populations, e.g. prisoners (World Health Organization
et al., 2018).
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TB incidence rates among prisoners are generally higher than in the general public
(Baussano et al., 2010) due to a number of factors facilitating the spread of the disease.
For instance, in many countries prisoners are held in confined, overcrowded spaces with
poor ventilation. Prolonged exposure to an active case greatly increases the probability of
contracting the disease (Reichler et al., 2018). Furthermore, prisoners frequently experi-
ence difficulties in accessing adequate medical services (Department of State of the United
States of America, 2012). Active case-finding campaigns in prisons should be highly effec-
tive in quickly identifying active cases and enabling the timely administration of effective
treatment. However, despite the relative ease of identifying TB cases in prisons, the dis-
crepancy in incidence rates between prisoners compared to the general public is shocking.
For instance, in 2013, the incidence of TB among prisoners in Georgia prisoners was 25.5
times higher than that in the general population, despite active case finding campaigns
being in place (World Health Organization, 2014b). Prisoners are also at a dramatically
increased risk of contracting drug-resistant strains (Aerts et al., 2000; Stuckler et al.,
2008; Kenyon, 2009), again demonstrating the partial failure of TB control programs.
Furthermore, there is a correlation between the proportion of incarcerated people and
the incidence of drug-resistant TB in the general population (Stuckler et al., 2008). The
impact of incarceration on the TB epidemic in the general public in countries of the for-
mer Soviet Union has not received sufficient attention. For instance, in the case of the
Republic of Georgia, there are no programs in place to ensure that prisoners continue to
be treated for TB after their release from prison. In 2012, following the exposure of ap-
palling human rights violations in Georgian prisons, nearly 10000 prisoners were released
from prison. In the absence of effective follow-up, the mass amnesty is very likely to have
had a profound impact on the epidemic of drug-susceptible and multidrug-resistant TB.
Investigating the reasons of why prisoners in Georgia appear to be at a great disadvantage
in terms of being TB-free is beyond the scope of this thesis. However, in Chapter 5, we
were able to show that neglecting the prison population has direct consequences for the
general public, as apparent from spillover events of highly transmissible TB strains from
prisons into the general public. We hope that such findings will invigorate programs to
reduce TB incidence in prisons and limit the spillover to the general public.
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1.3. Bacterial factors and transmissibility of drug
resistant TB
While improvements in DST and public health programs will reduce TB burden, design-
ing effective treatment regiments requires a thorough understanding of resistance and
compensation mechanisms. The great majority of antibiotics directly target essential
metabolic processes in bacteria (Chapter 3). Acquiring resistance to the drugs requires
mutating the genes encoding the drug target. However, these essential proteins are highly
conserved, and non-synonymous mutations frequently cause disruptions in the bacteria’s
physiology. The magnitude of drug resistance- induced disruption of physiological pro-
cesses, manifesting as a reduced in vitro growth rate, is known to depend on the resistance
mutation and the genetic background in M. tuberculosis and manifests itself as a reduced
in vitro growth rate (Gagneux et al., 2006b). The reduced growth may cause the drug-
resistant strain to generate fewer secondary cases compared to drug- susceptible strains in
absence of the drug. Secondary, so-called compensatory mutations, not directly involved
in conferring drug resistance, are able to mitigate these drug-resistance related fitness
costs and restore the capability of drug resistant strains to efficiently generate secondary
cases (Chapter 5, (Merker et al., 2018)). Furthermore, the concomitant presence of mul-
tiple drug resistance mutations affecting essential genes seems to generate a multitude
of targets of compensatory evolution (Moura de Sousa et al., 2017). We do not have
a good understanding of the molecular mechanisms underlying the measurable fitness
deficit and its compensation observed in drug resistant M. tuberculosis strains. The study
of population-based collections may help in elucidating what the targets of compensatory
evolution are, by analysing what mutations strains transmitting frequently acquire. Com-
bined with metabolomic, proteomic and transcriptomic data, this will greatly enhance our
understanding of fitness cost compensation in M. tuberculosis by linking genotypic with
phenotypic readouts. In Chapter 6 we present work in trying to identify genetic factors
involved in fitness cost compensation by analysing a population-based MDR-TB strain
collection by detecting which mutations appear in strains that transmit frequently. These
data will serve as a first step in elucidating how M. tuberculosis strains are capable of ac-
quiring resistance to an numerous drugs via chromosomal mutations in essential genes, yet
retaining the capability to generate secondary cases (Chapter 5, (Shah et al., 2017)).
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2. Objectives and outline
2.1. Thesis aims
This thesis aims at addressing multiple aspects concerning drug resistance in M. tuber-
culosis, ranging from inferring drug resistance profiles from whole genome sequences, the
evolution of drug resistance under sub inhibitory drug concentrations, the transmissibility
of multidrug resistant strains and the detection of mechanisms rendering drug resistant
variants transmissible.
2.1.1. Specific objectives
● Objective 1 Review the current knowledge on drug resistance mechanisms and the
evolution of acquired drug resistance in M. tuberculosis (Chapter 3).
● Objective 2 Assess the utility of whole genome sequencing to infer accurate drug re-
sistance profiles in clinical M. tuberculosis isolates (Chapter 4).
● Objective 3 Study transmission of multidrug-resistant M. tuberculosis strains in the
Republic of Georgia using a population-based collection M. tuberculosis strain and
infer bacterial, host and environmental factors associated with successful transmis-
sion (Chapter 5).
● Objective 4 Identify mutations or pathways under selection in transmissible multidrug-
resistant M. tuberculosis strains using the population-based collection of M. tuber-
culosis strains from Georgia (Chapter 6).
● Objective 5 Study the evolution of mono- and multidrug-resistance in clinical M. tu-
berculosis strains under selection of sub-inhibitory drug concentrations (Chapter
7).
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2.2. Outline
In Chapter 3, we reviewed mechanisms of intrinsic and acquired drug resistance in M.
tuberculosis and attempted to shed light on acquired drug resistance from an evolutionary
perspective.
In Chapter 4 we assess the utility of whole genome sequencing for the prediction of
quantitative levels of drug resistance in a diverse set of 176 clinical M. tuberculosis isolates
by comparing the results of two phenotypic drug susceptibility testing methods with the
genotype inferred from the whole genome sequences.
Chapter 5 aims at studying the transmission of highly drug-resistant M. tuberculosis
isolates and gaining insight into the epidemic of multidrug-resistant M. tuberculosis in the
former Soviet Union. For this we a subjected a population-based collection of multidrug-
resistant M. tuberculosis strains from Georgia collected between 2011 and 2013 to whole
genome sequencing to infer transmission networks. Based on the transmission networks,
we analysed bacterial, environmental and host factors for their association with successful
transmission. Chapter 6 is concerned with identifying mechanisms involved in mitigating
drug resistance-related fitness costs, enabling the drug resistant M. tuberculosis strains
to efficiently generate secondary cases. For this, we analysed the transmission networks
inferred in Chapter 5, identified mutations private to strains in transmission clusters and
subjected the mutations to network analysis-based pathway enrichment.
Chapter 7 investigates the effect of sub inhibitory drug concentrations of rifampicin and
isoniazid alone or in combination on the evolution of drug resistance. For this we subjected
three clinical M. tuberculosis strains with differing genetic backgrounds to serial passage
for approximately 180 bacterial generations. Drug concentrations increased from 1/64
to 4 x of the minimal inhibitory concentration. We subjected a subset of the surviving
endpoint cultures to whole genome sequencing to detect mutations associated with drug
resistance.
In Chapter 8, we summarise the findings of this thesis and puts them into context
of the current state of knowledge, while addressing remaining challenges and identifying
potential directions of future research.
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3.1. Abstract
Antibiotic-resistant Mycobacterium tuberculosis strains are threatening progress in con-
taining the global tuberculosis epidemic. M. tuberculosis is intrinsically resistant to many
antibiotics, limiting the number of compounds available for treatment. This intrinsic resis-
tance is due to a number of mechanisms including a thick, waxy, hydrophobic cell envelope
and the presence of drug degrading and modifying enzymes. Resistance to the drugs which
are active against M. tuberculosis is, in the absence of horizontally transferred resistance
determinants, conferred by chromosomal mutations. These chromosomal mutations may
confer drug resistance via modification or overexpression of the drug target, as well as
by prevention of prodrug activation. Drug resistance mutations may have pleiotropic ef-
fects leading to a reduction in the bacterium’s fitness, quantifiable e.g. by a reduction
in the in vitro growth rate. Secondary so-called compensatory mutations, not involved
in conferring resistance, can ameliorate the fitness cost by interacting epistatically with
the resistance mutation. Although the genetic diversity of M. tuberculosis is low, com-
pared to other pathogenic bacteria, the strain genetic background has been demonstrated
to influence multiple aspects in the evolution of drug resistance. The rate of resistance
evolution and the fitness costs of drug resistance mutations may vary as a function of the
genetic background.
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3.2. Introduction
Human tuberculosis (TB), a devastating disease caused by the gram-positive, acid-fast eu-
bacterium Mycobacterium tuberculosis, was classified as a global health emergency by the
World Health Organization in 1993. TB remains one of the deadliest infectious diseases
with an estimated 1.8 million deaths occurring per year, mainly in the developing world
(World Health Organization, 2016a). Although the incidence of TB has declined drasti-
cally over the past decades, there were an estimated 10.4 million new cases in 2015, of
which 0.48 million were caused by M. tuberculosis strains classified as multidrug-resistant
(MDR – resistant to the first-line drugs rifampicin and isoniazid). Drug-resistant M.
tuberculosis strains are a major global health concern because treatment of these cases
requires second-line drugs, which are less effective, more expensive and more toxic, as
well as sophisticated infrastructure for drug susceptibility testing not readily available
in resource-limited settings. TB treatment success rates of cases caused by MDR/XDR
variants of M. tuberculosis are alarmingly low, with only 54 % of MDR and 28 % of exten-
sively drug-resistant (XDR – MDR plus resistance to fluoroquinolones and any second-line
injectable aminoglycoside / cyclic peptide) cases resulting in cure, compared to 83 % of
drug-susceptible cases (World Health Organization, 2016a). For clarity we only refer to
MDR/XDR M. tuberculosis variants when the defined resistance profiles are meant. Oth-
erwise we use the term “drug resistance” to refer to the topic in general, irrespective of
specific drug resistance profiles.
The first effective antituberculous drug, streptomycin, was discovered in 1944 (Schatz et
al., 1944). The newly discovered drug was immediately used for treatment of TB patients.
The condition of many individual TB patients receiving streptomycin improved during
the first months of treatment, only to then deteriorate again as treatment continued.
It was soon understood that this was due to the evolution of resistant M. tuberculosis
strains, rendering streptomycin ineffective (Crofton et al., 1948). To limit the evolution of
resistance, the British Medical Research Council pioneered the first combination therapy
for the treatment of a disease by using para-aminosalicylic acid (Lehmann, 1946) together
with streptomycin for treatment of pulmonary TB (Medical Research Council, 1950). The
subsequent years saw the introduction of an array of different antituberculous drugs. The
discovery of rifampicin in 1965 (Sensi, 1983) and the subsequent use of the drug in TB
treatment was a game-changer, allowing dramatically shortened treatment duration from
18 months or more to 9 months (British Thoracic and Tuberculosis Association, 1975).
During the 1990s, the current standard 6-month regimen known as Directly Observed
Therapy Short Course (DOTS) was introduced by the World Health Organization (World
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Health Organization, 1997). This regimen consists of 2 months treatment with isoniazid,
rifampicin, ethambutol and pyrazinamide followed by 4 months of isoniazid and rifampicin
(World Health Organization, 1991), and is highly effective for drug-susceptible TB (Feng-
Zeng et al., 1996; Frieden et al., 1995).
A short treatment duration and reduction of adverse drug effects are crucial for in-
creasing patient treatment adherence, which is known to influence the evolution of drug
resistance (Mahmoudi et al., 1993). However, despite the early establishment of TB
combination therapies showing high cure and low relapse rates (British Thoracic and Tu-
berculosis Association, 1975), drug-resistant M. tuberculosis strains continued to evolve
in both high and low incidence settings. MDR M. tuberculosis variants evolved on mul-
tiple occasions in different parts of the world (Eldholm et al., 2015; Cohen et al., 2015).
Furthermore, differences in the quality of public health systems contributed to the spread
of drug-resistant M. tuberculosis variants leading to the unequal distribution of incidence
rates of drug-resistant variants around the world we observe today (World Health Orga-
nization, 2016a). In the absence of an effective vaccine (Kaufmann et al., 2014), there is
an urgent need for new treatment regimens, drugs and diagnostics to slow the evolution
of drug resistance and limit transmission of resistant variants, as well as to ameliorate the
treatment outcome of patients infected with MDR/XDR M. tuberculosis strains. Under-
standing the molecular mechanisms and the evolutionary trajectory of drug resistance is
important to limit the de novo evolution and subsequent spread of resistant M. tuberculo-
sis strains. The first part of this review will summarise intrinsic and acquired mechanisms
of drug resistance in M. tuberculosis ; these are analysed in more detail in several recently
published reviews (Nguyen, 2016; Zhang et al., 2015b; Smith et al., 2013; Nash, 2016).
The second part of this review will focus on our current understanding of the evolutionary
biology of drug resistance in M. tuberculosis.
3.3. Mechanisms of drug resistance in Mycobacterium
tuberculosis
Members of the genus Mycobacterium have long been noted for their intrinsic resistance
to a wide array of antibiotics. This has mainly been attributed to the unusually thick,
lipid-rich cell envelope (Jarlier et al., 1994). After penetrating the cell envelope, certain
antibiotics may be cleaved enzymatically or altered structurally to render them ineffective
(Wang et al., 2006; Chambers et al., 1995; Warrier et al., 2016). Furthermore, a number
of efflux systems have been identified in M. tuberculosis, but their significance in confer-
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ring clinically relevant levels of drug resistance is a matter of debate. As efflux systems
have been observed to be expressed under varying conditions (Li et al., 2015; Adams
et al., 2011; Gupta et al., 2010), they might serve as a stepping stone for high-level drug
resistance. A further peculiarity of M. tuberculosis is the apparent absence of ongoing
horizontal gene transfer (Cole et al., 1998; Bolotin et al., 2015; Gagneux et al., 2007).
Although there have been reports of horizontal gene transfer between “species” of the
genus Mycobacterium (Rabello et al., 2012), horizontal gene transfer does not seem to be
a driving factor in the acquisition of antimicrobial resistance in M. tuberculosis. The vast
majority of drug resistance phenotypes in M. tuberculosis can be explained by chromoso-
mal mutations and not by resistance plasmids or other mobile genetic elements. To study
the mechanisms of drug resistance, many studies have been performed on a multitude of
different mycobacterial species, due to the often lower pathogenicity/biosafety require-
ments and faster growth properties of these mycobacteria compared to M. tuberculosis.
The most widely used model is Mycobacterium smegmatis, an environmental mycobac-
terium with a genome roughly 1.5x the size of that of M. tuberculosis. We should
therefore be cautious in applying the results of these studies directly to M.
tuberculosis .
3.4. Intrinsic drug resistance in M. tuberculosis
3.4.1. The mycobacterial cell wall & drug penetration
The intrinsic resistance of mycobacteria against several classes of antibiotics has com-
monly been attributed to the unusual composition and structure of the mycobacterial
cell envelope. Compared to other gram-positive bacteria, the cell wall of members of
the genus Mycobacterium is much thicker and more hydrophobic, due to the presence of
a wide array of different lipids that include mycolic acids. Many studies (reviewed in
(Jarlier et al., 1994; Brennan et al., 1995; Nguyen et al., 2009; Sarathy et al., 2012) per-
formed in different mycobacterial species demonstrated that the composition of the cell
envelope and the low numbers of porins (Mailaender et al., 2004) contribute significantly
to the cell envelope’s low compound permeability. A major constituent of the cell wall is
a layer of lipids, which are covalently linked to the peptidoglycan layer via arabinogalac-
tan. Furthermore, the cell wall contains “extractable” immunogenic glycolipids (Brennan
et al., 1995). The lipid-rich nature renders the cell wall extremely hydrophobic and pre-
vents the permeation of hydrophilic compounds. It is thought that small hydrophilic
compounds, including many antibiotics active against M. tuberculosis, can only traverse
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the cell wall via water-filled porins. Heterologous expression of the M. smegmatis porin
MspA in M. tuberculosis did indeed decrease the minimal inhibitory concentration for
several hydrophilic drugs (Mailaender et al., 2004), indicating that porins might play an
important role in the diffusion of hydrophilic antibiotics across the cell wall of M. tuber-
culosis. However, until recently reports on the presence of porins in M. tuberculosis were
lacking. The outer membrane channel protein CpnT was demonstrated to be involved
in nutrient uptake in Mycobacterium bovis BCG and M. tuberculosis (Danilchanka et al.,
2014) and in mediating susceptibility to nitric oxide and antibiotics in Mycobacterium
bovis BCG (Danilchanka et al., 2015). CpnT seems to be under positive selection in clin-
ical M. tuberculosis isolates, demonstrated by the overrepresentation of non-synonymous
mutations in the gene encoding CpnT (Rv3903c). However, the role of CpnT in mediating
drug susceptibility to hydrophilic antibiotic compounds in M. tuberculosis needs further
investigation, as CpnT deletion mutants do not demonstrate drug resistance phenotypes
in vitro. However, the studies confirm the presence of porins in the outer membrane of
M. tuberculosis and their role in uptake of small hydrophilic compounds. Furthermore,
the physical organization of the cell wall lipids is believed to limit the membrane’s flu-
idity. A recent study (Rodriguez-Rivera et al., 2017) assessed the membrane fluidity in
live cells of M. smegmatis and other actinobacteria by measuring the reorganisation of
fluorescein-labelled therealose analogs by mycolyltransferases. The study demonstrated
that, compared to other actinobacteria, M. smegmatis has the lowest membrane fluidity.
This is thought to be a function of mycolic acid structure (length & presence of func-
tional groups). Interestingly, exposure of M. smegmatis to sub-inhibitory concentrations
of ethambutol increases the membrane’s fluidity and diffusion of compounds across the
cell envelope. This offers the possibility for novel drug combination therapies, as the re-
duction of the membrane fluidity using ethambutol can render M. tuberculosis susceptible
against drug classes it is normally resistant against (Abate et al., 1997; Bosne-David,
2000).
The peculiar characteristics of the mycobacterial cell envelope hinder the diffusion of
hydrophobic molecules including members of several antibiotics belonging to the classes
of macrolides, rifamycins, tetracyclines and fluoroquinolones (Brennan et al., 1995). How-
ever, it does appear that the rate of diffusion is a function of molecule hydrophobicity
to a certain extent, with hydrophobic molecules diffusing more readily through the my-
cobacterial cell envelope (Liu et al., 1999; Rastogi et al., 1990). The hypothesis that
the cell envelope lipids are a major factor in the intrinsic resistance of mycobacteria to
many hydrophobic antibiotics is further substantiated by studies performed with mutants
defective in lipid synthesis, which are susceptible to drugs that the corresponding wild
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type strain is resistant against (Liu et al., 1999). A recent study modelled the permeation
of compounds through the mycobacterial cell wall and demonstrated that lipophilicity
is an important but not exclusive factor of compound permeability (Janardhan et al.,
2016).
3.4.2. Drug inactivation by M. tuberculosis
After penetrating the cell wall as an initial defence layer, antibiotics may be cleaved
enzymatically to render them ineffective. One of the most prominent examples is the
enzymatic degradation of β-lactam antibiotics by β-lactamases, which hydrolyse the β-
lactam ring of the antibiotics. Early studies involving penicillin demonstrated that M.
tuberculosis is intrinsically resistant to this class of antibiotics (Abraham et al., 1941).
The genome of M. tuberculosis encodes a single class A β-lactamase termed BlaC thought
to localize to the periplasmatic space, either anchored in the outer leaflet of the plasma
membrane as a lipoprotein or unbound. The M. tuberculosis β-lactamase shows broad
substrate specificity (including carbapenems), albeit with varying affinities, and is consid-
ered an extended-spectrum β-lactamase. BlaC is irreversibly inhibited by the β-lactamase
inhibitor clavulanate (Wang et al., 2006; Hugonnet et al., 2007). Due to the increasing
numbers of cases caused by MDR/XDR M. tuberculosis strains, there has been a re-
newed interest in the use of β-lactam antibiotics in the treatment of TB. An early, small
study reported no beneficial effect of including an amoxicillin/clavulanate combination
in a salvage regimen (a regimen of last resort with unproven efficacy) to treat patients
infected with MDR M. tuberculosis strains (Yew et al., 1995). Since then, several in vitro
(Chambers et al., 1995; Hugonnet et al., 2009) and in vivo studies (Payen et al., 2012; De
Lorenzo et al., 2013) reported encouraging results on treatment outcomes with various
regimens by including β-lactam antibiotics with clavulanate. However, some MDR/XDR
M. tuberculosis isolates still appear to be resistant to mereponem/clavulanate or amox-
cicillin/clavulanate without harboring any mutations that could explain the observed
variability in susceptibility to these drugs (Cohen et al., 2016). The true value of β-
lactam antibiotics for the treatment of drug-resistant M. tuberculosis variants still needs
further assessment. Given the positive results in diverse studies, the demonstrated safety
profile of β-lactam antibiotics/β-lactamase inhibitors and the limited treatment options
for MDR/XDR TB, warrants further investigation into treatment regimens including this
class of antibiotics.
Apart from drug cleavage, antibiotics may be inactivated by modification, e.g. by
methylation or acetylation. To date, the best described mechanism of drug inactiva-
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tion by chemical modification in M. tuberculosis is the acetylation of various aminogly-
coside/cyclic peptide antibiotics used for the treatment of MDR TB by the enhanced
intracellular survival protein (Eis). Eis has been demonstrated to acetylate and inacti-
vate the clinically relevant second-line injectable aminoglycoside antibiotic kanamycin A
(Zaunbrecher et al., 2009), as well as the cyclic peptide antibiotic capreomycin (Houghton
et al., 2013). Several promotor mutations identified in clinicalM. tuberculosis isolates lead
to overexpression of Eis, which in turn confers low-level resistance against kanamycin A
but not amikacin (Zaunbrecher et al., 2009; Kambli et al., 2016). It is not clear if Eis over-
expression alone leads to clinically relevant levels of capreomycin resistance (Kambli et al.,
2016). Overexpression of Eis therefore might serve as a stepping stone for the evolution
of high-level aminoglycoside/cyclic peptide resistance. Recently, a novel mechanism of
drug inactivation was discovered in M. tuberculosis. The pyrido-benzimidazole compound
“14” was described as having potent bactericidal activity against aerobically growing M.
tuberculosis (Warrier et al., 2015). Compound 14 may be N-methylated by a previously
unknown methyltransferase encoded by the gene Rv0560c. The methylated compound 14
is unable to inhibit its target, the decaprenylphosphoryl-β-D-ribose 2-oxidase (DprE1),
which is involved in arabinogalactan synthesis (Warrier et al., 2016). Although this is a
novel mechanism of drug resistance in M. tuberculosis, and in bacteria in general, it has
no known clinical relevance to date.
3.4.3. Enzymatic drug target modification
Many antibiotics in use are natural products produced by bacteria, which requires the
producing bacteria to be resistant to these compounds; some of the mechanisms used by
these bacteria are conserved in mycobacteria. Streptomyces spp. produce diverse classes
of antibiotics, e.g. macrolides, lincosamides and streptogramins. These antibiotics inhibit
the bacterial ribosome by binding to the 50S ribosomal subunit. Streptomyces spp. are
resistant to these antibiotics by expressing methyltransferases which mono- or dimethylate
the adenosine residue 2058 (Escherichia coli notation) of the 23S rRNA, preventing the
aforementioned drugs from binding to the ribosome and inhibiting translation. The M.
tuberculosis genome encodes the methyltransferase Erm(37), a homolog of Erm methyl-
transferases found in many actinomycetes. However, the substrate specificity of Erm(37)
differs from its homologues – Erm(37) is able to monomethylate residues 2057-2059 of
the 23S rRNA, instead of only residue 2058. Monomethylation of positions 2057-2059
confers resistance to various macrolide antibiotics (Madsen et al., 2005; Buriánková et al.,
2004).
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3.4.4. Drug efflux in M. tuberculosis
Efflux systems are important constituents of bacterial and eukaryotic physiology. Multiple
reviews have been published (Silva et al., 2011; Louw et al., 2009; Anthony Malinga et
al., 2016; Szumowski et al., 2012) focusing on efflux systems in M. tuberculosis ; the main
points are briefly summarised here. Early comparative studies revealed that the genome
of M. tuberculosis encodes a multitude of different putative efflux systems, belonging
to the classes of ATP-binding cassette, major facilitator super-family, small multidrug-
resistance, multidrug & toxic-compound extrusion systems and resistance-nodulation-cell
division (Paulsen et al., 2001).
The relevance of drug efflux for generating clinically relevant drug resistance in M.
tuberculosis is controversial but has gained more attention in recent years. The observation
that about 30 % of isoniazid (Louw et al., 2009) and 3 % of rifampicin (Telenti et al.,
1993) resistant clinicalM. tuberculosis isolates do not show any known resistance mutation
might be explained by drug efflux. However, this unexplained resistance is potentially
confounded by the fact that not all mutational targets of drug resistance are known. For
certain antibiotics e.g. isoniazid, an array of different resistance mechanisms is already
known (Vilchèze et al., 2014). On the other hand, resistance to rifampicin is thought
only to be conferred by mutations in the gene encoding one constituent of the drug
target (further discussed below), making the contribution of efflux pumps to unexplained
resistance phenotypes more likely.
Efflux pumps exhibit high levels of substrate promiscuity and are able to extrude a
multitude of structurally unrelated compounds. Furthermore, efflux systems have been
shown to be essential in M. tuberculosis for intracellular growth in macrophages (Lamich-
hane et al., 2005). Mycobacterial efflux pumps are able to extrude nearly all antitu-
berculous drugs, including streptomycin, rifampicin, isoniazid, clofazimine, bedaquiline,
fluoroquinolones and ethambutol (Anthony Malinga et al., 2016). Expression of efflux
pumps can be viewed as a plastic trait, meaning that expression levels are modified via
non-mutational processes upon changes in the environment. We can therefore say that ef-
flux pumps are induced or upregulated when a specific environmental cue (e.g. antibiotics
or the intracellular environment of a macrophage) is present. The term “overexpression”
should only be used for mutants where expression levels exceed the reaction norm (Box
3.1) of the wild type strains. To our knowledge, there have not been any studies system-
atically investigating the reaction norm of efflux pumps in M. tuberculosis.
It has been demonstrated in model systems of M. tuberculosis that efflux pumps are in-
duced upon infection of macrophages, which coincides with increased minimal inhibitory
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concentrations for isoniazid (Adams et al., 2011). A subset of the strains were resistant
to higher levels of isoniazid at the peak serum concentrations (Park et al., 2016). The
expression of the efflux systems persists even after the mycobacterial cells have been re-
leased from the macrophages. However, in accordance with the concept of efflux pumps
as a plastic trait, not all bacterial cells upregulate the expression of efflux systems (Adams
et al., 2011; Gupta et al., 2010). Several antituberculous drugs have been demonstrated to
induce the expression of efflux pump genes, but there is considerable variability between
strains and no general pattern of efflux pump expression was recognizable (Gupta et al.,
2010). Furthermore, MDR M. tuberculosis isolates have been shown to constitutively
express genes involved in drug efflux (Li et al., 2015). Although there are reports on
the upregulation of efflux systems generating minimal inhibitory concentrations slightly
beyond the epidemiological cutoff (Box 3.1), the clinical relevance of efflux pumps is not
clear and warrants more investigation (Adams et al., 2011). The majority of drug-resistant
strains harbour chromosomal mutations linked to drug resistance (further discussed be-
low). However, there are examples of clinically relevant levels of resistance conferred by
overexpression of efflux pumps. Mutations in the transcriptional repressor MmpR lead to
overexpression of the multisubstrate efflux pump Mmpl5 (Milano et al., 2009), which co-
incides with cross-resistance to clofazimine and the new antituberculous drug bedaquiline
(Bloemberg et al., 2015; Hartkoorn et al., 2014). As Mmpl5 is also involved in isoni-
azid extrusion, MmpR mutants are likely also to be resistant to isoniazid (Milano et al.,
2009).
However, efflux systems may act as a stepping stone for the evolution of high-level resis-
tance, as convincingly demonstrated by in vitro studies (Machado et al., 2012), (Schmal-
stieg et al., 2012). As efflux pumps seem to be essential for macrophage infection (Lamich-
hane et al., 2005), efflux pump inhibitors might be used to inhibit bacterial growth and
lower the MICs for certain drugs (Pule et al., 2016).
3.5. Acquired drug resistance in M. tuberculosis
Apart from the intrinsic resistance mechanisms mentioned above, the majority of clinically
relevant drug resistance in M. tuberculosis is conferred by chromosomal mutations. These
chromosomal mutations confer drug resistance via a large array of different mechanisms
and may confer different levels of resistance (Figure 3.1). The most common targets of
chromosomal mutations conferring drug resistance are summarised in Table 3.1. Depend-
ing on the antibiotic in question, there may be multiple mechanisms of resistance.
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Figure 3.1.: Levels of drug resistance conferred by different mechanisms. The red X indicates
a chromosomal mutation. a) Low level resistance due to induction of efflux pumps. Depic-
tion of efflux pumps is omitted later stages for clarity b) Low level resistance due to target
overexpression caused by chromosomal mutation. c) High level resistance due to drug target
modification conferred by chromosomal mutation. d) High level resistance due to overex-
pression & modification of drug target conferred by independent chromosomal mutations.
3.5.1. Drug target alteration
The most common mechanism of drug resistance in M. tuberculosis is drug target alter-
ation. Interactions of drug and drug target moieties are highly specific. Changes in the
drug-drug target interaction sites may reduce or completely abolish drug binding and
therefore confer resistance to the drug in question. Nonsynonymous mutations in drug
target encoding gene(s) (Table 3.1) or nucleotide substitutions in the operon encoding the
ribosomal RNA are frequently observed to confer drug resistance in M. tuberculosis as
in the case of resistance against rifamycins, isoniazid, fluoroquinolones, aminoglycosides,
cyclic peptides, para-aminosalicylic acid and oxazolidinones (e.g. linezolid). For example,
mutations in the active site of the DNA-dependent RNA polymerase, corresponding to
the 81 bp region known as the Rifampicin Resistance Determining Region (RRDR), con-
fer resistance to rifampicin, by decreasing the affinity of rifampicin for target (Campbell
et al., 2001). Antibiotics target essential cellular functions and the drug targets perform-
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ing these functions are highly conserved. The highly conserved nature of the drug targets
limits the mutational target size (Box 3.1) as the resistance mutation has to accomplish
two things: first it has to prevent the antibiotic from inhibiting the target and secondly
it must ensure that the essential function of the drug target can still be performed. In
many but not all cases this leads to a reduction in the bacterial cell’s fitness in absence
of the drug.
3.5.2. Abrogation of prodrug activation
Several antimycobacterial drugs are prodrugs, and abrogation of the drug activating mech-
anisms leads to resistance as in the case of the first-line drugs isoniazid and pyrazinamide,
the second-line drugs ethionamide and para-aminosalicylic acid, as well as the two new
nitroimidazole drug candidates delamanid and pretonamid. In certain cases, the prodrug
activating enzyme is not essential for mycobacterial growth and survival (e.g. pncA/ddn
– Table 3.1). The target size for drug resistance-conferring chromosomal mutations is
therefore large – many point mutations, insertions/deletions, insertion of mobile genetic
elements etc. will cause disruption of the prodrug-activating gene product without com-
promising bacterial survival. Furthermore, mutations in the promoter of the gene might
lead to lower transcript and therefore lower levels of the enzyme activating the prodrug.
Lower levels of the prodrug activating enzyme will then in turn lead to higher minimal
inhibitory concentrations for the drug in question. In pyrazinamide resistant M. tuber-
culosis strains, we observe a wide array of different mutations in the gene pncA which
encodes the enzyme metabolizing pyrazinamide to its active form pyrazinoic acid. The
mutational target size for delamanid/pretomanid resistance is considerably larger as mul-
tiple enzymes and cofactors are involved in the metabolism of prodrugs to their active
forms. This suggests that resistance to the latter two drugs may evolve swiftly due to
the large mutational target size (Box 3.1). On the other hand, the gene katG, encoding a
catalase/peroxidase involved in the activation of isoniazid is required for robust replication
of M. tuberculosis in macrophages (Manca et al., 1999). The mutational target size for
isoniazid resistance is small, compared to pyrazinamide or delamanid/pretomanid. The
resistance conferring mutation in katG must retain the (in vivo) essential function of the
enzyme (catalase/peroxidase – detoxification) as well as prevent the activation of isoni-
azid. Most clinicalM. tuberculosis isolates harbour the point mutation KatG S315T which
retains most catalase/peroxidase functions as well as conferring high level isoniazid resis-
tance (Pym et al., 2002). On the other hand, KatG is not essential for in vitro replication
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– this greatly enlarges the mutational target size for in vitro resistance, as any mutation
disrupting the function of KatG will lead to resistance (Bergval et al., 2009).
3.5.3. Overexpression of drug targets
Overexpression of the drug target may overcome the inhibition by the drug in question
due to an overabundance of the target. Mutations in transcriptional repressors or the
promoter of the drug target may cause the overexpression of the drug target as in the
case of isoniazid, ethambutol and cycloserine. Drug target overexpression confers low level
resistance (e.g. to isoniazid or cycloserine), which usually can be overcome by increasing
the dosing of drugs administered. Drugs are administered at fixed doses, often adjusted
for patient weight/age. This is generally done to achieve the maximum effectiveness of
the drug whilst minimizing adverse effects of administered drugs. As certain antibiotics
(e.g. cycloserine (Desjardins et al., 2016a)) show dramatic adverse effects, the dose given
to patients is reduced as much as possible, which means there is little room for increasing
the drug doses to overcome resistance due to drug target overexpression. Overexpression
of drug targets may serve as a stepping stone to high level resistance, which is conferred
either by drug target alteration or abrogation of prodrug activation (Figure 3.1).
3.6. Evolution of drug resistance in M. tuberculosis
The evolution of drug-resistant M. tuberculosis variants has generally been attributed
to inadequate implementation of control measures, interrupted drug supply, low quality
drugs, and patient non-adherence. However, it is increasingly evident that these factors
alone are insufficient to explain the evolution of drug resistance in TB, as resistant M.
tuberculosis strains evolve in well-functioning health systems and under strict treatment
adherence (Calver et al., 2010; Caminero, 2008). Pathogen and host determinants are
increasingly recognized to influence the evolution of drug resistance. For instance, the
emerging field of pharmacogenomics has demonstrated that the current dosage regimen
for TB treatment fails to generate sterilizing concentrations of certain antituberculous
drugs in all patients and may contribute to treatment failure, as well as facilitate the
evolution of drug resistance (Gumbo, 2010; Swaminathan et al., 2012). Furthermore,
recent studies have demonstrated that there is considerable variability in drug penetration
into TB lesions, generating spatial and temporal variation in drug concentrations within
the infected lung (Prideaux et al., 2015). It is well-established that sub-inhibitory drug
concentrations facilitate the evolution of drug resistance (Andersson et al., 2014; Gillespie
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et al., 2005; Gullberg et al., 2011), and heterogeneity between and within patients may
mean that some TB cases are being unwittingly exposed to sub-inhibitory treatment
regimes.
Although the genus Mycobacterium in general and M. tuberculosis in particular show
low genetic diversity compared to other bacteria (Achtman, 2008), the standing genetic
diversity (Box 3.1) exhibited byM. tuberculosis translates into phenotypic diversity. There
are seven extant M. tuberculosis lineages, which demonstrate specific phylogeographic
patterns. Lineages 5 and 6 are restricted to West Africa and lineage 7 to the Horn of
Africa. Lineage 1 is found along the rim of the Indian Ocean and lineage 3 is predominantly
found in East Africa and South Asia. Lineage 4 and to a lesser extent lineage 2 are globally
distributed (Borrell et al., 2011; Coscolla et al., 2014). Lineage 2 and lineage 4 have been
frequently associated with drug resistance (Cohen et al., 2015; Fenner et al., 2012).
To better understand the de novo evolution of drug resistance, it is helpful to separate
the different processes involved. The rate of evolution of resistance (Ford et al., 2013)
and the effect of drug resistance on bacterial life history traits like growth rate/yield may
differ as a function of the strain genetic background. Drug resistance is often associated
with reduction in bacterial fitness (Box 3.1) in the absence of the drug. This reduction is,
however, not universal and can vary as a function of the genetic background (Gagneux et
al., 2006b). The fitness cost of drug resistance may be ameliorated by secondary, so-called
compensatory mutations, which do not contribute to resistance on their own (Casali et
al., 2012; Comas et al., 2012; Hughes et al., 2013; Vos et al., 2013). Furthermore, several
drug resistance conferring mutations present in a single strain might interact epistatically
(Box 3.1) and influence bacterial fitness (Borrell et al., 2013; Gagneux et al., 2006b). This
means that the strain genetic background, compensatory mutations and the presence of
multiple resistance mutations may interact to influence the fitness of drug-resistant M.
tuberculosis strains (Figure 3.3).
The spread and maintenance of resistant variants in the population not only depends
on the effect of drug resistance on the bacterial life history traits, but is also strongly
dependent on the pathogen’s population structure and effective population size, as well
as genetic drift (Box 3.1). In the case ofM. tuberculosis, genetic drift is thought to strongly
influence the genetic diversity of the organism, as the effective population size is believed
to be small and subject to large bottlenecks during patient-to-patient transmission (Box
3.1) (Hershberg et al., 2008).
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































24 3. Review: Antimicrobial resistance in MTB
3.7. De novo evolution of drug resistance
There are three important factors influencing the de novo evolution of drug resistance:
the population size, as it relates to the number of binary fission events the population has
undergone, the mutation rate, and the mutational target size (Box 3.1). Together, these
factors determine the rate of resistance acquisition. The strain genetic background may
influence any of these parameters. It is, however, not trivial to determine the contribution
of each of the factors, as they are either difficult to study in vivo or are not independent
of each other.
3.7.1. Population size
In a series of iconic experiments, Luria and Delbrück demonstrated that, for simple traits
(e.g. most bacteriophage/antibiotic resistance), bacterial populations which undergo a
sufficient number of doubling events inevitably harbour resistant variants, following what
is now called a Luria-Delbrück distribution (Luria et al., 1943). The larger the popula-
tion, the more cell division events the population experienced, and therefore the larger
probability for a drug resistance mutation to arise. Furthermore, if a resistance conferring
mutation evolves early during population expansion, the vast majority of the population
will be resistant to a given drug even before treatment onset. We unfortunately do not
have good estimates of the number of M. tuberculosis cells present in human lungs during
infection. The number of bacteria present in a single lesion is estimated to be in the order
of 108 bacterial cells per lesion (Shimao, 1987), although it is not clear what the basis of
this estimate is. The best estimates of viable M. tuberculosis cells were obtained from the
lungs of cynomolgus macaques (Macaca fasicularis) infected with M. tuberculosis. The
disease presentation in macaques resembles that observed in humans. The study demon-
strated that a macaque lung contains anything between ≈ 105 and 5 x 108 cells, depending
on the individual macaque (Lin et al., 2009). However, most monkeys did not develop
cavitary disease. It is believed that M. tuberculosis may reach very high cell densities
when replicating on the interior surface of open (i.e. with access to the airways) lung cav-
ities, but the exact cell numbers have, to our knowledge, never been assessed in humans.
There is evidence that drug resistant M. tuberculosis variants are predominantly found
where cell densities are high, i.e. at the interior of cavitating granulomas (Kaplan et al.,
2003a). It is exceedingly difficult to obtain reliable estimates of bacterial cell numbers in
the lungs of TB patients. Recent studies have highlighted that the disease presentation
in the lung is far more dynamic as previously believed (reviewed in Lenaerts, Barry and
Dartois 2015). The number of granuloma cannot directly be used to estimate the number
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of bacterial cells present in a patient lung, as there is a large diversity of microenviron-
ments within granuloma and not all environments allow bacterial replication. However, if
we solely focus on cavitating granuloma, we might be able to use disease severity, i.e. the
number and extent of cavitations as a very rough proxy for population size. The fewer
cavities present in a patient’s lung, the smaller the population size of tubercle bacilli.
There are reports of differences between lineages in terms of disease severity (reviewed
in (Coscolla et al., 2010; Coscolla et al., 2014)). Lineages 2 and 4, especially the so-
called “Beijing” sublineage of lineage 2, have been associated with more severe disease
presentation compared to other lineages. The M. tuberculosis lineages 2 and 4 are also
associated with drug resistance (Casali et al., 2014; Cohen et al., 2015; Ford et al., 2013;
Merker et al., 2015; Mokrousov et al., 2012; Niemann et al., 2010; Pardini et al., 2009).
Differences in bacterial population sizes between lineages might therefore contribute to
the differential association of specific lineages with drug resistance.
In general, we can say that the probability of evolving resistance is dependent on the
number of binary fission events. M. tuberculosis is an intracellular pathogen and its pri-
mary niche is the macrophage. Although M. tuberculosis is able to survive and replicate
inside macrophages, the tubercle bacteria seem to be inhibited in growth when the bac-
terial numbers are small (Welin et al., 2011). It is not clear if this is due to killing or
growth inhibition by the macrophage. However, there is evidence that the innate immune
system is able to clear M. tuberculosis infections before the onset of adaptive immunity
(Verrall et al., 2014). It is therefore likely that a proportion of the tubercle bacilli are
killed by the macrophage. This means that a M. tuberculosis population of a given size
has likely undergone more binary fission events than expected from exponential growth,
as the immune system continuously removes bacterial cells from the population. As killing
of tubercle bacilli by macrophages is likely to occur stochastically, one can view this as
a form of genetic drift (Box 3.1), potentially slowing the rate of drug resistance evolu-
tion. A recent study demonstrated that there are differences in the replication potential
between different M. tuberculosis lineages – lineage 2 and 4 being proficient in replicating
in macrophages, and strains belonging to lineage 3 and Mycobacterium africanum less
so (Reiling et al., 2013). However, it is not clear if the high cell densities observed in
macrophages infected with M.tuberculosis strains belonging to lineage 2 and 4 are due
to better survival in the macrophage or faster growth or both. In conclusion, it is not
entirely clear if there is substantial variability in terms of number of binary fission events
between lineages of M.tuberculosis The recent adaptation of a fluorescence dilution assay
to M.tuberculosis offers the exciting possibility to assess the number of doubling events
and the extent of cell death experienced by mycobacterial bacilli during macrophage in-
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fection (Helaine et al., 2016). Measuring growth properties of different M.tuberculosis
lineages in an ex vivo system will help to clarify if there are differences between lineages
concerning the number of binary fission events and therefore the rate of drug resistance
evolution.
3.7.2. Mutation rates
The mutation rate is thought to be largely defined by the replication fidelity of the
bacterial DNA polymerases. The basal mutation rate of M.tuberculosis is difficult to
study as the long generation time makes mutation accumulation experiments unfeasi-
ble. A workaround is expressing the M.tuberculosis DnaE1 DNA polymerase heterolo-
gously in M.smegmatis. The generation time of M. smegmatis is much lower compared
to M.tuberculosis, but it has the drawback that the effect of the genetic background (Box
3.1) on mutation rates cannot be taken into account. Using the heterologeous DnaE1
expression approach, the mutation rate has been determined to be 4.52 x 10-10 (2.95-7.35
x 10-10 95 % confidence interval) per bp and generation, which is on the lower end of the
spectrum compared to other bacteria (Rock et al., 2015). Other studies have assessed
the mutation rate using whole genome sequencing (Ford et al., 2011). However, there
are potentially many more factors influencing the mutation rate, including the intracel-
lular environment of macrophages which are rich in reactive oxygen and nitrogen species,
expression of error-prone DNA polymerases (DnaE2) due to the stressful macrophage
environment, enzymes involved in repair – replication – recombination, existing drug re-
sistance mutations, exposure to UV radiation and/or desiccation during aerosolisation
(McGrath et al., 2014).
3.7.3. Mutational target size
Given a mutation rate, the number of potential sites which may be mutated to confer
drug resistance is an important factor involved in determining the rate of drug resistance
evolution. As mentioned earlier, the mutational target size varies depending on resistance
mechanism (Box 3.1). The mutational target size for prodrugs activated by nonessential
enzymes is much larger compared to the target sizes for mutational drug target alteration.
The mutational target size for drug target alteration is in the range of 81 bp in the
gene rpoB for rifampicin resistance (Musser, 1995) and 117 bp in the gene gyrA for
fluoroquinolone resistance (Maruri et al., 2012). The majority of resistance-conferring
mutations are found in these regions in clinico (Sandgren et al., 2009). Furthermore, the
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number of mutations conferring drug resistance is dependent on the resistance level in
question. Drug resistance mutations differ in the level of resistance they confer. There is
an inverse relationship between the drug resistance level that mutations confer and the
mutational target size – the higher the selective concentration, the smaller the target size,
i.e. there are fewer mutations conferring high-level than low level resistance (Ford et al.,
2013). Drug resistance mutations interact epistatically with the genetic background of
a strain – a given drug resistance mutation may have different trait effects (Box 3.1) in
different genetic backgrounds. This may lead to a reduction in the mutational target size
in the broader sense when the interaction of a resistance mutation with the strain genetic
background results in a detrimental trait effect in absence of the selective agent.
3.7.4. Rate of drug resistance acquisition
The rate of drug resistance acquisition is defined by the mutation rate and the mutational
target size in the broader sense and may be calculated by Luria-Delbrück fluctuation
assays (Luria et al., 1943). In the past, there has been considerable debate on the influence
of the genetic background on the rate of resistance acquisition. As mentioned previously,
lineage 2 and lineage 4 have been disproportionately associated with drug resistance. It
was found previously that M.tuberculosis strains belonging to lineage 2 carry mutations
in genes involved in DNA replication, repair and recombination (Mestre et al., 2011),
potentially elevating mutation rates. However, this would imply that lineage 2 in general
should demonstrate greater average genetic diversity compared to other lineages, which
does not appear to be the case (Coscolla et al., 2014). Multiple studies have focused on
the rate of resistance acquisition in M.tuberculosis. The rate of resistance acquisition is
influenced by the basal mutation rate and the mutational target size in the broader sense.
Some studies report differences in resistance acquisition rates between lineages, where
strains from the Beijing sublineage of lineage 2 show higher rates of resistance acquisition
compared to other lineages (Ford et al., 2013; Steenwinkel et al., 2012), others reported
similar rates between lineages (Werngren et al., 2003). If there are differences in the rate
of resistance acquisition between lineages, this could indicate that the mutational target
size in the broader sense is different between lineages. Even if the results are discrepant,
we are still missing a large part of the picture. Due to the labour-intensive nature of
conducting Luria-Delbrück fluctuation assays with M. tuberculosis, all studies have so far
focused on the rate of acquisition of resistance to rifampicin; there are no data available on
differences in drug resistance acquisition rates between lineages for other drugs commonly
in use to treat TB.
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3.7.5. De novo evolution of drug resistance & treatment with
drug combinations
TB cases caused by drug-susceptibleM.tuberculosis strains are treated with a combination
of 4 drugs to limit the evolution of drug resistance, as a strain would need to acquire at
least 4 independent resistance mutations in order to achieve high level resistance, which
is theoretically unlikely to happen if the M.tuberculosis bacilli carry no pre-existing resis-
tance mutations and are exposed to all drugs at the same time. However, in some patients
the tubercle bacilli evolve drug resistance despite strict treatment adherence (Calver et
al., 2010). This may be caused by functional monotherapy and/or subinhibitory drug
concentrations as discussed above, known to facilitate the evolution of drug resistance
(Andersson et al., 2014; Gillespie et al., 2005). Suboptimal drug concentrations can arise
due to the differential potential of certain drugs to penetrate bacteria containing lesions
in the human lung. For instance, pyrazinamide and rifampicin have been demonstrated
to be able to diffuse and accumulate in the hypoxic and acidic granuloma, whereas the
other first-line drugs do not accumulate in these structures (Prideaux et al., 2015). These
processes are likely to generate spatial and temporal variation in drug concentrations, fa-
cilitating the evolution of drug resistance (Moreno-Gamez et al., 2015). Drug penetration
into TB lesions is dependent on multiple factors including lipophilicity and solubility. De-
tailed knowledge of the chemical properties needed for effective distribution throughout
all M. tuberculosis containing lesions will aid the design of novel, more effective antitu-
berculous drug regimens (Dartois, 2014).
3.7.6. Drug resistance levels & the strain genetic background
Apart from the rate of resistance evolution, the genetic background may influence the level
of resistance conferred by a drug resistance mutation. In the case of isoniazid resistance,
it has been shown that the level of resistance conferred by different mutations varies
with the genetic background of M.tuberculosis, whereby the isoniazid resistance mutation
KatG S315T conferred lower levels of resistance in strains belonging to lineage 1 compared
to lineage 2, 3, and 4 (Fenner et al., 2012). This phenomenon could also contribute to
different mutational target sizes in the broader sense in different genetic backgrounds (Ford
et al., 2013). Depending on the concentration of the drug, fewer resistance mutations
might be available to certain lineages, which in turn would lower the rate of resistance
evolution.
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3.7.7. Fitness of drug-resistant M. tuberculosis strains
Drug resistance was long believed to be universally associated with a reduction in the
drug-resistant organism’s fitness in the absence of antibiotics (Box 3.1). In the case of
mycobacteria this dogma was established by early studies performed with isoniazid resis-
tant M.tuberculosis variants. These studies demonstrated a marked reduction in virulence
of certain, but not all, isoniazid resistant strains in guinea pigs and mice (Barnett et al.,
1953; Middlebrook et al., 1953). The observation that most drug resistance is associ-
ated with a reduction in fitness is further corroborated by studies performed in other
pathogenic microorganisms (Melnyk et al., 2015). Early mathematical models predicted
that MDR-TB would remain a localized public health problem (Dye et al., 2001; Dye et
al., 2002). Hence, initially, the WHO recommended focusing on Directly Observed Ther-
apy Short Course (DOTS) for patients with drug-susceptible TB and against treating
patients infected with MDR M.tuberculosis strains, as treating these patients is exceed-
ingly expensive and the MDR strains were not believed to transmit enough to establish
a sustainable infection chain (Espinal et al., 2005).
Mathematical models predict that the probability of a drug-resistant strain spreading
in the absence of antibiotic pressure is largely dependent on the resistant variant’s re-
productive fitness (Blower et al., 2004; Cohen et al., 2004; Knight et al., 2015; Luciani
et al., 2009). The ultimate measure of fitness would be the effective reproductive num-
ber R (Box 3.1), which measures the average number of secondary cases generated per
infected individual in a population of susceptible and resistant hosts. The effective re-
productive number R is a high level composite measure comprising all aspects concerning
transmission, including pathogen, host and environmental factors. Changes in R due to
drug resistance mutations can lead to changes in allele frequencies over time. However,
assessing R in vivo requires prospective cohort studies which are labour-intensive and ex-
pensive to conduct. Although cohort studies allow assessment of epidemiological factors
associated with transmission, they often suffer from small sample sizes and are restricted
to a single setting relevant for transmission (e.g. households).
To better study the impact of drug resistance on the fitness (i.e. R) of M. tuberculosis,
it is helpful to separate the effect of drug resistance on bacterial life history traits – the
trait effect (Box 3.1), from effects of drug resistance on allele frequencies in the popula-
tion – the selective effect (Hall et al., 2015). Trait effects of drug resistance mutations
may be assessed by measuring life history traits like growth rate/yield of drug-resistant
M. tuberculosis variants in vitro. Drug resistance mutations may have diverse pleiotropic
effect on bacterial physiology resulting in a reduced in vitro growth (Figure 3.2). How-
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ever, this reduction in growth yield/rates is not universal; it is strongly dependent on the
mechanism of resistance, as well as the specific mutation in question. Furthermore, there
is a strong effect of the strain genetic background on the fitness costs. Fitness costs may
be ameliorated by secondary, so-called compensatory mutations, which do not contribute
to drug resistance on their own. Compensatory mutations may lead to the retention of
drug-resistant M. tuberculosis variants in the population in absence of selective pressure
due to the drug. Epistatic interactions between the genetic background and the resistance
conferring mutations seem to be pervasive and an important determinant in shaping the
population biology of drug-resistant M. tuberculosis variants. Measuring in vitro fitness
of drug resistance mutations as a proxy for in vivo fitness has been criticized for not
capturing the complex dynamics involving nutrient limitation, activity of the immune
system, host genetics and comorbidities (Björkman et al., 2000). However, the frequency
of resistance alleles in the population correlates well with the in vitro fitness of the strains
carrying mutations for rifampicin, fluoroquinolone and aminoglycoside resistance in labo-
ratory adapted, as well as in clinical M. tuberculosis isolates (Borrell et al., 2013; Böttger
et al., 2008; Böttger et al., 1998; Gagneux et al., 2006b; Sander et al., 2002). However,
all in vitro fitness cost assessments are based on the ability of the M. tuberculosis strain
being able to readily grow in artificial growth media. It is well established that not all
bacilli present in patient sputum will demonstrate in vitro growth. This is problematic
as our frequency estimates for drug resistance alleles are based on culturing M. tubercu-
losis bacilli from patient sputum, isolating genetic material and subsequent sequencing.
However, there is no a priori reason to assume that the frequencies of drug resistance mu-
tations are different in the populations of culturable and unculturable bacilli. Culture-free
metagenomic approaches will offer a less biased view on the frequencies of drug resistance
mutations present in the lungs (sputa) of TB patients (Koch et al., 2014).
3.7.8. In vitro fitness of drug-resistant M. tuberculosis strains
There are two methods for assessing in vitro fitness of resistant variants: growth rate
measurements and competition assays. Growth rate assessment focuses on the replication
rate of a strain during exponential growth in absence of any drug pressure. In competition
assays, the resistant variant is co-cultured with the susceptible wild type strain for one or
several bacterial growth cycles in absence of the drug. At the endpoint of the experiment,
the ratio of resistant to susceptible variants is assessed. Both methods allow calculation
of selection coefficients. The advantage of competition assays is that they take growth
yield as well as growth rate into account. Selection on growth rate occurs when there is
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no population structure and resources are freely available to all individuals. On the other
hand, growth yield is favoured in structured populations where resources are restricted and
efficiency in nutrient utilisation is favoured (Frank, 2010). Populations of M. tuberculosis
in human lungs have been thought of as highly structured, as observed by the concurrent
presence of strains carrying different resistance mutations in separate parts of the of the
infected lung (Kaplan et al., 2003a; Lieberman et al., 2016; Post et al., 2004).
Several studies have investigated the effect of drug resistance mutations on in vitro
fitness of M. tuberculosis or M. smegmatis either using competition assays or growth rate
assessments. These studies have focused on assessing the impact of rifampicin (Gagneux
et al., 2006b; Song et al., 2014), aminoglycoside (Freihofer et al., 2016; Sander et al., 2002)
and fluoroquinolone (Borrell et al., 2013) resistance on the bacterium’s fitness compared
to the susceptible ancestor in absence of the drug. We do not have reliable data on
isoniazid resistance as the in vitro resistance mechanism differs from that observed in
vivo (Bergval et al., 2009). However, there is reason to assume that there are no or very
low fitness costs of the most frequent isoniazid resistance mutation (KatG S315T), as M.
tuberculosis variants carrying this mutation transmit efficiently and are virulent in mice
(Doorn et al., 2006; Gagneux et al., 2006a; Pym et al., 2002; Soolingen et al., 2000).
For the same reasons we do not have reliable data on the fitness of clinical MDR/XDR
strains. We are restricted to measuring the fitness of such strains relative to each other –
rather than to their cognate drug-susceptible ancestor (Naidoo et al., 2014; Spies et al.,
2013).
Most rifampicin resistance mutations carry a significant fitness cost in M. tuberculosis
(Billington et al., 1999; Gagneux et al., 2006c; Koch et al., 2014; Kaplan et al., 2003b)
(Figure 3.2). However, there are some mutations (e.g. RpoB S450L – M. tuberculosis
notation (Andre et al., 2017)) which only cause a small defect in fitness. There seems to
be some influence of the genetic background on the cost of rifampicin resistance, whereby
lineage 2 experiences smaller reductions in fitness compared to lineage 4 (Gagneux et al.,
2006b). Interestingly, the fitness costs of rifampicin resistance is elevated under nutrient
restricted conditions (Song et al., 2014). Nutrient limitation is pervasive in the human
host, indicating that there will be strong selection against costly drug resistance muta-
tions. Fluoroquinolone resistance mutations show varying degrees of costs inM. smegmatis
(Borrell et al., 2013). Some mutations conferring fluoroquinolone resistance even show a
fitness benefit, but this could be an artefact of the in vitro assessment conditions. Most
aminoglycoside resistance is also costly. There are, however, also resistance mutations
which do not demonstrate any discernable fitness cost (Freihofer et al., 2016; Sander et
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Figure 3.2.: Fitness of drug resistant M. tuberculosis strains in absence of the drug. Solid
arrows indicate the trajectories of drug resistance. Dashed arrow indicates the unlikely
possibility of reversion. The red X indicates a chromosomal mutation a)Induction of efflux
pumps at no or minimal fitness cost. b) Large variation in fitness costs due to resistance
via chromosomal mutations – ranging from very low/no to lethal. The observed variation
may arise due to epistatic interactions of the strain genetic background and the resistance
mutation(s). c) Variation in fitness levels of strains harbouring secondary compensatory
mutations – ranging from comparable to wild type levels to slightly below.
al., 2002). The effect of the strain genetic background on the fitness cost of aminoglyco-
side resistance is yet to be determined. The in vitro fitness of MDR and especially XDR
M. tuberculosis strains is variable. Some strains demonstrate very low replication rates,
whilst others replicate at rates similar to drug-susceptible strains (Naidoo et al., 2014;
Spies et al., 2013). However, it is striking that combinations of low cost resistance muta-
tions rifampicin (RpoB S450L – M. tuberculosis notation) and isoniazid (KatG S315T) in
MDR/XDR strains are frequently observed in clinico. TB caused by XDR M. tuberculosis
strains is a rather new phenomenon. It is thought that most XDR M. tuberculosis isolates
arise due to de novo evolution rather than transmission (Casali et al., 2014; Gandhi et al.,
2006). The isolation of XDR M. tuberculosis strains with very low replication rates could
reflect the fact that selection has not yet removed the most unfit XDR strains from the
population. However, it is remarkable that there is a strong association of MDR/XDR
strains with lineages 2 and 4 (Casali et al., 2014; Cohen et al., 2015; Ford et al., 2013;
Merker et al., 2015; Mokrousov et al., 2012; Niemann et al., 2010; Pardini et al., 2009).
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This might indicate that strains belonging to these lineages experience lower fitness costs
due to drug resistance. On the other hand, lineages 2 and 4 are also the most widespread.
The association of these lineages with drug resistance could just be due to the large num-
bers of TB patients infected with strains from these lineages. To elucidate if the frequent
association of lineages 2 and 4 with drug resistance is due to lower fitness costs of drug
resistance experienced by these strains, we need detailed assessments of the population
structures of drug-resistant and susceptible M. tuberculosis strains over time.
Figure 3.3.: Pervasive epistatic interactions influencing the physiology and population biology
of drug-resistant M. tuberculosis strains. The effect of drug resistance mutations alone
or in combination, as well as the presence of compensatory mutations affect the fitness of
drug-resistant M. tuberculosis strains as a function of the strain genetic background.
3.7.9. Compensation of fitness costs
Fitness costs caused by drug resistance mutations may be ameliorated by secondary so-
called compensatory mutations (Figure 3.2). These mutations do not contribute to drug
resistance directly. Fitness cost compensation results from the epistatic interaction of the
compensatory mutation with the drug resistance mutation and the genetic background of
the strain (Figure 3.3, Box 3.1). Fitness cost compensation is poorly understood. Whole
genome sequencing studies have demonstrated that MDR and especially XDR strains
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tend to harbour a multitude of mutations (Merker et al., 2015; Zhang et al., 2013). A
high proportion of these mutations are thought to have functional consequences. As these
strains are resistant to many antibiotics, the reported mutations can be speculated to be
involved in compensation of fitness costs. To date, we know of three distinct mechanisms
involved in the compensation of fitness costs (Andersson et al., 2010). First, secondary
mutations in the genes encoding the drug target might restore or improve the mutated en-
zyme’s function to levels comparable to the wild type enzyme (Casali et al., 2012; Comas
et al., 2012; Hughes et al., 2013). To be classified as a putative compensatory muta-
tion, these mutations should only be found in resistant strains and never in susceptible
strains. However, only fitness measurements can confirm or refute the compensatory role
of the mutation. Second, overexpression of an enzyme which performs a similar function
to the drug target may compensate for the diminished or abolished function of the drug
target (Heym et al., 1997; Sherman et al., 1996). Third, non-mutational gene regulatory
responses may compensate for the fitness defect inflicted by the resistance mutation (Frei-
hofer et al., 2016). However, the latter case is a form of phenotypic plasticity and the term
“buffering” of fitness costs would be more appropriate than compensation. Compensatory
evolution has been demonstrated to occur very frequently for rifampicin resistance (Casali
et al., 2012; Comas et al., 2012; Hughes et al., 2013). Fitness costs of rifampicin resis-
tance due to mutations in the β’-subunit of DNA dependent RNA polymerase encoded
by RpoB can be compensated by mutations in rpoABC. The molecular basis of fitness
costs and their compensation in rifampicin-resistant M. tuberculosis strains is not well un-
derstood. However, studies performed with rifampicin-resistant Pseudomonas aeruginosa
have indicated that rifampicin resistance mutations in rpoB reduce the transcriptional
efficiency of the DNA-dependent RNA polymerase and may explain the observed fitness
costs. Compensatory mutations restored the transcriptional efficiency to wild type levels
in rifampicin-resistant strains (Qi et al., 2014). The connection between transcriptional
efficiency and in vitro growth rate (fitness cost) seems plausible in fast-growing bacteria
like P. aruginosa.
However, it remains to be demonstrated that fitness costs inflicted by mutations in
rpoB are caused by reduced transcriptional efficiency in slow-growing bacteria like M.
tuberculosis. Interestingly, the compensatory mutations are often found at the interface
between the different RNA polymerase subunits. More specifically, the compensatory
mutations home to positions in the vicinity of the active site and the RNA exit tunnel
(Song et al., 2014). Compiling data from several studies (Bloemberg et al., 2015; Casali
et al., 2014; Comas et al., 2012; Eldholm et al., 2015; Farhat et al., 2013; Lanzas et al.,
2013; Merker et al., 2015; Müller et al., 2013; Song et al., 2014; Vos et al., 2013), ri-
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fampicin resistance mutations in rpoB and putative compensatory mutations in rpoABC
offer some striking insights. In M. tuberculosis, most compensatory mutation in rpoA/C
(Figure 3.4 b and c) are associated with the most clinically frequent rifampicin-resistance
mutation RpoB S450L (Figure 3.4 a and d). The rifampicin resistance-conferring muta-
tion RpoB S450L consistently shows the lowest fitness cost in vitro (Casali et al., 2014;
Cohen et al., 2015; Meftahi et al., 2016; Vos et al., 2013). There are two non-exclusive
explanations for this observation. First, the low average fitness cost of RpoB S450L might
offer a large mutational spectrum for compensation, i.e. there are a multitude of differ-
ent mutations in rpoABC which compensate for the fitness cost of RpoB S450L. More
costly rifampicin resistance mutations might have a more restricted mutational target for
compensation. An alternative explanation would be a sequential nature of resistance and
compensatory mutation acquisition. M. tuberculosis strains carrying RpoB S450L are
able to outcompete other rifampicin resistance mutations due to its low cost. This will
lead to an overabundance of strains carrying the RpoB S450L mutation in the popula-
tion, making it more likely for these strains to acquire compensatory mutations. Loss of
function mutations in the gene katG are known to confer resistance to isoniazid (Table
3.1). However, the catalase/peroxidase activity of KatG is essential for efficient in vivo
growth of M. tuberculosis. Besides KatG, the genome of encodes the peroxidase AhpC.
Certain clinical isoniazid resistant strains have been noticed to harbor mutations in the
regulatory regions of the gene ahpC, which leads to overexpression of AhpC. However,
it was noticed that overexpression of ahpC does not compensate for the reduction in
virulence observed in katG deletion mutants. Overexpression of ahpC might therefore
only partially restore the fitness costs of katG deletions by enhancing detoxification of
detrimental reactive oxygen species (Heym et al., 1997; Sherman et al., 1996). Recently,
a non-mutational mechanism of fitness cost compensation was described. Upregulation
of tlyA expression in capreomycin-resistant strains was found to partially compensate
(buffer) the fitness cost inflicted by the mutation conferring resistance to capreomycin
(Freihofer et al., 2016). Resistance to capreomycin can be conferred by mutations in the
ribosomal RNA (Table 3.1). The gene tlyA encodes a methyltransferase which methylates
nucleotides of the ribosomal RNA. Methylation of the ribosomal RNA nucleotide directly
adjacent to the resistance conferring mutated nucleotide seems to partially restore fitness
levels (Freihofer et al., 2016). Mitigation of fitness costs via non-mutational processes can
be viewed as a plastic trait.
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Figure 3.4.: Summary of rifampicin resistance and fitness cost compensatory mutations in
rpoB and rpoA/C respectively. (a) Frequency of rifampicin resistance mutations in
rpoB. (b) Frequency of putative compensatory mutations in rpoC affecting codons 420-540.
(c) Frequency of putative compensatory mutations in rpoA affecting codons 170-200. (d)
Association of rifampicin resistance mutations in rpoB with putative compensatory mutations
in rpoA/C.
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3.7.10. In vivo fitness of drug-resistant strains
Although in vitro fitness measurements have provided us with valuable estimates of the
fitness costs inflicted by drug resistance, the ultimate measure incorporating all steps from
establishing an infection to transmission of are captured by the effective reproductive
number R (Box 3.1). Several studies have attempted to approximate R by conducting
prospective cohort studies. These have mainly focused on the number of secondary cases
generated in households of TB patients infected with drug-susceptible or drug- resistant
strains. These studies (reviewed in Fox et al. 2013)) have revealed conflicting results,
with some showing considerably lower transmission rates among MDR vs. susceptible M.
tuberculosis strains and others showing comparable transmission rates. The heterogeneity
in the determined transmission rates might reflect differences in study design.
Household contact studies are expensive and labour intensive to conduct. A more con-
venient and powerful way of assessing the in vivo fitness of drug-resistant M. tuberculosis
strains is a population-based high resolution genotyping study. The combination of whole
genome sequencing together with high quality epidemiological data will allow assessment
of transmission rates at high spatial and temporal resolution. Several studies have already
demonstrated the value of whole genome sequencing for inferring transmission networks
(Casali et al., 2014; Hatherell et al., 2016; Luo et al., 2014; Walker et al., 2013; Yang
et al., 2016).
3.7.11. Epistatic interactions between drug resistance
mutations
TB infections are always treated with a combination of drugs. There is therefore strong
selection for M. tuberculosis strains which are concomitantly resistant to several drugs
used for treatment. The effect of multiple drug resistance mutations on the organism’s
phenotype is dependent on the epistatic interactions of the different resistance mutations
with each other and with the genetic background of the strain. Certain combinations of
resistance mutations may therefore be especially favoured if they do not confer a fitness
deficit. Due to the vast number of different combinations of different drug resistance
mutations, it is difficult to assess the contribution of different combinations of resistance
mutations to the phenotype experimentally, especially inM. tuberculosis. However, assess-
ing allele frequencies from clinical isolates may inform us about successful vs. detrimental
combinations of drug resistance alleles.
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Several drugs target the information pathway from DNA to mRNA to proteins by in-
hibiting key enzymes involved in these processes. Mutations in these enzymes alone or
in combination have pleiotropic effects on the fitness of M. tuberculosis. Infections with
MDR M. tuberculosis strains are treated with drug regimens containing fluoroquinolones.
Per definition, these strains are resistant to isoniazid and rifampicin. Fluoroquinolone
resistance mutations will therefore mostly evolve in rifampicin-resistant M. tuberculosis
strains. Rifampicin targets the DNA dependent RNA polymerase and fluoroquinolones
target the DNA-gyrase and these two enzymes work in concert. Studies performed with
M. smegmatis demonstrated that depending on the combination of rifampicin and flu-
oroquinolone resistance mutation, the effects on the in vitro growth rate range from
detrimental to even beneficial. This goes so far, that fitness cost of a resistance mutation
is fully compensated by the presence of a second resistance mutation. In certain cases,
the double-resistant strain had an even faster growth rate than the drug-susceptible wild
type. Combinations of the most beneficial resistance alleles are also the most frequent in
clinical M. tuberculosis isolates (Borrell et al., 2013). In vitro studies have demonstrated
that pre-existing isoniazid resistance mutations influence which rifampicin resistance mu-
tations are subsequently acquired. This is probably due to a reduction in the mutational
target size in the broader sense (Box 3.1) due to epistatic interactions between the two
resistance conferring mutations, resulting in a dramatic reduction in fitness of specific
combinations (Bergval et al., 2012). Streptomycin inhibits the bacterial ribosome and
resistance is often conferred by mutations in the gene rpsL. Streptomycin was the first
active antituberculous drug in use and resistance to this drug is widespread. Household
contact studies have determined that M. tuberculosis strains harbouring the streptomycin
resistance-conferring mutation RpsL K43R together with the isoniazid resistance muta-
tion KatG S315T generated significantly fewer secondary cases indicating an epistatic
interaction between the streptomycin and isoniazid resistance mutations resulting in a
fitness cost (Salvatore et al., 2016). However, this is in contrast to other studies, which
have found that the combination of RpsL K43R with KatG S315T does not reduce fitness
of M. tuberculosis harbouring these mutations (Spies et al., 2013). These discrepancies
demonstrate the large variability in these interactions, highlighting the influence of the
strain genetic background on all these interactions. In turn, drawing general conclusions
from rather small datasets is not possible or at best challenging.
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3.8. Population genetics of drug resistance in M.
tuberculosis
The forces of evolution may determine the fate of drug-resistant M. tuberculosis variants
at multiple stages during infection. During transmission, M. tuberculosis populations un-
dergo stark bottlenecks (Box 3.1) as new infections are thought to be established only by
a few bacilli (Jacobs, 1941). This means that in most cases, the bacterial populations in
the lungs of TB patients will demonstrate only very low levels of genetic diversity. Only
about 12 % of all infections with M. tuberculosis will result in active disease within the
life time of a patient (Dheda et al., 2016). After the formation of the primary complex,
M. tuberculosis bacilli are disseminated throughout the lung where they form new foci.
The bacteria present in these foci are thought to form isolated subpopulations with little
migration between the populations, at least in the early stages of the infection. Struc-
tured populations are thought to select for growth yield optimisation, as they do not have
to compete for resources with other, faster growing variants due to the private nature
of the resources (Frank, 2010). Indeed, sampling bacteria from different lesions revealed
the presence of distinct subpopulations throughout the lungs of TB patients (Lieberman
et al., 2016). However, sampling M. tuberculosis bacteria from patient sputum during
treatment at different time points revealed a dynamic picture of the bacterial popula-
tion. Multiple different resistance alleles e.g. conferring resistance to fluoroquinolones
were present concomitantly – a phenomenon known as heteroresistance. Furthermore,
certain drug resistance alleles were increasing over time whilst others were disappearing.
Moreover, there was selection for strains harbouring less costly resistance and/or known
compensatory mutations (Bernard et al., 2016; Bloemberg et al., 2015; Eldholm et al.,
2014; Merker et al., 2013). Selection for M. tuberculosis variants with higher growth rates
might indicate that resources available in a patient’s lung are not private and that the
bacterial populations are less structured than we had anticipated. Indeed, studies per-
formed in cynomolgus macaques and TB patients (Coleman et al., 2014; Lin et al., 2013)
demonstrate a much more dynamic picture. During the course ofM. tuberculosis infection,
existing foci have been observed to be eliminated by the immune system, whereas new foci
seem to appear, without any discernable pattern. The immune system is apparently able
to eliminate foci and presumably kill the bacteria present in these lesions. The removal
of bacteria from these lesions by the immune system can be viewed as a form of genetic
drift. This has implications for the de novo evolution of drug resistance. Populations of
de novo evolved resistant M. tuberculosis variants inevitably start out with low numbers.
Populations with small effective population sizes are vulnerable to extinction by genetic
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drift. This means that the action of the immune system might slow the de novo evolu-
tion of drug resistance, by stochastically removing resistant variants from the population.
Host directed therapies (Zumla et al., 2015) boosting the action of the immune system in
clearing TB infections will inevitably also reduce the rate at which drug-resistant variants
evolve de novo.
3.9. Conclusion and outlook
The intrinsic resistance of M. tuberculosis against many classes of antibiotics, the ever
rising numbers of drug-resistant strains, as well as the scarcity of novel antituberculous
compounds is threatening the progress in containing the disease. The remarkable capa-
bility of M. tuberculosis to evolve drug resistance against all efficacious drugs at low or
no cost underlines the necessity of a multi-pronged strategy to reduce the incidence of
both drug-susceptible and drug-resistant M. tuberculosis variants. Aside from improv-
ing the quality of public health systems in resource-limited settings, novel, cost-effective
point-of-care diagnostic tools, drugs, as well as an effective vaccine are urgently needed.
Furthermore, the influence of the strain genetic background on virtually all aspects of
drug resistance evolution highlights that it is not sufficient to focus research on labora-
tory strains. It is crucial to include M. tuberculosis strains which ideally represent the
whole phylogenetic space of the species in order to assess the impact of a novel drug, or for
that matter, any planned intervention on the population biology of this extraordinarily
successful pathogen.
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Box 3.1 Commonly used terms in evolutionary biology
Bottleneck
A bottleneck describes the stark reduction of the population size and therefore the
genetic diversity of the population due to random sampling, i.e. genetic drift. In
the context of M. tuberculosis infections, only a subset of the whole population of
bacteria present in the lungs of a patient will gain access to the airways and may be
aerosolized. Furthermore, presumably only a subset of that aerosolized population
will survive the harsh environmental conditions found outside of the host, and is able
to infect a new host – if one is present to inhale the aerosols.
Effective population size
In the context of bacterial (haploid), non-recombining, obligate pathogens like M.
tuberculosis, the effective population size describes the proportion of the population
e.g. in a patient, which has the possibility to transmit to a new host. M. tuberculosis
is able to establish infections in nearly all tissues – however, all of them are “evolu-
tionary dead ends”, pulmonary (or in rare cases laryngeal) infections being the only
exception. Consider the case of a patient with pulmonary and extra-pulmonary TB.
The effective population size could be defined as the total number of M. tuberculosis
cells present in a patient minus the number of cells in the extra-pulmonary location,
ergo the pulmonary (laryngeal) M. tuberculosis population – as only this population
will be able to transmit to a new host. Furthermore, transmission of M. tuberculosis
requires substantial lung damage that “allows” access to the bronchi, which is depen-
dent on the location of the foci within the lung, ergo not all M. tuberculosis cells in
the lung will have the potential to transmit, reducing the effective population size.
Epidemiological cutoff
The highest minimal inhibitory concentration of a drug observed in a wild type strain.
This is related to the reaction norm – see below.
Epistasis
Epistasis describes the phenomenon where the interaction of two or more genes/alleles
produce an effect on the phenotype (e.g. on fitness) which is unequal to the sum each
gene’s/allele’s effect on their own.
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Fitness
The fitness of an organism can be defined as the ability to survive and reproduce in a
given environment. In the case of an obligate parasite like M. tuberculosis this entails
establishing an infection in the human host, replicating and transmitting to a new
host. Fitness can be parameterized by the effective reproductive number R, which
quantifies how many secondary cases are produced on average by a single infected
individual in a population of susceptible and resistant hosts. However, R is notori-
ously difficult to assess in vivo. In absence of a better measure, fitness of bacteria is
often approximated by measuring life history traits e.g. in vitro growth rates and/or
growth yield in artificial growth media. However, there is some merit in measuring
in vitro growth rates/yields e.g. of resistant M. tuberculosis variants as their growth
rate/yields are often correlated with in vivo frequency of these variants.
Fitness cost
A fitness cost describes the reduction in the number of offspring produced by a geno-
type in a given environment caused e.g. by a drug resistance mutation, compared to
a drug-susceptible variant. Drug resistance has long been assumed to be generally
associated with a fitness cost in absence of the drug (i.e. a reduction in R, the number
of secondary cases generated). Using in vitro methods, a fitness cost would manifest
itself as a reduction in growth rate or yield.
Genetic background
The genetic background describes the genetic diversity present in a strain’s genome
resulting from mutations/insertions/deletions/rearrangements etc. when compared
to other strains. The genetic background is an important factor influencing epistatic
interactions.
Genetic drift
Genetic drift is an important mechanism of evolution whereby the genetic diversity of
a population is reduced by random sampling error. The sampling error results from
the differential probability of an organism to survive and reproduce based on chance.
The effect of genetic drift on allele frequencies is strongest in populations with a small
effective population sizes. Genetic drift can lead to the stochastic fixation or loss of
alleles in a given population.
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Natural selection
Natural selection is one of the major mechanisms of evolution and refers to the dif-
ferential survival of organisms based on their phenotype. The phenotype results from
the interaction of the organism’s genotype with the environment. The differential sur-
vival results from competition (e.g. for resources) among organisms and is dependent
on the degree of adaptation of the organism to its environment. The effect of natural
selection is strongest in large populations and leads to changes in allele frequencies
over time.
Mutational target size
The mutational target size in the narrow sense describes the number of different mu-
tations which may confer resistance to a certain drug. Depending on the resistance
mechanism, the mutational target size can vary greatly. The mutational target size in
the broader sense describes the number of different mutations which confer resistance
to a given drug and which do not result in lethality due to epistatic interactions with
the strain genetic background.
Reaction norm
The phenotype of an organism results from the interaction of the organism’s geno-
type with the environment. The range of different phenotypes of a given genotype in
different environments is called the reaction norm (Griffiths et al., 2005).
Standing genetic diversity
The term standing genetic diversity describes the presence of multiple alleles at a
locus which are segregating in the population. In other words, the sum of all genetic
backgrounds (see above) constitutes the standing genetic diversity of a species.
Trait effect
Hall et al. describe the trait effect as e.g. the effect drug resistance mutations may
have on life history traits like growth rate and/or yield of the strains carrying resis-
tance mutations. The magnitude of the trait effect inflicted by drug resistance muta-
tions is dependent on multiple factors including the genetic background, pre-existing
drug resistance mutations, compensatory mutations and the environment (Hall et al.,
2015).
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One sentence summary
Whole genome sequencing of clinical M. tuberculosis isolates accurately predicts drug
resistance profiles and may replace culture-based drug susceptibility testing in the fu-
ture.
Key words
Mycobacterium tuberculosis, quantitative phenotypic drug susceptibility testing, whole
genome sequencing, drug resistance, drug resistance level prediction
This chapter has been published in Antimicrobial Agents and Chemotherapy, Volume 63,
Issue 4, 1st of April 2019, Pages e02175-18
4. WGS for DST in MTB 47
4.1. Abstract
Whole genome sequencing allows rapid detection of drug-resistantM. tuberculosis isolates.
However, high-quality data linking quantitative phenotypic drug susceptibility testing and
genomic data have thus far been lacking. We determined drug resistance profiles of 176 ge-
netically diverse clinical M. tuberculosis isolates from Democratic Republic of the Congo,
Ivory Coast, Peru, Thailand and Switzerland by quantitative phenotypic drug suscepti-
bility testing for 11 antituberculous drugs using the BD BACTEC MGIT 960 system and
7H10 agar dilution to generate a cross-validated phenotypic drug susceptibility testing
readout. We compared drug susceptibility testing results with predicted drug resistance
profiles inferred by whole genome sequencing. Both phenotypic drug susceptibility test-
ing methods identically classified the strains into resistant/susceptible in 73-99 % of the
cases, depending on the drug. Changes in minimal inhibitory concentrations were read-
ily explained by mutations identified by whole genome sequencing. Using whole genome
sequences, we were able to predict quantitative drug resistance levels for many drug re-
sistance mutations. Predicting quantitative levels of drug resistance by whole genome
sequencing was partially limited due to incompletely understood drug resistance mecha-
nisms. The overall sensitivity and specificity of whole genome-based drug susceptibility
testing were 86.8 % and 94.5 %, respectively. Despite some limitations, whole genome se-
quencing has the potential to infer resistance profiles without the need for time-consuming
phenotypic methods.
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4.2. Introduction
Timely and accurate drug susceptibility testing (DST) of M. tuberculosis isolates is vi-
tal to prevent the transmission of multidrug-resistant strains (MDR – resistance to ri-
fampicin and isoniazid)(World Health Organization, 2010). However, the slow growth
and stringent biosafety requirements of M. tuberculosis make obtaining a full DST profile
by culture-based techniques a matter of weeks or months. In addition, culture-based DST
is notoriously challenging for several drugs, e.g. pyrazinamide and ethionamide due to
poor drug solubility in commonly used culture media (Domínguez et al., 2016).
Drug resistance in M. tuberculosis is mainly conferred by chromosomal mutations in a
few genes (Gygli et al., 2017), making it possible to detect drug resistance by sequencing
these genes or probing them by molecular hybridisation (Deggim-Messmer et al., 2016).
Several commercial tests for the detection of resistance-associated mutations are available,
e.g. the GenoType MTBDRplus V2 (Hain Lifescience GmbH, Nehren, DE) (Nathavitha-
rana et al., 2016), the AID TB Resistance Line Probe Assay (AID GmbH, Strassberg, DE)
(Ritter et al., 2014). The World Health Organisation (WHO) endorses line probe assays
for the detection of rifampicin resistance as a surrogate marker for multidrug-resistance
(World Health Organization, 2016b) and the GeneXpert® system (Cepheid, Sunnyvale,
CA, USA) for the detection of rifampicin and isoniazid resistant strains (WHO, 2013).
These molecular tests demonstrate high sensitivities for drugs with established target(s)
of resistance and for which only a few mutations are responsible for most resistance in clin-
ico (e.g. rifampicin, isoniazid) (Deggim-Messmer et al., 2016). However, molecular tests
show low sensitivity for heteroresistant strains (concomitant presence of wild type (wt)
and resistant or multiple different resistant variants in patient isolates), when frequencies
of resistant variants drop below 5-50 % (Engström, 2016; Streicher et al., 2012). Further-
more, there are no commercially available tests for many drugs currently/prospectively
in use (e.g. bedaquiline, delamanid, linezolid, p-aminosalicylic acid).
The past years have seen a wealth of genomic data on drug-resistant M. tuberculosis
become available (Coll et al., 2015; Walker et al., 2015). However, phenotypic DST
data are lacking for most of the genetic data sets. In addition, DST data are often
limited as the strains were classified as susceptible or resistant using only a single drug
concentration (The CRyPTIC Consortium and the 100000 Genomes Project, 2018). There
is an urgent need to link genotypic and phenotypic drug resistance readouts to obtain a
better understanding of the mechanisms influencing the evolution and spread of drug
resistance in M. tuberculosis.
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WGS of clinical isolates allows for accurate identification of established-resistance-
conferring chromosomal mutations (Coll et al., 2015; Colman et al., 2016; Shea et al.,
2017) and may ensure adequate treatment in days instead of months. We compared
whole genome-based drug resistance profiles with two culture-based quantitative DST
methods for a total of 11 drugs, including all group 1 drugs (rifampicin, rifabutin, iso-
niazid, ethambutol, pyrazinamide), all group two (streptomycin, kanamycin A, amikacin
and capreomycin), as well as selected group 3 (moxifloxacin) and group 4 drugs (ethion-
amide).
4.3. Material and methods
4.3.1. M. tuberculosis isolates
The initial data-set consisted of 189 M. tuberculosis isolates. A subset of 61 strains was
used to establish the phenotypic DST methodology. These 61 strains were collected by the
Swiss National Center for Mycobacteria between 2004-2015, and represent a broad spec-
trum in geographic origin and drug resistance profiles (Bloemberg et al., 2015; Springer
et al., 2009; Stucki et al., 2016). We then applied the quantitative DST methodology to
125 prospectively collected clinical isolates from clinics participating in the International
Epidemiology Databases to Evaluate AIDS (IeDEA) (Egger et al., 2012) in Peru, Thai-
land, Ivory Coast and the Democratic Republic of the Congo. Thirteen strains had to
be excluded due to failed WGS (n = 4, failed library preparation due to low DNA qual-
ity), irreproducible DST results (n = 1), no growth in the 7H10 agar dilution assay (n =
3), duplication (n = 1), mixed cultures (n = 2, cross-contamination or patient infected
with multiple strains) or transmission clusters (n = 2). The final set consisted of 176
strains.
4.3.2. Phenotypic DST
MGIT 960- and 7H10 agar dilution-based phenotypic DST were performed as described
previously (Springer et al., 2009). Critical concentrations used for the classification of
strains into resistant/susceptible aim to predict clinical outcome, i.e. treatment failure if
a given strain is resistant at the critical concentration. However, critical concentrations
should ideally be defined on the basis of the epidemiological cut-off (ECOFF: The highest
wild type MIC observed in absence of any detectable resistance mechanism (Schön et
al., 2017)), treatment outcomes and pharmako-kinetic and -dynamic data. However, as
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M. tuberculosis infections are treated with combination therapy, outcome data for single
drugs are difficult to obtain (Ängeby et al., 2012). This calls for definition of critical
concentrations solely based on the ECOFF (World Health Organization, 2018b). We
therefore classified strains as resistant/susceptible on the basis the ECOFF derived from
our data (World Health Organization, 2014a). Table 4.1 lists the epidemiological cut-offs
(ECOFF) used, Table A.4.2 the drug concentrations tested with the MGIT 960 and 7H10
agar-dilution assays and Table 4.2 the genes screened for mutations with WGS. Further
details are available in the supplementary materials.
4.3.3. Data analysis
The categorical agreement between the MIC determination by MGIT 960 and 7H10 agar
dilution was determined based on the ECOFF (Table 4.1). The numerical variation
between the two methods was quantified as the geometric standard deviation (SD, given
with its standard error) of the ratio MIC MGIT 960/MIC agar dilution, expressed as a
number of 2-fold dilutions and denoted by σ. The geometric SD was computed by fitting
a log-normal distribution to the ratio MIC MGIT 960/MIC agar dilution as implemented
in the R package fitdistrplus (v.1.0-9) (Delignette-Muller et al., 2015). If the data was
compatible with σ = 0, the geometric standard deviation could not be estimated and
was defined as “not applicable” (NA). The approach is a generalization of the Bland and
Altman method (Martin Bland et al., 1986), taking censoring of the data into account.
Strains for which the MGIT 960 MIC and 7H10 agar dilution MIC were both left-censored
or both right-censored were excluded since no information on the ratio could be derived.
Goodman and Kruskal’s gamma was used to quantify the rank correlation between the
two methods. No correlation could be calculated if the variance for either method was 0
(NA).
Distributions of wt and mutant MICs were analysed qualitatively based on the results
of 7H10 agar dilution. We divided the dataset into two groups: drugs for which the
MIC distributions of wt and mutant strains did not overlap, and those for which MIC
distributions overlapped.
Sensitivities and specificities of WGS-based resistance profile inference were calculated
based on the 7H10 agar dilution results for all drugs, except pyrazinamide– for which the
MGIT 960 results were used, based on resistance/susceptibility at the ECOFF defined
derived from our data and the presence or absence of a putative resistance-associated
mutation.
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4.3.4. Defining clinical breakpoints for high/low-level
resistance
The therapeutic window of a drug is defined as the maximal serum concentration which is
considered safe (Böttger, 2011). Mutations can increase the MIC beyond the therapeutic
window and render the drug clinically ineffective. Drugs may have large therapeutic
windows beyond the ECOFF. For these, MIC increases caused by mutations may still
be within the therapeutic window of a drug: these strains might still be treatable by
increasing the drug dose. We analysed the distribution of MICs of mutant strains, and
assessed if cut-offs for low-level (within the therapeutic window) and high-level (beyond
the therapeutic window) resistance were definable. There were sufficient data available to
define distinct low/high-level clinical breakpoint concentrations for isoniazid, rifampicin,
streptomycin and amikacin. For mutations conferring resistance to other drugs assayed in
this study, no distinct separation into high/low-level resistance was possible due to wide
ranges of MICs conferred by the individual mutations or the mutations conferred MICs
beyond the therapeutic window.
4.3.5. WGS and single nucleotide variant (SNV) calling
WGS and data analysis was performed as previously described (Ghielmetti et al., 2017)
and summarised in the supplementary materials. The performance of WGS-based DST
greatly depends on the availability of robust markers of resistance. We therefore focussed
on a set of high-confidence resistance-associated genes (Böttger, 2011; Gygli et al., 2017;
Walker et al., 2015) (Table 4.2). We additionally assessed the impact of eis promotor
mutations on amikacin and capreomycin resistance, as the association of mutations in the
eis promotor with resistance to the aforementioned drugs has been reported but is not
well established (Kambli et al., 2016; World Health Organization, 2018b).
4.3.6. Ethics
Local institutional review board or ethics committee approval was obtained at all lo-
cal study sites. Informed consent was obtained where requested per local regulations.
This project was approved by the Swiss Ethics Committee on research involving humans
(swissethics, Bern, Switzerland).
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4.4. Results
4.4.1. Agreement between MGIT 960 and 7H10 agar dilution
phenotypic DST
Table 4.3 and Figure 4.1 summarize the agreement between the semi-quantitative and
quantitative MIC determination by MGIT 960 and 7H10 agar dilution in terms of classi-
fying strains as resistant or susceptible according to ECOFF (Table 4.1). Agreement was
high for all drugs, except ethambutol (see below). For most drugs, the MGIT 960-based
MICs were higher than the 7H10 agar dilution-based MICs. MICs obtained using the
two methods were within 1-2 two-fold dilution steps of each other. The classifications
into resistant or susceptible demonstrated high rank correlations (Table 4.3 and Figure
4.1), except for capreomycin (Figure A1.4) due to few resistant strains included in the
study.
Table 4.1.: Epidemiological cutoffs (ECOFF) used for 7H10 agar dilution and MGIT 960
phenotypic DST. Values derived from wild-type MIC distributions determined in this study.
The values given in parentheses are the critical concentrations recommended by the WHO in
2014 (World Health Organization, 2014a)
.
Antibiotic ECOFF agar dilution (mg/L) ECOFF MGIT 960 (mg/L)
Ethionamide 1 (5) 5
Ethambutol 2 (5) 5
Capreomycin 4 2.5
Streptomycin 0.5 (2) 1
Kanamycin A 2 (5) 2 (2.5)
Amikacin 1 (4) 1
Moxifloxacin 0.25 (0.5) 0.25 (0.5)
Isoniazid 0.125 (0.2) 0.1
Rifampicin 0.5 (1) 1
Rifabutin 0.0625 0.1
Pyrazinamide NA 100
4.4.2. WGS and in silico resistance profile prediction
A total of 176 whole genome sequences with a median coverage of 67.6x (interquartile
range (IQR) = 37.48) were obtained. Median mapping percentage and percentage of
genome covered were 98.7 % (IQR = 0.94) and 99.4 % (IQR = 0.4), respectively. Genes
involved in drug resistance demonstrated high coverages with only 0.8 % of all positions
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suffering from coverages below 7x (see supplementary materials). All major M. tubercu-
losis Lineages, except Lineage 7, were represented in the study (L1 = 6, L2 = 36, L3 =
11, L4 = 123, L5 = 1, L6 = 1). The strains showed a range of drug resistance profiles
(Figure 4.2). Based on the set of analysed genes (Table 4.2), 25 strains were predicted
to be fully susceptible against all assayed drugs, 59 strains were mono-/poly-resistant, 91
strains demonstrated MDR phenotypes and two strains were extensively drug-resistant
(XDR: isoniazid, rifampicin, fluoroquinolone and aminoglycoside resistant).
4.4.3. Drug resistance profile prediction by WGS vs. phenotypic
DST
After exclusion of known phylogenetic markers not involved in resistance, WGS-based
prediction of drug resistance using a defined set of target genes (Table 4.2) was highly
congruent with the categorical classification based on the phenotypic DST for most drugs
(Table 4.3, Table 4.4, Figure 5). Based on the in silico resistance prediction, the MICs
of mutant and wt strains frequently followed a Gaussian distribution. However, the same
resistance marker may confer different MICs in different strains (Figures A1.1C, A1.2C,
A1.3C, A1.8C, A1.9C A1.10C). In some cases, the increase in the MIC conferred by a
certain resistance mutation fell within the distribution of the wt MIC (e.g. for gidB, eis
promotor mutations, Figures A1.3C A1.6C).
4.4.4. Distinct wt and mutant MIC distributions
MIC distributions of wt and mutant strains were well separated for rifampicin, rifabutin,
isoniazid, kanamycin A, amikacin, capreomycin, streptomycin and pyrazinamide, indicat-
ing that the resistance markers used had a high positive predictive power (88.9 % overall
positive predictive power of resistance markers). For streptomycin, two strains harboured
no mutations in the target genes, yet demonstrated high-level phenotypic resistance (Fig-
ure A1.3C).
4.4.5. Overlapping wt and mutant MIC distributions
MIC distributions of wt and mutant strains overlapped for ethambutol, moxifloxacin and
ethionamide (Figure 4.3). For ethambutol and ethionamide, overlapping MIC distribu-
tions of wt and mutant strains were associated with a large number of polymorphisms
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Figure 4.1.: Method agreement between phenotypic DST performed with MGIT 960 and
7H10 agar dilution represented as Bland-Altman plots for all drugs tested in this
study.
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in resistance-conferring genes (ethambutol resistance: 22 polymorphisms in embB, ethion-
amide resistance: 28 in ethA, 3 in inhA, 6 in inhA promoter). Solubility issues with
ethionamide led to quantitative differences in MGIT 960 vs. 7H10 agar dilution-based
DST (Table 4.3, Figure 5). The overlap in MIC distributions between wt and strains carry-
ing an embB mutation was reduced by adjusting the critical concentration for ethambutol
resistance from 5 mg/L to 2.5 mg/L (MGIT 960). However, there was variability in the
MICs for the same mutation (e.g. MIC EmbB M306I/V in 7H10 agar dilution: 4-16 mg/L
– Figure A1.2C). Moxifloxacin resistance was rare (n = 9, MGIT 960, critical concentra-
tion 0.25 mg/L) and MIC distributions of mutant strains partially overlapped with those
of wt. Sensitivity of the genome-based moxifloxacin resistance prediction 80.0 % (Table
4.1).
Table 4.2.: List of genes implicated in drug resistance in M. tuberculosis. Genes were screened
for polymorphisms by WGS. List adapted from (Gygli et al., 2017)
.
Drug Target gene(s)
Ethionamide ethA, inhA, inhA promoter
Ethambutol embB
Capreomycin rrs, eis promoter, tlyA
Streptomycin rrs, gidB, rpsL
Kanamycin A rrs, eis promoter
Amikacin rrs, eis promoter
Moxifloxacin gyrA
Isoniazid katG, inhA promoter
Rifampicin/rifabutin rpoB
Pyrazinamide pncA, pncA promoter
Table 4.3.: Summary statistics of the method agreement between 7H10 agar dilution- and
MGIT 960-based phenotypic DST for all drugs assayed in this study.
Antibiotic n Categorical agreement (%) SD of log2 (MIC MGIT 960/MIC agar dilution) γ
Ethionamide 56 95 1.9 ± 0.3 0.91
Ethambutol 171 73 1.9 ± 0.5 0.94
Capreomycin 56 98 1.5 ± 0.5 0.65
Streptomycin 56 93 1.5 ± 0.3 0.98
Kanamycin A 56 98 1.2 ± 0.2 0.8
Amikacin 174 98 1.4 ± 0.6 1
Moxifloxacin 173 99 1 ± 0.2 1
Isoniazid 173 96 1.2 ± 0.1 1
Rifampicin 174 99 NA 1
Rifabutin 56 96 0.8 ± 0.1 0.98





























































































































































































































Figure 4.2.: Phylogeny of 176 M. tuberculosis strains based on 20510 variable positions. Green
tip labels depict reference strains. Main Lineages are highlighted as follows: Red L4, purple
L3, blue L2, pink L1, green L6, brown L5. Scale bar: substitutions per site. Phylogeny rooted
on M. canettii. Colored bars indicate mutations per gene and within a distinct column (gene)
each colored bar represents a distinct mutation. Black bars indicate wt.
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4.4.6. Defining high-/low-level clinical breakpoint
concentrations
Isoniazid
Mutations in the promoter of inhA conferred low-level resistance < 1 mg/L (7H10 agar
dilution), compared to strains harbouring mutations in katG or combinations of inhA
promoter and katG mutations which demonstrated MIC levels ranging from > 1 mg/L to
> 32 mg/L in 7H10 agar dilution (Figure A1.8.C). Defining clinical breakpoint concentra-
tions (CBC) for low- (≤ 1 mg/L for MGIT 960/7H10 agar dilution) and high-level (> 1
mg/L MGIT 960/7H10 agar dilution) isoniazid resistance is warranted.
Rifampicin/Rifabutin
Most mutations in rpoB increased the MIC for rifamycins beyond the therapeutic win-
dow (peak serum concentration 10 mg/L (Böttger, 2011; Sekaggya-Wiltshire et al., 2018)).
However, some rare rpoB mutations (e.g. RpoB L452P, H445L – Figure A.1.9.C) demon-
strated MICs within the therapeutic window. Defining low- and high-level CBC may thus
be justified. For rifampicin, CBC were ≤ 4/2 mg/L for MGIT 960/7H10 agar dilution
and > 4/2 mg/L for MGIT 960/7H10 agar dilution, respectively. For rifabutin, our data
suggests CBC for low- and high-level resistance of ≤ 0.4/0.25 or 0.5 mg/L for MGIT
960/7H10 agar dilution and > 0.4/0.25 or 0.5 mg/L for MGIT 960/7H10 agar dilution,
respectively. Mutations in rpoB conferring resistance to rifampicin and rifabutin showed
highly correlated increases (Figure 4.4) of MICs beyond the therapeutic window for most
rpoB mutations 3 and Figure A.1.9.C & A.1.10.C), indicating that both drugs are ren-
dered clinically ineffective by the mutations identified in the dataset (Berrada et al., 2016)
and cannot substitute each other.
Amikacin
Few strains had mutations in the regions of rrs relevant for amikacin resistance or the eis
promoter (n=12). Mutations in rrs were associated with high-level (> 128 mg/L in 7H10
agar dilution) resistance. With regards to the eis promotor, only the C-14T mutation
increased the MIC and leads tos low-level (2-4 mg/L in 7H10 agar dilution) amikacin re-
sistance. Given the peak serum concentrations of amikacin (20-40 mg/L (Böttger, 2011)),
a CBC for low- (≤ 4 mg/L for MGIT 960/7H10 agar dilution) and high-level (4 mg/L for
MGIT 960/7H10 agar dilution) amikacin resistance may be warranted.
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Figure 4.3.: Histograms of MICs of (7H10 agar dilution) for all drugs assayed in this study.
Dashed bar indicates the epidemiological cutoff.
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Streptomycin
Certain mutations lead to MICs well beyond the peak serum concentrations (Böttger,
2011) of streptomycin (e.g. RpsL K43R, MIC 7H10 agar dilution > 128 mg/L, Figure
A.1.3.C). On the other hand, gidB mutations increase the MIC only moderately (MIC
7H10 agar dilution 1-4 mg/L, Figure A.1.3.C). Mutational combinations in gidB, rrs, rpsL
were common and produced a range of different MICs. However, there were mutations that
systematically lead to MICs beyond the therapeutic window, e.g. RpsL K43R. Defining
low- level (MGIT 960 ≤ 4 mg/L, 7H10 agar dilution ≤ 4-8 mg/L) and high-level CBC
for streptomycin resistance (MGIT 960 > 4 mg/L, 7H10 agar dilution > 4-8 mg/L) is
warranted.
Figure 4.4.: Correlation between MICs for 7H10 agar dilution rifampicin and rifabutin.
4.5. Discussion
We compared quantitative phenotypic DST with in silico or genomic resistance profile
prediction inferred from WGS using 176 clinical M. tuberculosis isolates. We observed
a bias towards Lineage 4 and 2 strains in our sample set. The initial strain set used to
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establish the methodology was collated with a specific aim to include drug-resistant strains
and given the frequent association of Lineage 2 and 4 with drug-resistance (Casali et al.,
2014; Cohen et al., 2015), the observed bias is not surprising. Furthermore, Lineage 2 and
4 strains are also frequently isolated at the collection sites of the strain set used to apply
the methodology (Ivory Coast, Peru and Democratic Republic of the Congo). Similarly,
resistance against a number of drugs (amikacin, capreomycin, kanamycin, moxifloxacin)
was rare, reflecting the scarcity of pre-XDR/XDR phenotypes in Switzerland (initial strain
set) and at the sites of prospective sampling.
The results of MGIT 960 and 7H10 agar dilution-based phenotypic DST methods were
highly correlated and suitable to separate susceptible from resistant variants. Based on
phenotypic DST results and WGS, we were able to define CBC for high- and low-level re-
sistance for isoniazid, rifampicin, streptomycin and amikacin. Defining such breakpoints
is important for preserving efficacious drugs for treatment of resistant M. tuberculosis
variants. Our data suggest that the current WHO-defined critical concentration for phe-
notypic DST of ethambutol by MGIT 960 (5 mg/L) is too high and may misclassify strains
as susceptible when compared to the 7H10 agar dilution-based classification. Given the
low peak serum concentrations for ethambutol, this may lead to mistreatment due to pre-
sumed ethambutol susceptibility. After adjusting the critical concentration to 2.5 mg/L
for MGIT 960, we observed a strong improvement of the categorical agreement between
MGIT 960- and 7H10 agar dilution-based classification.
Table 4.4.: Sensitivity and specificity of the genome-based drug resistance profile prediction.
The 7H10 agar dilution-based categorical classification was used as the gold standard for all
drugs except pyrazinamide, for which the MGIT 960 categorical classification was used.












4. WGS for DST in MTB 61
The mutations identified by WGS had a high predictive power to classify strains as re-
sistant. However, the predictive power depends on a number of factors. For instance, the
increase in MIC conferred by an identical resistance mutation can vary greatly in different
strains (e.g. EmbB M306I/V, RpsL K88R) (Ruesen et al., 2018). Such variation is clini-
cally relevant if there is a significant overlap between the MICs of mutant and wt strains
(Schön et al., 2017), as was the case for ethionamide, ethambutol and streptomycin (e.g.
gidB) resistance mutations. Furthermore, it is difficult to classify strains as resistant or
susceptible if the MIC increase lies within the therapeutic window of a drug. The overlap
between MICs of mutant and wt strains is confounded by the fact that we only screened for
mutations in genes which had previously been associated with drug resistance. We might
thus have missed possible resistance-conferring mutations in other genes. Additionally,
WGS will always produce distributions of coverages which in term will inevitably lead
to certain regions in the genome suffering from low coverage, preventing the detection of
mutations. However, in cases where we observed elevated MICs without any mutations
detected the target genes, coverage issues could not explain the absence of any muta-
tions.Furthermore, the strain genetic background (Fenner et al., 2012), non-mutational
mechanisms (e.g. modulation of gene expression) (Freihofer et al., 2016), as well as drug
efflux mechanisms (Silva et al., 2016) may contribute to the variability in increase of the
MIC conferred by resistance mutations.
The predictive power of mutations in target genes also depends on removing phy-
logenetic markers not involved in resistance. Separating phylogenetic from resistance-
associated markers works well for essential (highly conserved) genes such as rpoB, rpsL,
rrs but is problematic in non-essential genes involved in the conversion of prodrugs into
their active forms like pncA (pyrazinamide), ethA (ethionamide) or in genes that gener-
ally exhibit higher numbers of polymorphisms e.g. embB. Of note, the embABC operon
is highly polymorphic, harbouring more polymorphisms than expected by chance (muta-
tions in embABC operon = 81, expected = 44.8, p = 9.174e-07, binomial test). Muta-
tions conferring ethambutol resistance (Safi et al., 2013) will therefore inevitably evolve
in the presence of phylogenetic SNVs and may interact epistatically to produce the vari-
ability in MICs we observed for wt strains and for the most common ethambutol resis-
tance markers EmbB M306I/V. The embABC operon is involved in the biosynthesis of
decaprenylphosphoryl-β-d-arabinose, which is an integral component of the mycobacterial
cell wall. The cell envelope interacts with the host immune system and the high levels of
diversity of these genes might be the product of diversifying selection due to host immune
pressure. The influence of polymorphisms in the embABC operon on MICs in general
is supported by the observation that sub-inhibitory concentrations of ethambutol lower
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the MICs for isoniazid, rifampicin and streptomycin (Jagannath et al., 1995). Even small
changes in activity of the decaprenylphosphoryl-β-d-arabinose biosynthetic and utilisation
pathway might thus alter cell wall permeability and influence MICs of several drugs.
Similarly, in the case of streptomycin resistance, the RpsL substitution K88R exhibited
a range in MICs from low to high-level resistance making it difficult to judge the suscep-
tibility of a strain harbouring this mutation based on the genotype. Streptomycin was
the first effective antituberculous drug discovered (Schatz et al., 1944) and has been used
for decades. The long-term use has produced complex resistance profiles with multiple
streptomycin resistance mutations (e.g. in gidB, rpsL, rrs) occurring concomitantly, pro-
ducing wide ranges of MICs. Furthermore, many streptomycin resistant strains displayed
MDR/XDR phenotypes. Streptomycin resistance mutations are frequently found in back-
grounds which have mutations in genes affecting the information pathway (DNA → RNA
→ proteins) – e.g. gyrA (DNA gyrase), rpoB (DNA-dependent RNA polymerase), rrs
(ribosomal RNA). The simultaneous presence of multiple resistance mutations may alter
the adaptive landscape (Borrell et al., 2013; Moura de Sousa et al., 2017). In addition,
non-mutational processes (e.g. alteration of gene expression) may compensate for fitness
costs of drug resistance and at the same time alter the MIC for the drug (Freihofer et al.,
2016). This has not been demonstrated for streptomycin resistance in M. tuberculosis, but
it seems possible that compensation of fitness costs in MDR phenotypes might alter the
MIC for streptomycin (Moura de Sousa et al., 2017), considering that streptomycin is not
part of the current standard treatment regimen and selection for high-level streptomycin
resistance is relaxed.
With 63.6 % – 80.8 %, sensitivities were low for a number of drugs (i.e. for amikacin,
moxifloxacin, pyrazinamide) (table 4.4) (World Health Organization, 2018c), but were
comparable to other study not employing a database of pre-defined resistance mutations
(Farhat et al., 2016; Shea et al., 2017; Walker et al., 2015). The observed low sensitivities
for some drugs were either due to few resistant strains included in the dataset, the pres-
ence of additional resistance mutations in genes not assessed or due to unknown resistance
mechanisms and not due to low coverages prohibiting the detection of mutations. The use
of a curated SNV-database containing high-confidence drug-resistance mutations would
improve sensitivity for some drugs where additional targets, less well associated with
resistance, are known (Miotto et al., 2017; World Health Organization, 2018c). How-
ever, reliance on a predefined resistance mutation database comes at the cost of reduced
specificity. After known phylogenetic mutations have been removed, it is important to
treat any mutation in known target genes as potentially involved in drug resistance. In
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cases where previously unknown mutations (i.e. neither known to confer resistance, nor
a known phylogenetic SNV) in resistance-related genes are detected, targeted DST is
necessary to confirm or reject the drug-resistance conferring nature of a novel mutation
to achieve high sensitivities and specificities for whole genome sequencing-based DST.
Generating high-quality quantitative DST data using diverse M. tuberculosis strains is
important to accurately define the ECOFF and subsequently guide treatment decisions.
The two quantitative DST methods employed are difficult to standardize across labora-
tories, technically demanding and at best challenging to scale up. Microtiter plate-based
quantitative DST methods (Lee et al., 2014; Rancoita et al., 2018) have the potential to
aid in the generation of more high quality DST data due to their standardized formulation
and relative ease of application compared to established methods.
In conclusion, we demonstrate that MGIT 960 and 7H10 agar dilution-based phenotypic
DST provide highly congruent classifications of strains into resistant or susceptible. WGS
has high predictive power to infer resistance profiles without the need for time-consuming
phenotypic methods. Limitations due to overlapping distributions of wt and mutant
MICs, varying MICs for the same resistance mutations in different strains, presence of
phylogenetic markers in resistance-associated genes and rare resistance markers with low
frequencies will likely be resolved by on-going large-scale projects (e.g. ReSeqTB and
others (Starks et al., 2015; The CRyPTIC Consortium and the 100000 Genomes Project,
2018)) combining phenotypic DST withWGS of thousands ofM. tuberculosis isolates. Our
findings, together with those of on-going studies will pave the way for the replacement
of phenotypic DST with drug resistance profile prediction based on WGS in the coming
years.
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66 5. Transmission of MDR-MTB in Georgia
5.1. Abstract
Multidrug-resistant tuberculosis accounts for one third of the annual deaths due to antimi-
crobial resistance (O’Neill, 2014). Drug-resistance conferring mutations frequently cause
fitness costs in bacteria (Andersson et al., 1999; Andersson et al., 2010; Gagneux et al.,
2006a; Gygli et al., 2017). It is therefore widely believed that multidrug-resistant tuber-
culosis is mainly due to de novo evolution of resistance linked to patient non-adherence
rather than transmission (Frieden et al., 2007). Experimental work indicates that drug
resistance-related fitness costs may be mitigated by compensatory mutations (Comas et
al., 2012; Maisnier-Patin et al., 2002; Qi et al., 2014; Reynolds, 2000; Song et al., 2014).
Yet, the clinical relevance of compensatory evolution and its ecological determinants re-
main poorly understood. Here, we show that in the Republic of Georgia, at least 43 % of
multidrug-resistant tuberculosis was due to patient-to-patient transmission. Transmission
was independently associated with compensatory mutations and a patient history of incar-
ceration. Compensatory mutations were over-represented in prison-derived strains that
spilled over into the general population. We conclude that prisons fuel the epidemic of
multidrug-resistant tuberculosis in the Republic of Georgia by acting as ecological drivers
of highly transmissible strains.
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5.2. Main Text
Growing antimicrobial resistance is a threat to global public health and the economy
(O’Neill, 2014). In 2016, there were an estimated 560,000 new cases of human tuberculosis
(TB) caused by multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) strains
resistant to the two first-line antibiotics isoniazid and rifampicin. However, the number
of fatalities is small compared to the annual total of 1.6 million deaths due to TB in
general (O’Neill, 2014; World Health Organization, 2018a). Globally, only 4-6 % of the
10.0 million annual new TB cases are caused by MDR Mtb variants, and this proportion
has remained stable despite the fact that TB has been treated with antibiotics for decades
(Dye, 2009). Based on these observations, it has been suggested that MDR-TB might
be generally less transmissible due to fitness costs of MDR (Dye et al., 2001), and as a
consequence, MDR-TB was predicted to remain a localized problem (Dye et al., 2002).
Indeed, several geographical hotspots of MDR-TB exist, with the countries of the former
Soviet Union being heavily affected, for reasons not well understood. For instance, in the
Republic of Georgia, 11 % of all new TB cases and 30 % of retreatment cases in 2017
were caused by MDR strains (World Health Organization, 2018a).
In Mtb, drug resistance is mainly conferred by chromosomal mutations in the genes
encoding the drug target (Gygli et al., 2017). In vitro data demonstrated a fitness deficit
for rifampicin-resistant Mtb (Gagneux et al., 2006c). In contrast, analysis of paired clin-
ical isolates from patients who acquired rifampicin resistance during treatment revealed
that some of these strains did not carry any detectable fitness deficit in vitro. It was
hypothesized that these clinical strains acquired secondary, fitness-deficit compensating
mutations. Genome analyses of experimentally evolved Mtb laboratory strains together
with a collection of rifampicin-resistant clinical strains revealed the presence of com-
pensatory mutations in the RNA polymerase (Comas et al., 2012). Work conducted in
several bacterial species (Brandis et al., 2012; Reynolds, 2000; Song et al., 2014) showed
that secondary mutations in the RNA polymerase restored the transcriptional activity of
the enzyme. However, whether these compensatory mutations influence the transmission
fitness of Mtb in human populations remains to be established. While several studies
assessed the impact of compensatory mutations on the transmissibility of MDR-TB, find-
ings have been inconsistent (Casali et al., 2014; Liu et al., 2018; Merker et al., 2018; Vos
et al., 2013). Moreover, these previous studies relied on convenience sampling and did not
control for confounding factors. In this study, we tested for associations between various
bacterial and corresponding patient data with the transmission of MDR-TB isolates by
whole-genome analysis of a nation-wide collection of 659 Mtb strains
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Figure 5.1.: Phylogeny of 659 MDR M.tuberculosis strains together with the drug resistance
mutations per strain. Blue branches correspond to Lineage 2 (Beijing sublingeage), red
to Lineage 4, the black bar indicates the root (Mycobacterium canettii). Scale bar indicates
substitutions/site. Each unique mutation in the displayed target genes is coded with a
different color, except for pncA and ethA due to the large number of different mutations.
The orange bracket indicates the largest detected transmission cluster with n = 84 clustered
strains.
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from the Republic of Georgia isolated from 2011 to 2013. The dataset represents 53 % of
all culture-confirmed MDR-TB cases isolated in the Republic of Georgia in this timeframe
(Figures A.2.1-A2.3).
We first assessed the drug resistance profiles of the sequenced Mtb strains and found
that the epidemic of drug-resistant TB in Georgia is driven by highly resistant strains (Fig-
ure 5.1). Out of the 659 strains analyzed, 304 strains (46 %) were pXDR (pXDR: MDR
+ resistance to either aminoglycosides or fluoroquinolones), 257 (39 %) were MDR, and
98 (15 %) extensively drug resistant (XDR: MDR + fluoroquinolone and aminoglycoside-
resistant). The pXDR and XDR resistance profiles are strongly associated with treatment
failure (Ahmad et al., 2018; Lomtadze et al., 2009). Apart from the mutations defining
the drug resistance class, all strains carried a median of 3 additional resistance muta-
tions (25th percentile = 3, 75th percentile = 4). Control measures will be hampered by
the predominance of pXDR phenotypes and the high prevalence of additional resistance
mutations; for example, 92 % of the strains harbored streptomycin resistance-conferring
mutations (Figure 5.1). Treatment regimens including the novel drugs bedaquiline, pre-
tomanid, delamanid and linezolid will be necessary to combat the epidemic of MDR-TB
in Georgia (WHO, 2014). On that note, we identified 16 strains with mutations in the
promoter region or coding sequence of the transcriptional repressor Rv0678/MmpR (Fig-
ure 5.1). Mutations in the gene Rv0678/mmpR are implicated in bedaquiline/clofazimine
cross-resistance (Ismail et al., 2018) and bedaquiline has been used in Georgia on a com-
passionate basis since 2011 (World Health Organization, 2014b).
To identify putative compensatory mutations we screened RNA polymerase genes
rpoABC for the presence of nonsynonymous substitutions. After filtering for phylogenetic
markers (see Materials and Methods), we identified a total of 99 distinct substitutions
(RpoA: N = 11, RpoB: N = 53, RpoC: N = 53, Figure 5.2). Strains belonging to Lineage
2 were more likely to harbor compensatory mutations compared to Lineage 4 (χ2 = 29.16,
p < 0.001). Most compensatory mutations evolved only once in the dataset and were only
shared among a limited number of strains (Figure 5.2). However, several mutations were
shared by a large number of strains and independently evolved multiple times (Figure
5.2), indicating a strong selective benefit when carrying these mutations.
We next used the whole genome sequences to identify transmission clusters based on
the genetic distance between two given strains to determine whether MDR Mtb strains
evolved de novo in patients or stem from transmission. We identified 42 transmission clus-
ters with a median size of 3.5 strains (25th percentile = 3, 75th percentile = 5), resulting in
43 % (N = 281) of strains being clustered (Figure 5.1). The high proportion of strains in
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clusters indicates frequent transmission of MDR-TB. We detected a cluster containing 84
pXDR strains which is one of the largest transmission clusters of pXDR strains reported to
date (Figure 5.1). To test the hypothesis that compensatory mutations contribute to the
transmission fitness of MDR Mtb in Georgia, we performed multivariable logistic regres-
sion on a subset of 544 strains for which complete epidemiological records were available
(Fig. A.2.3). Supporting our hypothesis, we found that clustering was independently
associated with compensatory mutations in the RNA polymerase (ORadj = 2.27, CI95 =
1.38–3.79, p = 0.002; Table 1). Other independent predictors of MDR-TB transmission
included a patient history of incarceration (ORadj = 6.55, CI95 = 3.98–11.05, p < 0.001;
Table 1), in line with the known role of prisons in the epidemic of MDR Mtb in the former
Soviet Union (Aerts et al., 2000; Kenyon, 2009; Stuckler et al., 2008). Older age (ORadj
= 0.99, CI95 = 0.97–1.00, p = 0.04; Table 1) was negatively associated with clustering,
consistent with the epidemiology of TB in middle-/high-burden countries (Yates et al.,
2016). In concordance with previous reports (Merker et al., 2018; Niemann et al., 2010),
the Lineage 2/Beijing family of Mtb was associated with transmission, supporting the
notion that Lineage 2 strains may suffer from smaller drug-resistance related fitness costs
(Gagneux et al., 2006c).
Table 5.1.: Risk factors associated with clustering. ‡Odds ratios were estimated by multivariable
logistic regression adjusting for the presence of compensatory mutations, incarceration, Mtb
lineage, patient age, patient sex, TB diagnosis in the past, isolation year and the total number






ORadj‡ (CI95) P-value ORadj‡ CI95 P-value
Compensatory mut. in rpoABC 2.27 (1.38, 3.79) 0.002 1.66 (1.01, 2.76) 0.05
Incarceration 6.55 (3.98, 11.05) <0.001 4.28 (2.47, 7.53) <0.001
Lineage 2 strain 3.82 (1.94, 8.08) <0.001 2.87 (1.47, 6.02) 0.004
Age 0.99 (0.97, 1.00) 0.04 0.99 (0.97, 1.00) 0.09
Sex Male 0.90 (0.56, 1.46) 0.67 0.86 (0.53, 1.41) 0.54
TB diagnosis in the past 0.99 (0.66, 1.49) 0.96 0.97 (0.63, 1.49) 0.89
Isolation year 201 1.29 (0.79, 2.11) 0.54 1.3 (0.77, 2.2) 0.6
Isolation year 2013 1.06 (0.63, 1.78) 0.54 1.1 (0.64, 1.91) 0.6
Total number of DR mut. 1.22 (1.06, 1.41) 0.006 1.27 (1.09, 1.43) 0.002
































































































































































































































Figure 5.2.: Putative compensatory mutations. Mutations in rpoABC remaining after filtering for
phylogenetic markers. The homoplasic index indicates the number of independent evolution
events of the mutation in question. Only mutations with a homoplasy index > 1 are annotated.
The frequency of the mutation indicates the number of strains harbouring the respective
mutation. Numbers within the dots signify that there were > 1 distinct substitutions affecting
the same codon with identical numbers of strains harbouring the mutations. *Mutation has
been reported previously (Comas et al., 2012; Merker et al., 2018; Casali et al., 2014).
**Strain carrying multiple mutations affecting the same codon.







































posterior prob. > 0.5
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Figure 5.3.: Summary of the transmission network analysis given in numbers of transmission
events. Arrows indicate the directionality of the transmission event. * Number of trans-
mission events. ** Proportion of the total transmission events (n = 225). Panel A shows all
transmission events, panel B only shows high confidence transmission events with posterior
probabilities > 0.5. Panel C summarises the sources of compensated strains among civilians.
Of the total of N = 494 compensated strains, N = 198 were found in transmission clusters,
of which N = 89 were isolated from civilians. At least 35 % (n = 32, posterior probability
> 0.5) of the transmitted, compensated strains isolated from civilians have their origin in
prisons.
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Given the number of transmission events within prisons, we hypothesized that prisons
serve as a source for MDR-TB among civilians (Mabud et al., 2019; Warren et al., 2018).
To test this hypothesis, we first used the whole genome sequences, isolation dates, and
information on the time course of Mtb infections to reconstruct transmission networks and
infer infection chains including the directionality of transmission. Out of the total 225
transmission events, an estimate of 108 (median posterior probability 0.58, 25th percentile
= 0.40, 75th percentile = 0.84), or 48 % were directly linked to transmission from prisoners,
and an estimated 37 members of the general public were directly infected by prisoners
(Figure 5.3 A). When focusing only on high confidence transmission events (posterior
probability > 0.5), an estimated 70 cases (31 % of all transmission events) were associated
with prisons. We further quantified indirect spillover from prisons to the general public
by determining how many secondary cases were generated by members of general public
originally infected by prisoners. An estimate of 46 (N = 26 with posterior probability >
0.5, Figure 5.3 B) secondary cases were generated from members of the general public
originally infected by prisoners, of which 19 (N = 9 with posterior probability > 0.5,
Figure 5.3 B) were members of the general public. Overall, an estimated 154 cases or
68 % of all transmission events were directly or indirectly linked to incarceration. When
focusing only on high confidence transmission events, 96 or 43 % were linked to within or
out-of-prison transmission.
Given the strong association between transmission and incarceration, we next hypoth-
esized that repeated transmission of highly drug-resistant strains among prison inmates
allows for compensatory evolution. Frequent transmission events would then give rise to
highly transmissible strains capable of spilling over into the civilian population. To test
the hypothesis, we analyzed the prevalence of compensatory mutations among strains cir-
culating in the general public with or without a connection to prisons. In support of our
hypothesis, we found that compensatory mutations were more prevalent in the prison-
derived (97 %, 53/56) compared to non-prison derived strains (69 %, 33/48) (p = 0.001,
Fisher’s Exact Test). Furthermore, compensated strains in transmission clusters isolated
from civilians frequently originate from incarcerated patients (N = 32 or 35 %, posterior
probability > 0.5, Figure 5.3 C). Prisons therefore are not only sources of MDR-TB for the
general public (Mabud et al., 2019; Warren et al., 2018), but they also serve as ecological
drivers for compensated, highly transmissible strains.
Our study shows that a large proportion of the MDR-TB in Georgia is due to on-going
transmission of highly drug-resistant Mtb strains and not solely to de novo evolution
within patients. Moreover, our findings complement previous experimental findings by
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confirming that compensatory mutations in the RNA polymerase of Mtb contribute to
the transmission fitness of MDR strains in a human population. The strong association
between transmission of MDR-TB and incarceration is consistent with previous studies
(Aerts et al., 2000; Kenyon, 2009; Stuckler et al., 2008), and further highlights the role
of prisons in the epidemic of MDR-TB in the former Soviet Republics. Finally, our new
findings revealed a link between incarceration and compensatory evolution and suggest
that forcing people into a crowded environment, highly conducive of TB transmission,
may influence the evolutionary trajectories of highly drug-resistant bacteria.
5.3. Data availability
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6.1. Abstract
During the past 20-30 years, the epidemic of drug resistant TB has heavily affected the
countries of the former Soviet Union and South Africa. Drug resistance was previously
assumed to be universally detrimental to M. tuberculosis bacteria in the absence of the
drug, and drug resistant strains were not thought to be capable of sustaining an infection
chain. However, several studies have now demonstrated that the appearance of drug
resistant strains is not only due to de novo evolution of resistance within patients, but
due to transmission of drug resistant strains. In parallel, studies have reported that drug
resistance can come at low or no fitness costs or be accompanied by fitness-restoring
compensatory mutations. Thus, the current understanding is that drug resistance in
M. tuberculosis does not a priori exclude transmissibility. However, the demonstrated
cases of fitness compensation are largely restricted to reduction of fitness costs due to
RIF-resistance due to mutations in a limited set of genes. This is surprising, given the
fact that extensively drug resistant M. tuberculosis strains are resistant against at least 4
drugs, but frequently carry even more mutations. In the light of complex drug resistance
patterns, compensation of drug-resistance related fitness costs might not be driven by
mutations in small set of genes, but by a multitude of different mutations affecting e.g. a
biological pathway. As the propensity of homoplasy is reduced, as e.g. multiple mutations
in different genes of a pathway may confer similar phenotypes, the detection of patterns
is dependent on very large, unbiased datasets. Here we apply a network analysis-based
approach to detect pathways frequently hit by mutations to identify pathways contributing
to successful transmission of MDR M. tuberculosis strains in the Republic of Georgia.
The preliminary results of these analyses are reported in this working chapter and future
directions of research are outlined.
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6.2. Introduction
During evolutionary history, obligate pathogens, including M. tuberculosis, established
and adapted to an ecological niche within their host. Many intracellular pathogens demon-
strate low genetic diversity, for reasons not well understood (Achtman, 2008). One pos-
sible explanation is “diminishing returns epistasis”, wherein most mutations are at best
marginally beneficial (Chou et al., 2011) because the long history of coevolution between
the human host and M. tuberculosis (Brites et al., 2015; Gagneux, 2018) might have led to
high levels of adaptation. In this scenario, in early stages of adaptation, a few mutations
with large effects on fitness dominate and reach fixation in the population. Given a stable
environment, subsequent mutations will find themselves in a genetic background shaped
by previous mutations with which they interact epistatically. The number of mutations
with large effects diminishes with time and the number of mutations with small effects
on fitness increase as a result. While strongly deleterious mutations will vanish due to
purifying selection within the host they arose in, beneficial mutations will be prone to
extinction due to genetic drift. In these contexts, mutations will have to have a strong se-
lective advantage to reach the numbers within a host required to be transmitted, which, as
we have seen previously, is not likely to occur in stable environments and in a well-adapted
genetic background. However, there are mutations with large selective benefits in special
environments. Mutations conferring drug resistance are the canonical example (Merker
et al., 2018). Detection of drug resistance mutations in M. tuberculosis is relatively easy,
as most high-level resistance is conferred by chromosomal mutations with large selective
effects (Coll et al., 2015). However, drug resistance mutations frequently cause reduced
growth rates and are only beneficial in the presence of antibiotics. This creates strong
selection for mutations restoring (compensating) replicative fitness in absence of the drug
(Comas et al., 2012; Merker et al., 2018; Vos et al., 2013). The best known example
comes from the compensation of RIF resistance-related fitness costs caused by mutations
in the β′-subunit of the DNA-dependent RNA polymerase. Furthermore, mutations in
KatG, conferring isoniazid resistance, are known to reduce the catalytic activity of KatG
(Yu et al., 2003), which coincides with elevated oxidative stress. These effects may be
compensated by upregulation of the peroxiredoxin ahpC (Sherman et al., 1996).
Surprisingly, apart from these two examples, there are no other well-established mech-
anisms of fitness cost compensation in M. tuberculosis caused by chromosomal mutation.
The plastic upregulation of TlyA expression in capreomycin resistant mutants, reducing
capreomycin resistance-related fitness costs is better described as buffering of fitness costs
rather than compensation, as the fitness costs are only partially compensated (Freihofer
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et al., 2016). There are multiple possible explanations for this observation. Certain drug
resistance mutations might not inflict a fitness deficit (Gagneux et al., 2006b). Further-
more, combinations of drug resistance mutations have been demonstrated to alter the
adaptive landscape considerably. Fitness costs of drug resistance mutations may be mit-
igated by the presence of a further resistance mutation (Borrell et al., 2013). On the
other hand, the number of different targets of compensation is greatly enlarged in double
mutants (Moura de Sousa et al., 2017). The inflation of potential targets of compensa-
tion makes the detection of homoplasic compensatory mutations greatly dependent on
the sample size. Furthermore, genetic association studies in bacteria are hampered by
extensive linkage disequilibrium, making the separation of loci under selection from the
genetic background of a Lineage challenging (Chen et al., 2015). In fact, most tools aim-
ing at detecting homoplasy after adjusting for phylogenetic relatedness, have only been
able to detect a small number mutations occurring multiple times (Farhat et al., 2013).
The failure to detect homoplasy could be a consequence of the genetic determinants un-
der selection not being reducible to convergence on the mutational or even gene-level, at
least not using highly skewed convenience samples as a basis for identifying mutational
convergence.
Antibiotics target essential bacterial pathways, and drug resistance mutations can have
pleiotropic downstream effects (Perkins et al., 2008). It is therefore plausible that compen-
sation for drug resistance-related fitness costs inflicted by a single mutation, e.g. RpoB
S450L for rifampicin (RIF) resistance, may involve multiple different aspects. Recent
work on fitness costs of RIF resistance-related fitness costs has demonstrated that dif-
ferent RIF resistance mutations cause different phenotypes, for example deficiencies in
initiation, elongation and termination in transcription (Stefan et al., 2018), which in turn
might be differentially influenced by compensatory mutations. The different components
of fitness costs of RpoB mutations might explain why we see preferential association of
certain resistance mutations with secondary mutations in RpoA/C.
Surpassing the demonstrated compensatory effects of single mutations, compensation
might also take place at the pathway level. To our knowledge there is currently no known
example of convergent evolution on the pathway level compensating for drug resistance-
related fitness costs. However, mutations targeting the gene alr in M. tuberculosis confer
resistance to cycloserine, by abrogating the utilisation of pyruvate. The downstream effect
of loss of function mutations in alr is that there is an overabundance of the substrate of
the drug target, inhibited by cycloserine (Desjardins et al., 2016b). In principle, such
a process would also be a possible mechanism for compensating drug resistance-related
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fitness costs resulting from drug resistance mutations in essential enzymes, for example
those that lead to lower enzymatic processivity. If inactivating any enzyme in a metabolic
pathway would have the same downstream effect, e.g. disrupting the possibility to utilize
pyruvate, there would be little convergence expected on the mutation or gene level, as any
disruptive mutation in any of the genes in the pathway would have the same effect.
Here, we report a first attempt to discover pathways under selection in multidrug-
resistant M. tuberculosis strains, which could be involved in compensation of drug
resistance-related fitness costs. To do this, we applied a network analysis-based approach
developed by Verbeke et al. (Verbeke et al., 2015), which uses prior information derived
from gene-gene interaction networks together with mutation data to infer which path-
ways are affected more frequently by mutations than expected by chance. As an input,
we used mutational data extracted from the population-based M. tuberculosis sample set
described in chapter 5. We first identified strains belonging to transmission clusters and
then extracted mutations specific to the transmission cluster. These mutations putatively
contribute to the success (transmissibility) of these strains.
6.3. Materials and Methods
6.3.1. M. tuberculosis strains & transmission cluster inference
For the analyses described in this chapter, we used the mutational data generated in
chapter 5 as an input. Briefly, we used a sample set of 659 clinical M. tuberculosis
strains displaying at least an MDR phenotype, isolated in Georgia between 2011 – 2013
and subjected them to whole genome sequencing. The sample set consists of 53 % of
reported MDR M. tuberculosis strains in the sampling timeframe of the study. We used
the mutational data generated from whole genome sequences to create a variable position
pseudoalignment which served as a basis for inferring a distance matrix. To identify
transmission clusters based on genetic distance, we applied hierarchical agglomerative
clustering with the unweighted pair-group average method implemented in the agnes
function of the R package cluster (v.2.0.6.) to the previously inferred distance matrix.
We chose to cut the resulting tree at an average of 5 single nucleotide variants, as this has
proven to be a sensible cut-off for likely patient-to-patient transmission (Walker et al.,
2013).
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6.3.2. Inferring mutations private to transmission clusters
One major issue with genome-wide association studies in bacteria is linkage disequilibrium.
This is especially problematic for M. tuberculosis, which does not undergo horizontal gene
exchange, leading to a clonal population structure. One way to address this problem
is by using population-based sample sets. Although we only sequenced ca. 53 % of all
MDR M. tuberculosis cases isolated in Georgia between 2011 and 2013, the sample set
is not biased towards outbreaks. To extract mutations private to transmission clusters,
we compared the drug resistance profile of transmission clusters to the drug resistance
profile of their parent nodes. Parent nodes sharing the same drug resistance profile as a
given cluster were assumed to belong to the same, larger transmission cluster and that
mutations compensating for fitness costs were acquired earlier. We therefore compared
drug resistance profiles from a given cluster to all of its parent nodes until the drug
resistance profile differed by more than 2 mutations. We then took the set difference
between the intersect of all mutations in a cluster with the parent node, resulting in the
mutations private to the transmission cluster. We then filtered the list for drug resistance
mutations acquired since divergence from parent.
6.3.3. Pathway analysis
We used all mutations which were private to the different transmission clusters to rank
pathways by relevance using an adaptation of Verbeke et al.’s network-based approach. Al-
though the original approach integrates multiple types of data (gene expression, mutation,
methylation and copy number data) together with a priori knowledge about gene-gene in-
teractions to rank pathways, we focused on using only mutation data in this first attempt.
Our adaptation constructs a global network where M. tuberculosis strains, mutations and
genes are represented as nodes. Relationships between nodes, represented as undirected
edges, include: i) the presence of a mutation in a particular strain, ii) the assignment of a
mutation to a particular gene (intergenic mutations were assigned to a particular gene if
the mutation located before the start codon) and iii) the physical or functional interaction
between genes. We constructed a reference gene-gene interaction network derived from
KEGG pathways; pathways only containing a single gene were discarded. As described
by Verbeke et al., the degree of relatedness between each pair of nodes was inferred by
applying the Laplacian Exponential Diffusion (LED) kernel on the graph, followed by
normalization, producing a global similarity matrix. Since applying a kernel on graph
nodes assumes a fully connected network, we applied the kernel on the largest connected
component of our global network if it was not fully connected. The LED kernel is in-
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fluenced by a diffusion parameter (α), which was set to 0.1; however, results were stable
between 0.001 and 0.1. Given an M. tuberculosis strain and a pathway composed of a
set of genes, the average of the similarities between the M. tuberculosis strain and each
gene in the pathway corresponds to the pathway importance score for that M. tuberculosis
strain. The pathway importance score for a set of M. tuberculosis strains is obtained by
averaging their importance scores. To get the probability of obtaining an importance
score at least as extreme as the one obtained by chance, a random score distribution is
obtained for the pathway. This random distribution is obtained by repeatedly calculating
the pathway importance score from sets of genes randomly sampled from the similarity
matrix. The size of the randomly sampled gene sets is equal to the size of the pathway
gene set. Thus the pathway importance score is ultimately converted to a p-value.
6.4. Results and Discussion
6.4.1. Mutations private to transmission clusters
As reported in chapter 5, there were a total of 42 transmission clusters with a median size
of 3.5 strains (figure 6.1) and a total of 301 clustered strains. We identified a total of 1192
mutations private to transmission clusters out of a total of n = 10435 variable positions
in the complete dataset, in a total of 1372 genes. Most mutations were only shared by 1-2
clusters, indicating that the approach is successful in removing most of the phylogenetic
signal. (Figure 6.2). A number of SNVs do, however, occur in a large proportion of
strains, indicating the presence of phylogenetic markers. To avoid including phylogenetic
markers, the “tree walking” algorithm could be altered. Instead of looking for parent
nodes of clusters with differing drug resistance profiles, the algorithm could be purely
distance-based. From the work of Walker et al., we know that the likelihood of direct
transmission between two patients drops if the pairwise genetic distance between the two
patient isolates is larger than 5 mutations. This could be exploited by including parent
nodes until the genetic distance between the two patient isolates within a cluster reaches
a certain threshold. The threshold could be initially set at 12 mutations, as Walker et al.
demonstrated that when strains differed by more than 12 mutations, no epidemiological
links between two strains could be identified (Walker et al., 2013). The mutations private
to the transmission cluster would then again be determined by the set difference between
the intersect of all mutations within the transmission cluster and the parent node.
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0.006
Figure 6.1.: Maximum likelihood phylogeny of the 659 M. tuberculosis strains included in the
network analysis study. Strains belonging to clusters inferred by hierarchical agglomera-
tive clustering are colored in red. Blue shading indicates strains belonging to Lineage 2, red
shading indicates strains belonging to Lineage 4. Scale bar indicates substitutions per site
with a total of 10435 variable positions.
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Figure 6.2.: Histogram of how frequently mutations occurred in clusters. Certain mutations
appeared in 30 clusters and were most likely phylogenetic markers.














MDR+ samples in transmission clusters
Figure 6.3.: Pathways with the highest score.
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6.4.2. Pathway relevance ranking– proof of concept and intriguing
findings
Figure 6.3 shows the pathways that carried mutations more often than expected by chance.
A total of 12 pathways were hit more frequently than expected by chance at a significance
level of p < 0.05. Most pathways show hits in multiple genes, whereas most individual
genes do not show multiple mutations (figure 6.4). The RNA polymerase pathway was
among the highest ranked pathways; the genes most frequently affected in those pathways
were rpoA and rpoC (figure 6.4). This served as a proof of concept, as we expected the
pathways containing the known targets of compensation to be enriched. However, it is
interesting that the pyrimidine biosynthesis pathway, as well as alanine, aspartate and
glutamate metabolism (nucleotide precursors) pathways are ranked highly, as this might
hint at a connection to the RNA polymerase and therefore RIF resistance. We observed a
total of 64 unique mutations in the pathways involved in nucleotide biosynthesis. Exclud-
ing mutations in the RNA polymerase, RIF-resistant strains have more non-synonymous
mutations in genes belonging to the pyrimidine and nucleotide precursor synthesis com-
pared to RIF-susceptible strains (median number of mutations in RIF resistant = 35
vs. susceptible = 30, p < 2.2 x 10-16, Mann-Whitney U test). The RIF-resistant RNA
polymerase might have altered affinities for nucleotides, potentially requiring more nu-
cleotides for optimal function. Indeed, work performed on RIF-resistant Escherichia coli
demonstrated that RIF-resistant RNA polymerases have a lower affinity for nucleotides
(Jin et al., 1991). This raises the question of whether mutations in nucleotide biosyn-
thesis pathways are involved in fitness-compensation, independent of the effect that rpoC
mutations have on restoring transcription in rpoB mutants (Stefan et al., 2018). Fur-
thermore, preliminary metabolomics data generated from 3 clustered and 3 unclustered
strains picked from the same dataset used in this analysis, clustered strains show increased
uracil concentrations compared to unclustered strains. The clustered strains share two
nonsynonymous mutations in carB (pyrimidine biosynthesis pathway) and apt (purine
biosynthesis pathway). Furthermore, the Georgian dataset revealed that, although many
canonical compensatory mutations have been detected (e.g. RpoA T184A, RpoC V483G),
there were some that locate to the secondary channel of the RNA polymerase and may
interact with nucleotides. These results hint at the potential existence of alternative
pathway for compensating RIF-resistance related fitness costs in M. tuberculosis either
via altering the RNA polymerase, potentially to increase the affinity of the RIF resistant
enzyme to nucleotides or by increasing nucleotide levels.
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Figure 6.4.: Genes within the pathways with the highest relevance scores. Genes are color coded
according to the number of different mutations detected within a gene.
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There are is a caveat in that the wealth of mutations detected in the nucleotide biosynthe-
sis pathways spread over a number of different genes does not offer any directly apparent
mechanism in which non-synonymous mutations in these genes could increase nucleotide
levels. However, the regulation of nucleotide biosynthesis in bacteria is complex in general
(Turnbough et al., 2008), and there is little information on regulation of these pathways
in M. tuberculosis. More detailed metabolomics experiments of strains carrying these
mutations will be required to link genotypes and phenotypes.
6.4.3. Other highly ranked pathways and potential
connections
Mutations identified in the quorum sensing pathway mainly map to the gene Rv2351c,
which encodes a phospholipase. However, mapping the mutation on the phylogenetic tree
revealed that all Lineage 2 strains have acquired 3 mutations within this gene, confirming
the mutation list still contains phylogenetic variants. The high ranking of pathways
associated with lipid metabolism (glycerophospholipid & ether lipid metabolism), as well
as inositol phosphate metabolism might indicate a connection to cell wall biosynthesis.
Lipids are a major constituent of the mycobacterial cell (Jackson, 2014) wall and inositol
phosphate is crucial to link arabinogalactan to the outer cell membrane (Movahedzadeh
et al., 2010). Multiple antituberculous drugs, including including isoniazid, ethambutol,
pyrazinamide and ethionamide, target cell wall biosynthesis. The contribution of two-
component systems to compensation of fitness costs is more difficult to establish. Two-
component systems perform a multitude of different tasks in intracellular signalling and
are grouped in this pathway based on their general function (sensor kinases), rather than
acting in a concerted manner.
6.5. Future directions
As a first step, we propose to repeat the identification of mutations private to transmission
clusters purely on a distance-based measure to be able to exclude the vast majority of
phylogenetic mutations. The detection of a potential new pathway of compensation is
exciting, and it is not surprising that it is related to RIF resistance as resistance to
this drug is known to inflict substantial fitness deficits in some strains. However, the
method also detected several pathways related to cell wall biosynthesis. We would like to
investigate these pathways in more detail by stratifying the dataset into groups of strains
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resistant to drugs targeting cell wall biosynthesis vs. others. For this, we need to include
more samples to increase numbers in the different compartments. Sequencing efforts in
Georgia continue and a wealth of strains from subsequent years (2013 onwards) will be
available soon.
6.5.1. Hypotheses
We furthermore want to follow up on the potential involvement of nucleotide levels in the
compensation of RIF-resistance related fitness costs concerning the following hypothe-
ses:
1. Fitness costs of RIF resistance mutants vary as a function of pyrimidine (uracil)
availability.
2. Mutations in the secondary channel of the RNA polymerase influence nucleotide
affinity and reduce fitness costs of RIF resistance.
3. Mutations found in nucleotide biosynthesis pathways do not occur or occur less
frequently with RNA polymerase mutations in the secondary channel.
4. Strains with mutations in nucleotide precursor or pyrimidine biosynthesis pathways
demonstrate higher levels of uracil.
6.5.2. Objectives
We want to test these hypotheses by addressing the following objectives
1. Generate pyrimidine auxotrophic Mycobacterium smegmatis strains by disrupting
the pyr operon responsible for pyrimidine biosynthesis in RIF resistant backgrounds
involving a high (RpoB H445Y) and low cost (RpoB S450L) mutation. Perform
growth curves in presence of varying uracil concentrations.
2. In the backgrounds outlined under point 1, generate strains carrying mutations in
the secondary channel of the RNA polymerase and perform growth curves in varying
uracil concentrations.
3. Using the Georgian MDR M. tuberculosis strain set from 2011-2013 and subsequent
years, assess patterns of coexistence/mutual exclusivity of mutations in nucleotide
biosynthesis pathways and mutations in the secondary channel of the RNA poly-
merase.
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4. Perform large scale metabolomics analyses of clustered (n = 150) and unclustered (n
= 100) MDR M. tuberculosis strains and assess differences between the two groups
with a special emphasis on nucleotide levels (project is already underway).
6.5.3. Expected outcomes
Reduced pyrimidine levels in RIF resistant backgrounds should inflate the fitness costs, as
the affinity of the RNA polymerase for pyrimidines is reduced compared to RIF susceptible
strains. Furthermore, mutations in the secondary channel of the RNA polymerase should
increase the growth rate of RIF resistant strains dependent on the uracil concentrations in
the medium. If there are two ways of coping with the lower affinity of RIF resistant RNA
polymerases, namely increasing the intracellular pyrimidine levels or restoring affinity via
mutations in the secondary channel of the RNA polymerase, the two pathways should
be, to some degree, mutually exclusive. We expect that strains we inferred as clustered
will differ from unclustered strains in terms of intracellular nucleotide levels; clustered
strains would be predicted to have higher pyrimidine levels. If this effect is observed,
the large scale of the experiment will help to establish a genotype-phenotype relationship
between mutations in the nucleotide precursor and biosynthesis pathways and nucleotide
levels.
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7.1. Abstract
Drug-resistant M. tuberculosis variants may evolve in single patients even under optimal
treatment conditions. It is believed that sub inhibitory drug concentrations (sub-MIC)
contribute to treatment failure, by giving resistant variants, omnipresent in populations of
sufficient size, a selective benefit over drug-susceptible variants. Drug efflux mechanisms
have been implicated in low-level drug resistance and their induction by the presence
of antituberculous drugs has been demonstrated. M. tuberculosis infections are treated
with at least 4 active antituberculous drugs- However, the influence of drug combinations
at sub-MIC on the evolution of drug-resistance in M. tuberculosis is unknown. Here we
present a study investigating the influence of sub-MIC of two drugs, rifampicin (RIF) and
isoniazid (INH), alone and in combination on the evolution of drug resistance in three
drug-susceptible clinical M. tuberculosis isolates. The strains were passaged for ≈180
bacterial generations in the presence increasing concentrations of RIF and INH alone and
in combination, starting at a fraction of the wt MIC and ending at 4 x MIC. Whole
genome sequencing was performed of three endpoint cultures per treatment and strain.
We report the detection of drug-resistance conferring mutations in most cultures that
survived until the end of the experiment.
7. Experimental Evolution of MTB 93
7.2. Introduction
The de novo evolution of drug-resistant M. tuberculosis variants is generally thought to
be a result of inadequate treatment due to interrupted drug supply, delayed drug sus-
ceptibility testing, prescription of inadequate treatment regimens, patient non-adherence,
or low drug quality (Law et al., 2017). Furthermore, there are a number of factors spe-
cific to human hosts which can generate sub-MIC drug environments within patients,
also resulting in selection for resistant variants (Gullberg et al., 2011). Patients may
differ in terms of how well drugs are absorbed and how fast they are metabolized and
rendered ineffective, as demonstrated for RIF and INH (Gumbo et al., 2007; Van Ingen
et al., 2011; Pasipanodya et al., 2013). Furthermore, antituberculous drugs have vastly
different chemical properties and as a result, drugs differ in their capacity to diffuse into
mycobacteria-containing tissues. Unequal penetration of drugs in combination therapy
will generate spatio-temporal variation in drug concentrations (Prideaux et al., 2015)
known to select for multidrug-resistance (MDR: resistance against rifampicin and isoni-
azid) (Moreno-Gamez et al., 2015). Gullberg et al. demonstrated that sub-MIC drug
concentrations lead to the stable coexistence of resistant and susceptible variants, or can
even select for a fully resistant population. Drugs at sub-MIC will reduce the growth rate
of susceptible strains in a dose dependent manner, creating an ecological niche for drug-
resistant bacteria suffering from drug-resistance-related fitness costs. If the growth rate
of the drug-susceptible strains is reduced to the level of the resistant variants, coexistence
of resistant and susceptible variants in the same population is the result. Drug-resistant
variants will outgrow the drug-susceptible strains if the growth rate of the drug-susceptible
strains is reduced to levels below that of the resistant variant, or if the drug resistant vari-
ants acquire compensatory mutations. The lowest drug concentration at which resistant
strains have a selective benefit is termed the “minimal selective concentration” (MSC).
There are no data on the MSC for antituberculous drugs alone or in combination.
Regimens containing multiple drugs are highly effective in treating TB infections and
preventing the evolution of resistant variants in M. tuberculosis (Feng-Zeng et al., 1996).
Yet, even under optimal conditions, drug resistant variants may evolve in individual pa-
tients (Bloemberg et al., 2015; Srivastava et al., 2011). It has been hypothesized, that the
evolution of drug resistant variants in M. tuberculosis is due to “functional monotherapy”
as a result of one of the factors described above that reduces drug concentrations to sub-
MIC levels (Colijn et al., 2011; Warner et al., 2006). M tuberculosis strains may also find
themselves in the presence of multiple drugs at sub-MIC levels. The influence of sub-MIC
drug combinations on the evolution of MDR M. tuberculosis strains is largely unexplored
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(Ankomah et al., 2012). Apart from selecting for chromosomal resistance, it is known
that sub-MIC drug levels induce the expression of drug efflux pumps (Gygli et al., 2017),
potentially serving as a stepping stone for high-level, chromosomally encoded resistance.
The influence of efflux pumps on generating high-level resistance is a matter of current
debate. There seems to be great variability in the expression of efflux pumps among
clinical isolates (Li et al., 2015; Machado et al., 2017). However, most strains displaying
clinically relevant levels of RIF and/or INH resistance have chromosomal mutations in
rpoB and katG, respectively. In the clinics, RIF resistance is used as a surrogate marker
for MDR strains, as RIF mono-resistance is rare. In contrast, INH mono-resistance is
frequently observed.
Here we report preliminary analyses of a serial passage experiment involving three
clinical M. tuberculosis strains exposed to increasing concentrations of RIF and INH
alone and in combination, starting at a fraction of the wild type MIC and ending at 4 x
MIC. Whole genome sequencing was performed on three endpoint replicates (endpoint:
180 generations) per strain and treatment.
7.3. Materials and methods
7.3.1. M. tuberculosis strains
We selected three clinicalM. tuberculosis isolates from three different genetic backgrounds:
a Lineage 2 strain (N0155, Beijing sublineage) due to the frequent association of Lineage 2
with drug resistance phenotypes (Chapter 3), a Lineage 4 strain (N1283, Ural sublineage),
as Lineage 4 strains are endemic in Georgia, the site of a large sampling project (see
Chapters 5 and 6), in addition to being frequently associated with drug resistance, and
a Lineage 1 strain (N0157, Manila sublineage), a Lineage in which drug resistance is
relatively rare, despite causing a considerable number of cases in South-East Asia (Roa
et al., 2018).
To select individual colonies, strains were plated on Middlebrook 7H10 agar and in-
cubated at 37° C for 3 weeks. 10 individual colonies were picked and sub-cultured in
Middlebrook 7H9 medium to an OD600 of ≈0.5. Stocks equivalent to OD600 = 0.5 were
generated by spinning the cells down, removing the culture supernatant and resuspending
the pellet in the respective amount of H2O containing 10 % (v/v) glycerol.
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7.3.2. Culture medium & culture vessel
For all experiments, we applied Middlebrook 7H9 ADC liquid medium, supplemented
with 0.1 % Tween80 to reduce clumping. Serial transfer experiments were performed in
10 ml standing cultures in inkwells sealed with a vented cap to allow for air exchange.
Biosafety concerns due to the likely generation of MDR strains made the use of agitated
cultures unfeasible. Growth properties in standing cultures were assessed by measuring
the optical densities achieved after 21 days of incubation of 6 replicate cultures per strain.
Two different inocula were evaluated: 5 x 106 cells and 0.5 x 106 cells.
7.3.3. MIC determination
We determined the MICs for the selected strains for RIF, INH and RIF and INH in com-
bination using a resarzurin microtiter assay (Franzblau et al., 2012) in a checkerboard
layout (Orhan et al., 2005). We screened the strains for susceptibility to drug concen-
trations in twofold dilutions. For RIF, the concentration range assayed was 6.25 x 10-3
µg/ml – 2.44 x 10-5 µg/ml and for INH, 40 µg/ml – 1.56 x 10-3 µg/ml. For the screen-
ing, we cultured the strains to mid log phase (OD600 ≈0.5), diluted the cultures to 106
cells/ml and added 10 µl of the diluted suspension to the microtiter wells containing 90
µl Middlebrook 7H9 medium including the drugs. We incubated the plate for 6 days at
37° C, after which 10 µl 0.02 % (w/v) resazurin was added to the wells and incubated
overnight. A fluorometer was used to measure the concentration of metabolized resazurin
as an indicator of bacterial metabolic activity (excitation wavelength 572 nm, emission
wavelength 583 nm). “No bacterial growth” at a given drug concentration was defined as
a reduction of the relative fluorescence by > 90 % compared to a no-drug control.
7.3.4. Serial passage
There were 10 replicate cultures per genetic background and treatment. There were in
total four treatments: RIF alone, INH alone and RIF + INH, as well as a no-drug control.
As there is no prior information on the MSC for any drug in M. tuberculosis, we decided
to start the serial passage experiment at 1/64 of the MIC. Initial cultures were set up by
inoculating 20 µl of the calibrated stock suspension (OD600 = 0.5) into 10 ml of 7H9 ADC
medium containing 0.1 % tween 80. Due to the light sensitive nature of RIF, cultures of
treatment 1 and 3 were protected from light. Cultures were grown for 3 weeks at 37° C
and sub cultured by inoculating 10 µl of the grown culture into 10 ml of fresh medium
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(see results). Every second passage, stocks were frozen and the drug concentration was
doubled.
7.3.5. Fractional inhibitory concentration index (FIC)
The FIC for a drug A was calculated by dividing the MIC of drug A in combination
with drug B by the MIC of drug A alone. The sum of the FIC of drug A and drug B
determined the interaction between the two drugs: σFIC ≤ 0.5: synergistic, σFIC > 0.5
< 2: indifferent, σFIC ≥ 2: antagonistic (Orhan et al., 2005).
7.3.6. Growth indices
All cultures appeared to grow robustly until generation 110 (passage 11 – 0.5 x MIC).
Growth indices were collected from generation 110 onward by assessing robustness of
growth by eye using the following keys: 1: scant growth, 2: intermediate growth, 3:
robust growth.
7.3.7. Whole genome sequencing
We sequenced three end point cultures from generation 180 from treatments 1, 2, 3 (only
N0155 and N1283) and 4. As no replicates of N0157 survived until the end of the ex-
periment in treatment 3, we sequenced 3 replicates from generation 130 cultures instead.
Whole genome sequencing, mutation identification and annotation was performed as de-
scribed previously (Ghielmetti et al., 2017; Gygli et al., 2018).
7.4. Results
7.4.1. MIC for RIF, INH and RIF + INH combinations
All strains demonstrated similar MIC values for the two drugs alone and in combination
(table 1) and differed by at most one dilution step. The interaction between INH and
RIF in combination was indifferent for N1283 (σFIC = 2) and N0157 (σFIC = 2) and
antagonistic for N0155 (σFIC = 3). Indifference between RIF and INH has been reported
previously (Dickinson et al., 1977). As the maximum difference in MIC between the
strains was within one dilution step, we used the same MIC for all strains to reduce the
complexity of the experiment.
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Table 7.1.: MICs for isoniazid and rifampicin alone and in combination.
Strain MIC INH only MIC INH in combination
N0155 0.05 µg/ml 0.05 µg/ml
N0157 0.05 µg/ml 0.05 µg/ml
N1283 0.05 µg/ml 0.1 µg/ml
MIC RIF only MIC RIF in combination
N0155 1.563 ng/ml 1.563 ng/ml
N0157 0.781 ng/ml 0.781 ng/ml
N1283 0.781 ng/ml 0.781 ng/ml
7.4.2. Assessment of growth in standing cultures
M. tuberculosis achieves the highest growth rates in well-oxygenated cultures. However,
due to biosafety concerns in selecting for MDR M. tuberculosis variants, cultures were not
subjected to continuous shaking. To test growth properties of the three selected strains,
we assessed growth in 10 ml standing cultures with vented caps. All strains achieved
similar optical densities after 3 weeks of incubation with both inocula (OD600 = 0.8-1.1).
We chose to subculture every three weeks applying a bottleneck of 1:1000, corresponding
to ca. 0.5 x 106 cells, to achieve ≈200 generations within a manageable time frame (1 –
1.5 years) (Comas et al., 2012; Reynolds, 2000).
7.4.3. Whole genome sequencing results
The median fold coverage of the sequenced strains was 68.0x (25th percentile = 52.7x, 75th
percentile = 78.6x, interquartile range (IQR) = 25.9).The median mapping percentage
was 98.9 % (25th percentile = 98.8 %, 75th percentile 99.0 %, IQR = 0.2).
Mutations detected in the ancestors and the strains from treatment 4 (no drug control)
were removed from the mutations detected in strains from treatment 1-3, to exclude
putative media adaptations and to generate a list of mutations which were acquired during
serial passage. There were a median of 2 fixed (25th percentile = 1, 75th percentile = 4, IQR
= 3), 23 unfixed (25th percentile = 17.5, 75th percentile = 28, IQR = 10.5) and 3 unfixed
indels (25th percentile = 2, 75th percentile = 4, IQR = 2) detected per culture.
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Figure 7.1.: Mutations detected in canonical resistance genes. A Mutations in drug resistance
genes in strains from treatment 1 (RIF). B Mutations in drug resistance genes in strains
from treatment 3 (RIF + INH).
Table 7.2.: rpoB and katG mutations detected in the three treatments
Target gene Treatment 1 (RIF) Treatment 2 (INH) Treatment 3 (RIF + INH)
rpoB Ser450Leu, Asp435Gly, Leu430Arg,Asp435Ala -
Gln172, Ser450Trp, Asp435Gly,
Ser441Leu, Val170Phe
katG Gly285Asp, Gly120Asp Met105Ile,Val1?, Leu415Met, Lys274Glu
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7.4.4. Mutations in genes encoding efflux pumps
As a first step, we were interested in seeing if there were any mutations in regulatory
regions of known/putative efflux pumps (Silva et al., 2016), potentially conferring low level
resistance to RIF and/or INH. We were unable to detect mutations in genes previously
associated with drug efflux, potentially indicating that overexpression of efflux pumps is
not a relevant mechanism for RIF and/or INH resistance.
7.4.5. Mutations in drug resistance conferring genes
We observed mutations in canonical RIF and INH resistance-related genes (rpoB and
katG). No mutations were observed in the gene inhA (target of activated INH) or its
promoter. Surprisingly, we identified katG mutations in treatment 1 (RIF), in absence
of any rpoB mutations, however not the opposite (no rpoB mutations in treatment 2
(INH)) (Figure 7.1). In total, six out of nine sequenced strains from treatment 1 carry
katG mutations. Furthermore, two out of three N1283 replicates from treatment 1 do not
carry any rpoB mutations, yet survive at 4x of the RIF MIC. All strains in treatment 2
harboured katG mutations. In treatment 3, all but one strain of the replicates surviving
until generation 180 harboured katG and rpoB mutations. Of the three replicates of
N0157 from generation 130, two harboured frame shift mutations in katG, but no rpoB
mutations.
Table 7.3.: Proportion of replicates surviving until generation 180.
Strain Treatment 1 (RIF) Treatment 2 (INH) Treatment 3 (RIF + INH)
N0155 100 % 100 % 30 %
N0157 100 % 100 % 0 %
N1283 60 % 100 % 70 %
7.4.6. Growth indices, survival and extinction
In all treatments, strains demonstrated robust growth until generation 110 (0.5 x MIC),
after which growth inhibition was observed in a number of cultures. We observed fluc-
tuating growth indices in all treatments as a function of increasing drug concentrations
(figures 7.2, 7.3, 7.4). Growth indices decreased when the antibiotic concentration was
doubled and increased again after the subsequent dilution step where the strains spent
another 3 weeks at the same antibiotic concentration. The different strains demonstrated
different mean growth indices within the three treatments, indicating that there are
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Figure 7.2.: Growth indices of all cultures in treatment 1 (RIF) starting at generation 110
(0.5 x MIC).
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Figure 7.3.: Growth indices of all cultures in treatment 2 (INH) starting from generation 120
(0.5 x MIC).
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Figure 7.4.: Growth indices of all cultures in treatment 3 (RIF + INH) starting from gener-
ation 110 (0.5 x MIC).
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differences in how the three strains react to increasing drug concentrations 1 (F= 79.4,
p = 4.9 x 10-12, repeated measurement ANOVA), treatment 2 (F = 38.7, p = 1.17 x
10-08, repeated measurement ANOVA) and 3 (42.2 4.8 x 10-09, repeated measurements
ANOVA). The observed fluctuations were least pronounced in treatment 2, compared to
treatments 1 and 3. Strains N0155 and N1283 do not seem to suffer from growth reduction
in treatment 2, potentially indicating the early acquisition of mutations generating high-
level INH resistance. Indeed, all sequenced endpoint cultures of treatment 2 harbour
katG mutations. However, there are fluctuations in growth in strain N0157 in treatment
2, albeit on a high level (reduction from growth index 3 to 2). Mutations abrogating KatG
function confer high-level INH resistance. The observed fluctuations in growth indices in
N0157 in treatment 2 might be explained by katG, mutations which do not completely
abrogate INH activation. Not all strains survived until the experiment was terminated
in treatments 1 and 3 (table 7.2). Interestingly, not all strains from N1283 survived in
treatment 1, but had the largest proportion of strains surviving in treatment 3. On the
other hand, all N0157 replicates survived in treatment 1 but went extinct in treatment
3.
7.5. Discussion
After ≈180 generations of serial passage, we observe distinct patterns of growth between
the different strains. For instance, RIF seems to exert a stronger influence on population
density than INH, as demonstrated by the different growth patterns observed in treat-
ments 1 and 3. This is not surprising, as the target size for in vitro INH resistance is
larger compared to RIF (Bergval et al., 2009); any mutation abrogating the activity of
KatG will lead to INH resistance, whereas RIF resistance-conferring mutations are largely
restricted to an 81 bp long region, termed the RIF resistance-determining region (Meftahi
et al., 2016).
The peculiar rebound pattern observed in all treatments containing RIF might be a
sign of adaptation to higher drug concentrations not driven by resistance mutations.
The growth dynamics in vented caps indicate that growth is comparable to agitated
cultures when cell densities are low and the medium is sufficiently oxygenated for optimal
growth. Changes in the endpoint cell numbers are therefore presumably due to inhibition
action of the drugs in the early growth phases in the standing cultures. RIF degrades
in 7H9 medium with a half-life of about a week (Yu et al., 2011) but is not affected
by the presence of INH. The inhibitory effect of RIF is therefore a function of time,
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potentially giving strains the opportunity to survive either by upregulating drug efflux
mechanisms, or by entering a non-replicative state until the RIF levels have degraded
sufficiently (Brake et al., 2018; Machado et al., 2012). The observation of katG mutations
in cultures that have never experienced INH is unexpected and prompted us to assess the
possibility of experimental error including mislabelling vessels and tubes or swapping of
experimental treatments. Mislabelling of the tubes used to prepare DNA for exploratory
sequencing can be easily addressed by performing confirmatory PCRs on the replicates of
treatment 1 carrying katG mutations. However, the presence of rpoB and katG double
mutants in treatment 1 and differing katG mutations in the strains from treatment 2
(INH) make the swapping of labels between treatments 1 and 2 unlikely. The presence of
double mutants in N0157 in treatment 1 also makes swapping labels between treatment
1 and 3 unlikely, as no cultures of N0157 survived the combination treatment. The
appearance of double mutants might point towards swapping of experimental treatments,
thus generating periodic selection potentially subsequently selecting for double resistant
strains. However, swapping of experimental treatment would not be reconcilable with
the observed growth indices, as these show repeating patterns. Furthermore, we do not
observe rpoB mutations in the INH treatment, making it unlikely that the experimental
treatments of treatment 1 and 2 were swapped.
If we exclude the possibility of experimental error, the presence of katG mutation in
treatment 1 raises questions about their potential function in RIF resistance. Although
we cannot be sure that all detected katG mutations in treatment 1 actually confer INH
resistance, it is striking that 5/9 replicates in treatment 1 show katG mutations, whereas in
the control experiment (no drug), only 1 strain acquired a katG mutation. The mechanism
of INH resistance in vitro differs from that observed in clinico (Bergval et al., 2009).
INH resistance in vitro is conferred by any loss of function mutation in katG, whereas a
functional katG is essential for pathogenicity of M. tuberculosis in vivo (Barnett et al.,
1953). The appearance of katG mutants in treatment 1 might indicate that the katG
mutants have an altered susceptibility to RIF, presumably conferring the ability able to
survive in the sub-MIC RIF environment. Unfortunately, there is only scarce quantitative
drug susceptibility testing data assessing the RIF MIC of INH mono-resistant katG mutant
strains. However, comparing RIF MIC data of 4 katG mutants with katG wild types
presented in Chapter 4 indicates that the mean MIC of katG mutants is slightly higher
(mean RIF MIC of katG mutants = 0.108 mg/L 7H10 agar dilution, mean RIF MIC katG
wt = 0.95 mg/L, p = 0.051, Mann-Whitney test), although the difference only approaches
significance and there are very few data points. The elevation of the RIF MIC in katG
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mutants might have gone unnoticed, as the elevation of RIF MIC in katG mutants is
subtle and might not cause elevations beyond the critical concentration.
The gene katG encodes a catalase/peroxidase involved in detoxification of reactive
oxygen species. Losing the activity of this key detoxification enzyme might lead to the
accumulation of toxic compounds and the subsequent induction of efflux mechanisms,
potentially causing a slightly elevated RIF MIC. Indeed, efflux pumps have been demon-
strated to be upregulated in MDR M. tuberculosis variants (Li et al., 2015) and upon
exposure of susceptible strains to the critical concentration of multiple drugs (Machado
et al., 2017). Furthermore, upregulation of efflux pumps seems to persist even after the
acquisition of chromosomal mutations (Machado et al., 2012). In treatment 3, the subtle
increase in RIF MIC in katG mutants might aid the survival of INH mono-resistant strains
in host tissues experiencing fluctuations in drug concentrations including sub-MIC RIF
environments, especially in the light of current dosing regimens failing to generate steriliz-
ing serum concentrations of RIF in certain patient groups (Chapter 3). Further evidence
of the RIF MIC elevating effect of katG comes from the observation that in treatment
1, rpoB mutations conferring low-level RIF resistance (RpoB L430R, D435G), (Chapter
4, (Miotto et al., 2018)) are only found in strains carrying katG mutations (3/9 strains).
On the other hand in single mutants, rpoB mutations conferring high-level RIF resistance
only RpoB S450L is found (2/9 strains). Given the frequent occurrence of katG mutants
in treatment 1, it is not surprising that we find strains in treatment 3 without an rpoB
mutation (2/6 strains). However, the detection of 2 katG mutants in N0157 in treatment
3 at generation 130 does not seem to fit the hypothesis that katG mutations increase the
baseline RIF MIC, as all of the N0157 replicates in treatment 3 went extinct.
Interestingly, a recent study demonstrated that even small differences in RIF and INH
MICs of otherwise susceptible strains are able to predict treatment failure and the evolu-
tion of drug resistant phenotypes in M. tuberculosis (Colangeli et al., 2018). The observa-
tion that the distribution of katG mutations in clinico is skewed towards the S315T mu-
tation (Chapter 5, Casali et al., 2014; Merker et al., 2018), rarely observed in vitro, might
reflect the requirement of acquiring INH resistance while retaining catalase/peroxidase
activity but might further offer a selective benefit by elevating the RIF MIC.
7.6. Future directions
First, we want to exclude experimental error by 1) confirming the fixed mutations iden-
tified by whole genome sequencing by Sanger sequencing from DNA directly isolated
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frozen stocks from two consecutive freezer checkpoints (e.g. generation 160 & 180) and
2) sequencing the remainder of surviving endpoint cultures from generation 180.
7.6.1. Hypotheses
Assuming that experimental error is not the source of the reported observations, we want
to address the following hypotheses:
1. katG mutations elevate the RIF MIC.
2. Elevated RIF MICs are the result of efflux pump upregulation
3. Efflux pump upregulation is a consequence of oxidative stress
4. katG mutations precede rpoB mutations in treatment 3 and treatment 1
7.6.2. Objectives
We want to test these hypotheses by addressing the following objectives:
1. Determine fine-scale RIF MICs (Colangeli et al., 2018) for strains from treatment
1, 2 and 3 only carrying katG mutations. Furthermore, determine RIF MICs for
strains which went through a single selection step for INH resistance, to exclude the
possibility of other mutations acquired during serial passage, affecting RIF MICs
2. Determine fine-scale RIF MICs of katG mutants from treatment 1, 2 and 3 in
presence and absence of efflux pump inhibitors (e.g. verapamil or reserpine)
3. Perform transcriptomic analyses of katG mutants and wild-type strains in presence
/ absence of sub-MIC RIF.
4. Measure fine-scale RIF MICs of katG mutant and wild-type strains in medium
without additional catalase and/or medium supplemented with H2O2.
5. Sequence replicates from treatments 1 and 3 from a) generations predating the
observed inhibitory effect of RIF (e.g. generation 80), b) generation (100 – growth
inhibition becomes apparent)
7.6.3. Expected outcomes
If katG mutations elevate RIF MICs, we should be able to detect these with fine-scale MIC
measurements. If these elevations are due to the induction of efflux pumps, the addition
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of efflux pump inhibitors should reduce the RIF MIC again. Transcriptomic analyses will
aid in detecting the putative cause of elevated MICs in katG mutants. If the elevation
in RIF MICs is driven by oxidative-stress induced efflux mechanisms, the alteration in
MIC might correlate with the level of oxidative stress, testable by varying the amount
of H2O2 added to the culture medium. Finally, if katG mutations confer some resistance
to RIF, we would expect them to evolve prior to RIF resistance mutations, as the target
size for INH resistance in vitro is considerably larger (2.2 kb) than for RIF (95 % of RIF
resistance mutations are within an 81 bp region of rpoB).
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8. General discussion
The vast majority of TB cases are caused by drug-susceptible M.tuberculosis variants.
However, certain parts of the world are heavily affected by drug-resistant variants, either
due to the sheer number of incident TB cases in countries with large population sizes (e.g.
China, India, The Democratic Republic of the Congo) or due to high proportions of cases
caused by drug resistant variants among new cases (e.g. Georgia, Russia, South Africa)
(World Health Organization, 2018a). There is an urgent need to better understand the
ecology and evolution of drug resistance in M. tuberculosis to halt the spread and de novo
evolution of drug resistant variants. This thesis examined multiple aspects of the biology
of drug resistance in TB relevant for detecting drug resistant variants and predicting
quantitative levels of drug resistance from the genotype (Chapter 4), understanding how
drug resistant variants spread (Chapter 5), understanding the factors influencing the
transmission of resistant variants (Chapter 6) and examining conditions which favour the
evolution of multidrug-resistant variants (Chapter 7).
8.1. Remaining challenges for implementing WGS in
routine drug susceptibility testing in TB
In Chapter 4, we investigated the utility of whole genome sequencing for the detection
of drug-resistant M.tuberculosis variants, as well as for predicting quantitative levels of
drug resistance. The early and timely detection of drug resistant variants is a prerequisite
for ensuring adequate treatment of patients and limiting the spread of drug resistant
variants, benefiting individual patients and populations at large. Despite the fact that we
were able to show that WGS is a powerful tool for detecting drug resistance-and partially
predicting quantitative levels of drug resistance, there are still some challenges ahead for
implementing the technology in routine diagnostic use.
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8.1.1. Standardization of WGS analysis for DST
The reproducibility of WGS-based DST may in part depend on the methods used to
identify mutations, as well as the sequencing technology used to generate the sequencing
data (Phelan et al., 2016). These observations call for standardized approaches or at least
establishment of best practices to sequence and identify mutations for WGS-based DST in
the clinics. Several standardized pipelines have been published in recent years. A system-
atic review correlating phenotypic DST data with mutations identified by the different
pipelines would help to establish optimal procedures to obtain the optimal sensitivity
and specificity for WGS-based DST in M.tuberculosis. However, the diagnostic power of
WGS-based DST is not only dependent on reproducible analysis strategies, but also on
the ability to separate phylogenetic variation from mutations causing drug resistance. To
avoid false positive results, there is a need for a comprehensive database of phylogenetic
markers not involved in conferring resistance. This requires large-scale sequencing efforts
combined with phenotypic DST. Such efforts are well under way to resolve many issues
related to the presence of phylogenetic markers in drug resistance genes (Starks et al.,
2015; The CRyPTIC Consortium and the 100000 Genomes Project, 2018).
8.1.2. Reducing diagnostic delay
Reducing the diagnostic delay is crucial to provide effective treatment to patients and sub-
sequently reduce transmission of TB. Sequencing-based DST is a powerful tool to detect
drug-resistance conferring mutations and, compared to phenotypic DST methods, comes
with a much shorter turnaround time. However, it still requires a culture step to gener-
ate sufficient DNA for sequencing. This culture step is time- consuming and skews the
sample towards cells which were able to grow in the medium, reducing sample diversity
and potentially losing drug resistant variants, which would lead to false-negative results.
Sequencing directly from patient sputum eliminates the culture step and retains a maxi-
mum in diversity, as the cells present in the sputum do not have to be viable/culturable
and (non-dormant) (Chengalroyen et al., 2016). Considerable advances on sequencing
directly from patient sputa have been made recently, which constitute important steps in
eliminating the need for a culture step (Brown et al., 2015).
8.1.3. Limitations of WGS for DST in M. tuberculosis
We observed considerable variability in minimal inhibitory concentrations conferred by
identical drug resistance mutations for a number of drugs. This variability might be ex-
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plained by epistatic interactions between the resistance mutations and the genetic back-
ground and would in turn be amenable to study using WGS. However, it is becoming
increasingly apparent that non-mutational mechanisms may influence minimal inhibitory
concentrations (MIC). Specifically, the plastic expression of efflux mechanisms is involved
in conferring clinically relevant increases in MIC (Mazando et al., 2017). Differences in
efflux pump expression are not detectable with WGS. However, drug-resistant strains
with upregulated efflux pumps usually also harbour bona fide drug resistance mutations,
indicating that the expression of efflux pumps might act as a stepping stone in evolv-
ing high-level drug resistance. More in-depth analyses are required to establish or refute
a connection between efflux pumps and elevated MICs in absence of genetic resistance
mechanisms.
8.2. Drug combinations and the evolution of drug
resistance
TB infections are treated with a combination of drugs, requiring us to view the evolution of
resistance against single drugs in the in the context of combination treatment. In Chapter
7, we report the peculiar observation that mutations in the gene katG, which are typically
associated with INH resistance, seem to confer low-level RIF resistance. It seems likely
that the elevated RIF MICs in katG mutants are driven by drug efflux mechanisms. If this
observation can be confirmed, it will prompt us to investigate how resistance mutations
in general influence MICs of drugs via the expression of efflux mechanisms, potentially
generating an environment permissive for the evolution of strains resistant to multiple
drugs. Furthermore, it highlights the necessity to study how sub-MIC environments are
generated within the body and how one can prevent them. In the case of RIF, the
solution would be fairly easy, as one could increase the dose of RIF administered. Clinical
trials have already demonstrated that increased doses of RIF are safe and have better
treatment outcomes (Boeree et al., 2017). Given the mounting evidence that the plastic
expression of efflux pumps has clinical consequences, it might be wise to study whether
efflux pump inhibitors might slow the evolution of resistant strains (Pule et al., 2016). In
the light of novel antituberculous drugs bedaquiline, pretomanid and delamanid (Zumla
et al., 2014) being used to treat MDR-TB, as well as being part of novel treatment
regimens, we need to remain exceptionally vigilant to ensure that these drugs do not lose
their utility early on due to the evolution of resistance. For this, we need to understand
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the resistance mechanisms in detail, especially how sub-MIC concentrations affect the
evolution of resistance against these novel drugs.
8.3. From genome sequences to public health
interventions
Going beyond predicting drug resistance profiles in M.tuberculosis, WGS is exceptionally
useful to infer transmission chains (Walker et al. 2013; Stucki et al. 2016a). How-
ever, phylogenetic models are inadequate to describe relationships between highly similar
strains frequently found in pathogen transmission studies. Strains often do not display
any sequence differences, violating the key assumption of shared ancestry in phylogenies.
Furthermore, methods solely relying on genetic distance are unable to infer the direc-
tionality of transmission events. New methods (Klinkenberg et al. 2017) allow for the
simultaneous inference of phylogenetic and transmission trees, by incorporating models on
the time course of the infection with isolation dates. In Chapter 5, we were able to demon-
strate the utility of WGS to infer transmission using a nation-wide and population-based
collection of MDR-TB strains from Georgia. We were able to demonstrate that prisons
stand at the centre of the MDR-TB epidemic in Georgia, as well as quantify the over-
all effect of prisons on case numbers of MDR-TB outside of prisons. There is reason
to believe that the situation in Georgia can serve as a proxy for many countries of the
former Soviet Union (Droznin et al., 2017). We uncovered one of the largest transmission
clusters of pre-extensively drug resistant TB ever reported, reflecting the difficulties pris-
oners have in accessing adequate medical treatment (Department of State of the United
States of America, 2012). It is puzzling how such a large transmission cluster could have
gone unnoticed. In light of the frequently observed transmission in Georgian prisons,
there is an urgent need for public health interventions. In addition to providing adequate
treatment within prisons (World Health Organization, 2015), follow-up of former prison
inmates diagnosed with TB is an urgent task to tackle. Former prison inmates frequently
have low socio-economic status and lack resources to access medical services after being
released from prison and should be actively followed up. Concerted public health inter-
ventions in settings frequently found in the former Soviet Union can be highly effective, as
demonstrated by the rigorous implementation of the WHO End-TB strategy in Georgia’s
neighbour country Azerbaijan. TB incidence in Azerbaijani prisons dropped by a factor
of 2.5 in the past 15 years (Gurbanova et al., 2016). Public health interventions require
urgent governmental action and funding, especially since the TB control program in Geor-
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gia was funded in part by the Global Fund, which is phasing out its financial support in
the coming years (World Health Organization, 2015).
8.3.1. Whole genome sequencing for real-time monitoring of the
TB epidemic
The cost of sequencing has decreased dramatically over the past years
(https://www.genome.gov/sequencingcostsdata/), creating a number of intriguing op-
portunities. Together with the advances in laboratory automatisation, the decreased
sequencing costs will make it feasible to routinely sequence all strains isolated from pa-
tients. Platforms like Nextstrain (https://nextstrain.org/) will be exceptionally useful, as
they allow putting sequences to be put directly into the context of all other submitted
sequence data. This will allow for the direct detection of transmission clusters in real
time and aid to in direct active case finding campaigns, greatly increasing the ability
of public health systems to interrupt transmission and reduce the TB burden. Occur-
rences of transmission clusters of the size described in Chapter 5 would be unlikely to
occur. Data like these will offer unprecedented insight into pathogen biology and help to
monitor public health system interventions. Not only will we be able to monitor public
health interventions, we will be able to measure how human interventions influence the
evolutionary trajectories of pathogens.
8.4. Population-based samples and the study of
adaptation
Even if routine sequencing of all patient isolates will not be feasible in the short term,
sampling efforts in Georgia continue. The National Centre of Tuberculosis and Lung
Diseases in Tbilisi is collecting and storing all patient isolates (ca. 3-4000 strains per
year) from 2013 onwards, enabling the study of the whole population when sequencing
costs have decreased sufficiently. Such a sample set will allow researchers to study the
compensation of drug resistance-related fitness costs with the best possible resolution
using network analysis-based approaches such as those outlined in Chapter 6. The advent
of long-read sequencing technologies will make the reliable and in-depth study of structural
genome variation feasible. In the absence of detectable horizontal gene transfer, structural
variation is believed to be an important source of variation in M.tuberculosis (Gagneux
et al., 2006c). Furthermore, in Chapter 5, we had to exclude a number of strains due to an
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excess of unfixed positions, indicating either cross-contamination of cultures in the lab or
mixed infections (Cohen et al., 2012). Given the high transmission rates observed within
prisons, infections with multiple strains appear possible. Third-generation sequencers
will offer the possibility to reliably reconstruct haplotypes. Combined with high-density
population-based samples we will be able to study how mixed infections shape the TB
epidemic.
8.5. Conclusions
Despite the overall declining incidence of TB (World Health Organization, 2018a), the
epidemic is far from being under control. Furthermore, the extensive prevalence of highly
drug resistant strains, especially in countries of the former Soviet Union, calls for extensive
and tightly monitored public health interventions. Whole-genome sequencing can provide
the means for generating accurate and timely antibiograms, as well as understanding
transmission of highly resistant strains. Furthermore, population-based strain collections
offer the possibility to monitor the impact of public health interventions. However, we still
lack a comprehensive understanding of which genetic determinants make drug-resistant
strains transmit efficiently. This understanding will help us to develop methods to detect
strains with the capability to efficiently generate secondary cases. Finally, understand-
ing the effects of sub-MIC drug combinations on the evolution of drug resistance, with a
particular focus on the influence of drug efflux mechanisms, will help us to develop inter-
ventions to slow or prevent the evolution of highly resistant M.tuberculosis strains.
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A. Appendix
A1. Supplement to Chapter 4
A1.1. Materials and Methods
Culture conditions
Strains were isolated from clinical material following established decontamination proce-
dures. Bacteria were cultured in BD MGIT 960 tubes and Middlebrook 7H10 agar media.
Strains collected as a part of the IeDEA study were cultured on Löwenstein-Jensen slants
and sent to the National Center for Mycobacteria (University of Zürich, Zürich, Switzer-
land) for phenotypic drug susceptibility testing.
Phenotypic drug susceptibility testing – BD MGIT 960
DST for first- and second-line anti-TB drugs was performed using the Becton Dickin-
son (BD) MGIT 960 and EpiCenter devices equipped with the TB eXiST module (BD,
Franklin Lakes, NJ, USA) (Springer et al., 2009). The MGIT 960 system was used for
primary bacterial isolation and DST for first-line drugs (rifampicin, isoniazid, ethamb-
utol, pyrazinamide) as recommended by the manufacturer, using currently established
epidemiological cut-offs (ECOFF – epidemiological cut-off, i.e. the highest observed wild-
type MIC (Ängeby et al., 2012)) summarized in Table 4.1 in the main text. MGIT tubes
enriched with 0.8 ml of supplement (MGIT 960 OADC supplement; BD) were inoculated
with 0.1 ml of the drug solution (Table A.1.2) and 0.5 ml of the test strain suspension.
For the drug-free growth control tube, the M. tuberculosis suspension was diluted 1:100
in sterile saline and 0.5 ml was inoculated into the tube (proportion testing).
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Phenotypic drug susceptibility testing - Proportion method by 7H10 agar
dilution
M. tuberculosis strains were grown in Middlebrook 7H9 liquid broth with 10 % OADC
supplement (BD) until McFarland 0.5 was reached. Using a replicator micropipettor
robot VIAFLOW96 (Integra Biosciences, Zizers, Switzerland), 1 µl of the culture suspen-
sion was inoculated onto Middlebrook 7H10 agar plates with twofold serially diluted drug
concentrations to determine the MIC (Table A.1.2), whereby the MIC is defined as the
lowest drug concentration that inhibits growth of more than 99 % the bacteria during
21 days of incubation at 37° C (Sirgel et al., 2009). Agar plates were read automatically
using an AID Microplate reader and automated software developed by AID (AID Diag-
nostika, Strassberg, Germany). Phenotypic DST for all strains was performed at the Swiss
National Center for Mycobacteria (University of Z[ü]rich, Z[ü]rich, Switzerland).
Whole genome sequencing
Libraries were prepared using the Illumina Nextera XT kit and sequenced on an Illumina
HiSeq 2500, generating 125 bp paired-end reads. Sequencing was performed at the ge-
nomics facility of the ETHZ/University of Basel in Basel, Switzerland and at the Broad
Institute, Cambridge, Massachusetts, United States. The raw data was processed with
an in-house python pipeline as follows: reads were adaptor clipped and quality trimmed
with Trimmomatic (v.0.33), whereby resulting reads < 20 bp were discarded. Overlap-
ping paired-end reads were merged using SeqPrep (https://github.com/jstjohn/SeqPrep).
The processed reads were subsequently mapped to a reconstructed hypothetical MTBC
ancestor (Comas et al., 2010) with BWA (v.0.7.12) (Li et al., 2009a). Duplicated reads
were marked with Picard (v.2.1.1) (https://github.com/broadinstitute/picard) using the
MarkDuplicates module. Local realignments of reads around indels were performed with
the GATK (v.3.4.0) modules RealignerTargetCreator and IndelRealigner (McKenna et
al., 2010). Pileups were generated with Samtools (v.1.2) (Li et al., 2009b) and SNVs
were subsequently called with VarScan (v.2.4.1) (Koboldt et al., 2012) using the following
thresholds: minimum mapping & minimum base quality of 20, minimum read depth of
7x at a given position. For a SNV to be called, the alternative base call needed to be
supported by at lest 5 reads without strand bias. Furthermore, SNVs were considered
as fixed when they reached a frequency of ≥ 90 %. The position was called as ancestral
when the frequency was found to be < 10 %. SNVs were annotated with SnpEff (v.4.11)
(Cingolani et al., 2012) corresponding to the M. tuberculosis H37Rv reference annotation
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(NC_000962.3). SNVs in regions that share a minimum of 50 bp of sequence identity
with other regions in the genome were excluded (Stucki, 2015).
Variable SNV alignment and phylogenetic analysis
A variable SNV alignment was generated by concatenating all filtered SNVs in the dataset,
whereby the IUPAC nucleotide ambiguity codes were used for unfixed positions (10 % ≤
variant frequency ≤ 90 %). Positions were considered variable if at least one genome
had SNV-call at the position in question. If the SNV fell into an excluded region (see
above) or was covered by less than 7 reads it was encoded as X in the alignment. If
there was no sequence information at all available for a position, it was encoded as a
gap. Furthermore, positions known to be involved in drug resistance were not considered
in the alignment. The variable SNV alignment was used to infer a maximum likelihood
phylogeny with RAxML (v.8.2.8) (Stamatakis, 2014), using the general time-reversible
model of sequence evolution and branch support values were inferred by bootstrapping
the highest scoring maximum likelihood tree (1000 pseudoreplicates). Mycobacterium
canettii (SRR011186) was used to root the phylogeny. The genomes were classified into
main and sublineages based on the presence of previously established markers (Coll et
al., 2014). Average genetic distances between strains based on fixed single nucleotide
variants (SNV) were calculated with the ape package (v.4.1) (Paradis et al., 2004) for
R (v.3.3.3) (R Core Team, 2013). Two strains were defined as clustered if their average
genetic distance was ≤ 12 SNVs (Walker et al., 2013) and one strain was subsequently
omitted from the analysis at random. Phylogenetic trees with associated metadata were
visualized with the R package ggtree (v.1.6.11) (Yu et al., 2017).
WGS-based resistance profile inference
The WGS data was screened for non-synonymous mutations and indels in genes known to
be involved in drug resistance for the drugs assayed in M. tuberculosis (Gygli et al., 2017;
Safi et al., 2013). Phylogenetic markers in drug resistance-associated genes (Table 4.2 –
main text) shared by all strains belonging to a main- or sublineage (Coll et al., 2014; Stucki
et al., 2016) (Table A.1.1), as well as previously described phylogenetic markers (Coll et
al., 2015), including main lineage markers derived from an unpublished collection of 400
phylogenetically diverse strains, were removed. After filtering for phylogenetic markers,
all fixed non-synonymous polymorphisms in resistance-related genes were treated as linked
to drug resistance. Where necessary, WGS results were complemented by molecular DST
approaches as described previously (Ritter et al., 2014).
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Data availability
The datasets generated and analysed in the study were deposited at the National Center
National Center for Biotechnology Information (NCBI) under the BioProject IDs PR-
JNA454477 (http://www.ncbi.nlm.nih.gov/bioproject/454477) and PRJNA300846
(https://www.ncbi.nlm.nih.gov/bioproject/PRJNA300846). The quantitative readout of
the 7H10 agar dilution-based DST and the results of the MGIT 960-based testing at the


















































































































































































































































































































































































































































































































































































Figure A1.1.: Summary of DST results for ethionamideA Histogram of 7H10 agar dilution MICs
for ethionamide. B Method agreement between phenotypic DST by MGIT 960 and 7H10
agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations or for wt.
Top panel MGIT 960, bottom panel 7H10 agar dil.. "M1?" indicates an initiator codon
variant, "fs" indicates a frame shift variant, "*" indicates a stop-gain variant. Dashed lines
indicate the ECOFF.
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Figure A1.2.: Summary of DST results for ethambutolA Histogram of 7H10 agar dilution MICs
for ethambutol resistance. B method agreement between phenotypic DST by MGIT 960
and 7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations
in target genes or for wt. Top panel MGIT 960, bottom panel 7H10 agar dilution. In all
panels, dashed lines indicate the ECOFF.
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Figure A1.3.: Summary of DST results for streptomycin A Histogram of 7H10 agar dilution MICs
for streptomycin resistance. Bmethod agreement between phenotypic DST by MGIT 960
and 7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations
in target genes or for wt. Numbers in parentheses indicate the corresponding Escherichia
coli nucleotide numbering. Top panel MGIT 960, bottom panel 7H10 agar dilution. "fs"
indicates a frame shift variant. In all panels, dashed lines indicate the ECOFF.
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Figure A1.4.: Summary of DST results for capreomycin. A Histogram of 7H10 agar dilution MICs
for capreomycin resistance. B method agreement between phenotypic DST by MGIT 960
and 7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations
in target genes or for wt. Numbers in parentheses indicate the corresponding Escherichia
coli nucleotide numbering. Top panel MGIT 960, bottom panel 7H10 agar dilution. In all
panels, dashed lines indicate the ECOFF.
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Figure A1.5.: Summary of DST results for kanamycin A. A Histogram of 7H10 agar dilution MICs
for kanamycin A resistance. B method agreement between phenotypic DST by MGIT 960
and 7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations
in target genes or for wt.Numbers in parentheses indicate the corresponding Escherichia coli
nucleotide numbering. Top panel MGIT 960, bottom panel 7H10 agar dilution. Numbers
in parentheses indicate the corresponding Escherichia coli nucleotide number. In all panels,
dashed lines indicate the ECOFF.
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Figure A1.6.: Summary of DST results for amikacin. A Histogram of 7H10 agar dilution MICs
for amikacin resistance. B method agreement between phenotypic DST by MGIT 960 and
7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations in
target genes or for wt. Numbers in parentheses indicate the corresponding Escherichia
coli nucleotide numbering. Top panel MGIT 960, bottom panel 7H10 agar dilution. In all
panels, dashed lines indicate the ECOFF.
A. Appendix 163
Figure A1.7.: Summary of DST results for moxifloxacin. A Histogram of 7H10 agar dilution MICs
for moxifloxacin resistance. B method agreement between phenotypic DST by MGIT 960
and 7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations
in target genes or for wt. Top panel MGIT 960, bottom panel 7H10 agar dilution. In all
panels, dashed lines indicate the ECOFF.
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Figure A1.8.: Summary of DST results for isoniazid. A Histogram of 7H10 agar dilution MICs
for isoniazid resistance. B method agreement between phenotypic DST by MGIT 960 and
7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations in
target genes or for wt. Top panel MGIT 960, bottom panel 7H10 agar dilution. In all
panels, dashed lines indicate the ECOFF.
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Figure A1.9.: Summary of DST results for rifampicin. A Histogram of 7H10 agar dilution MICs
for rifampicin resistance. B method agreement between phenotypic DST by MGIT 960 and
7H10 agar dilution. C MICs of M. tuberculosis strains harboring resistance mutations in
target genes or for wt. Top panel MGIT 960, bottom panel 7H10 agar dilution. Numbers
in parentheses indicate the corresponding Escherichia coli codon numbers. In all panels,
dashed lines indicate the ECOFF (see Table 4.1 in the main text).
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Figure A1.10.: Summary of DST results for rifabutin. A Histogram of 7H10 agar dilution MICs for
rifabutin resistance. B method agreement between phenotypic DST by MGIT 960 and
7H10 agar dilution. A MICs of M. tuberculosis strains harboring resistance mutations in
target genes or for wt. Numbers in parentheses indicate the corresponding Escherichia coli
codon numbers. Top panel MGIT 960, bottom panel 7H10 agar dilution. In all panels,
dashed lines indicate the ECOFF.
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Figure A1.11.: Summary of DST results for pyrazinamide. A MICs of M. tuberculosis strains
harboring resistance mutations in the target gene for pyrazinamide resistance or for wt.
Only results for MGIT 960 are available. "*" indicates a stop-gain variant. Dashed line
indicates the ECOFF.
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A2. Supplement to Chapter 5
A2.1. Materials and methods
Sample set and associated metadata
A retrospective sample (n = 1,003) including all culture-confirmed Mtb isolates demon-
strating at least an MDR phenotype, collected between 2011 and 2013 and stored by the
National Centre for Tuberculosis and Lung Disease (NCTLD) in Tbilisi (Georgia) was re-
cultured and processed for DNA extraction for whole genome sequencing. A total of 344
strains were excluded from further analysis due to failed sequencing, no MDR-genotype,
large numbers of unfixed positions (potential mixed infections/cross-contamination), or
strains with multiple differing metadata entries (Figure A.2.1). The final dataset consisted
of 659 whole genome sequences of MDR Mtb strains, representing 53 % of all culture-
confirmed MDR Mtb strains isolated between 2011 and 2013. The per-year sampling cov-
erages were 34.7 % (165/475) in 2012, 82.7 % (286/346) and 52.0 % (208/400) in 2013.The
per year lineage proportions remained stable (Figure A.2.2). Limited anonymised patient
data including sex, age, incarceration history, current incarceration status, prior TB di-
agnosis was available. The ethics boards waived the need for individual patient consent
on the basis that only limited and anonymised data was provided and that any insight
gained from the data would directly be communicated to the public health authorities.
For 17.5 % of the analysed strains, no matching metadata was available; for all other
strains, complete records were available. The strains without metadata did not group
when plotted on the phylogenetic tree (Figure A.2.3.).
Ethical approval
Ethical approval for this study was obtained by the Institutional Review Board of the
National Centre for Tuberculosis and Lung Disease in Tbilisi, Georgia and the Ethics
Commission of North- and Central Switzerland.
Statistical analyses
Identification of risk factors associated with clustering was performed by multivariable
logistic regression. We tested the assumption of linearity between the continuous variables
(age and number of drug resistance mutations) and the log odds of the outcome. Fisher’s
exact and χ2 tests were used to analyse the association of compensatory mutations with
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incarceration and the spill-over of compensated strains to the general public. All analyses
were performed using R (v.3.3.3).
Whole genome sequencing
Sequencing libraries were prepared using the Illumina Nextera XT kit and subjected to
massive parallel sequencing on the Illumina HiSeq 2500 platform, whereby 125-bp paired-
end reads were generated. All sequencing runs were performed at the core sequencing
facility of the ETHZ/University of Basel in Basel, Switzerland. The reads were pro-
cessed using an in-house pipeline as described previously (Ghielmetti et al., 2017) as
follows: Trimmomatic (v.0.33) was used to clip adapters and filter for quality, whereby
< 20 bp reads were discarded. Overlapping paired-end reads were merged with Seqprep
(https://github.com/jstjohn/SeqPrep). The resulting reads were mapped to a recon-
structed hypothetical ancestor of the M. tuberculosis complex (Comas et al., 2012) with
BWA (v.0.7.12), duplicate reads marked with Picard (v.2.1.1)
(https://github.com/broadinstitute/picard) with the MarkDuplicates module. To en-
hance mapping of reads in the vicinity of indels, local realignments with the GATK
(v.3.4.0)
modules RealignerTargetCreator and IndelRealigner (McKenna et al., 2010). Pileups
were generated with Samtools (v.1.2) (Li et al., 2009b) and single nucleotide variants
(SNV) were subsequently called with VarScan (v.2.4.1) (Koboldt et al., 2012) applying
the following thresholds: minimum mapping / mimimum base quality of 20, minimum
read depth 7x at a given position. SNVs were called if at least 5 reads supported the
alternative allele without strand bias. A given SNV was considered fixed if its frequency
reached 90 % and a position was called as ancestral if the frequency was below 10 %.
The effect of the SNV was inferred using SnpEFF (v.4.11) (Cingolani et al., 2012) using
the M. tuberculosis H37Rv reference annotation (NC_000962.3). SNVs lying in regions
that share ≥ 50 bp sequence identity with other regions in the genome were excluded
(Ghielmetti et al., 2017). The unfixed position outliers were defined as having > 3x the
interquartile range (IQR) of the ratio between fixed and unfixed positions, whereby the
IQR was calculated separately for Lineage 2 and Lineage 4 strains.
Variable position alignment & phylogenetic analysis
Variable SNV pseudo alignments were generated by concatenating all quality filtered SNVs
in the dataset. IUPAC nucleotide ambiguity codes were used throughout for unfixed
positions, whereby positions were considered variable if at least one isolate in the dataset
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had an alternative allele called at a given position. A position was encoded as an X in
the alignment, if it was covered by less than 7 reads or if it fell into one of the excluded
regions (see above). If a position was not covered, it was encoded as a gap. Two separate
alignments were produced: One including genes known to be involved in drug resistance
and a separate alignment excluding variable positions in drug resistance-related genes.
The former alignment was used for genetic distance-based transmission cluster inference
(see below) and the latter was used to infer a maximum likelihood phylogeny using RAxML
(v.8.2.8) (Stamatakis, 2014). The phylogeny was inferred using the general time-reversible
model of sequence evolution, rooted on Mycobacterium canettii (SRR011186). Strains
were classified into main- and sub-lineages based on the presence of previously established
markers (Coll et al., 2014).
Drug resistance profile prediction
We collated a list of high-confidence drug-resistance mutations (mutations and sources
summarised in Table A.2.1.), which we used to screen the sequences. In addition, all non-
synonymous substitutions in ethA, pncA, and Rv0678/mmpR were regarded as conferring
resistance to ethionamide, pyrazinamide, and bedaquiline, respectively.
Identification of compensatory mutations
We screened the genes rpoA, rpoB and rpoC, encoding the DNA-dependent RNA poly-
merase, for the presence of non-synonymous mutations. This resulted in a list of rifampicin
resistance-conferring, phylogenetic and putative compensatory mutations. Per definition,
compensatory mutations must co-occur with rifampicin resistance-conferring mutations
but are never found on their own. To remove phylogenetic markers, we collated a list
of non-synonymous mutations in rpoABC identified in rifampicin susceptible strains (de-
fined as harbouring none of the high-confidence rifampicin resistance-conferring mutations
listed in Table A.2.1.) using a large collection of published (Menardo et al., 2018), as well
as an in house collection of genomes. After filtering for phylogenetic and rifampicin
resistance-conferring mutations, every mutation identified in rpoABC was assumed to
be a secondary, compensatory mutation. Strains harbouring two mutations affecting the
same codon in rpoB were assumed to be compensated if one of the mutations conferred
rifampicin resistance on its own, e.g. rpoB c.1349T>C (Ser450Leu – confers rifampicin
resistance) & rpoB c.1350G>C (Ser450Ser) combined these two mutations result in the
substitution RpoB Ser450Phe.
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Genetic distance-based transmission cluster definition
The likelihood of two strains being members of a transmission chain decreases with the
number of genetic differences between two strains. Previous analyses have demonstrated
that two TB strains isolated from patients with a proven epidemiologic link rarely differ
by more than 5 mutations from each other (Walker et al., 2013). A distance matrix based
on pairwise SNV distances between any given two strains was inferred using the variable
position pseudo alignment including variable positions in drug resistance-related genes
with the haplotypes package (v.1.0) for R (v.3.3.3). Insertions/deletions were considered
as missing data. Agglomerative clustering was performed using the R package cluster
(v.2.0.6) with the agnes function using the unweighted pair-group average method. A
threshold of 5 SNV on average was used as a cut-off for likely patient to patient trans-
mission (Walker et al., 2013). The function hclust was used to cut the tree at a height of
5 SNVs. The resulting transmission clusters were filtered for a minimum size of 3 clus-
tered strains, i.e. a minimum of two transmission events to reduce the influence of chance
events.
Transmission networks
Transmission graphs were inferred using the R package phybreak (v.0.2.0) (Klinkenberg et
al., 2017). Phybreak infers consensus transmission trees by combining transmission mod-
els, within-host dynamics, case observation and mutation rate. Phybreak uses Bayesian
inference combined with Markov-chain Monte Carlo sampling of the posterior distribu-
tion of model parameters, transmission and phylogenetic trees. Priors for the mean of the
sampling time (µ = 146.28) and mean of the generation time (µ = 173.67) distributions,
as well as the shape parameters (sampling time: k = 0.021, generation time: k = 0.027)
for both distributions were inferred from collated data on the time-course of M. tubercu-
losis infections (Behr et al., 2018) by fitting a gamma distribution with the R package
fitdistrplus (v.1.0-11). The mutation rate prior was set at 0.5 mutations per genome and
year (Walker et al., 2013). Five independent MCMC chains were run with a burn-in set
at 20000 cycles and the sampling of the independent chains was set at 100000 cycles to




Whole genome sequencing summary statistics
The final dataset included 659 strains with a median coverage of 123x (25th percentile =
101, 75th percentile = 141, interquartile range (IQR) = 40). We observed a high percentage
of reads that mapped to the reference genome (median = 99.00 %, 25th percentile = 98.73,
75th percentile = 99.09, IQR = 0.36), indicating the absence of major contaminants. The
median percentage of the genome with less than 7x coverage was 0.89 % (25th percentile
= 0.82, 75th percentile = 0.98, IQR = 0.16). Per genome, a median number of 906 fixed
mutations (25th percentile = 900, 75th percentile = 910, IQR = 10) and a median number















































Phylogenetic analysis / 
Cluster definition
Figure A2.1.: Flow chart of sample selection.
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Figure A2.2.: M. tuberculosis Lineage proportions per year. The proportions of M. tuberculosis
phylogenetic lineages remained stable during the time frame of the study 2011: 15 % ± 0.05
% Lineage 4, 2012: 13 % ± 0.04 % Lineage 4, 2013:19 % ± 0.06 % Lineage 4; there was no






Figure A2.3.: Maximum likelihood phylogeny of all 659 analysed M. tuberculosis genomes.
Lineage 2 strains highlighted in blue, Lineage 4 in red. Scale bar indicates substitutions
per site. 115 isolates were discarded as no metadata was available (Figure 1). Availability
of metadata for the strains is indicated with coloured tip labels. There is no clustering of
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